 
 
REDUCED -INTENSITY CONDITIONING FOR CHILDREN AND 
ADULTS WITH HEMOPHAGOCYTIC SYNDROMES  OR 
SELECTED PRIMARY IMMUNE DEFICIENCIES  (RICH I) 
(Posted on clinicaltrials.gov as NCT 01998633 ) 
 
BMT CTN PROTOCOL 1204  
VERSION 4.0 
 
Study Chairpersons  
Carl Allen, M D, PhD1   and   Michael Pulsipher , MD2 
 
Protocol Team  
 
K. Scott Baker , MD, MS3 
Catherine Bollard , MD4 
Lauri Burroughs, MD3 
Lisa Filipovich, MD5 
Stephen Grupp MD , PhD6 
Rabi Hanna , MD7 Leslie Kean , MD, PhD3 
Sung -Yun Pai , MD8 
Alyssa Ramirez9 
Philip Roehrs , MD10 
Kirk Schultz , MD11 
Shalini Shenoy , MD12 Julie -An Talano , MD13 
Peter Dawson , PhD9 
Pam Budnick14 
Mary Eapen , MD, MS13
 
Sponsored by the National Institutes of Health  
National Heart, Lung, and Blood Institute  
National Cancer Institute  
 
1Texas Children’s Cancer and Hematology  
Center s 
2University of Utah School of Medicine  
3Fred Hutchinson Cancer Research Center  
4Children’s National Medical Center  
5Cincinnati Children’s Hospital 
  6Children’s Hospital of Philadelphia  
7Cleveland Clinic Foundation  
 8Boston Children’s Hospital  
9The EMMES Corporation  
10University of North Carolina at Chapel Hill  
11BC Children’s Hospital  
12Washington University School of Medicine  
13Medical College of Wisconsin  
14National Marrow Donor Program  
 
 
 
___________________________________________   ________________________________________  
Approval Signature (Protocol Chair/Officer)    Approval Signature (Protocol Chair/Officer)  

BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
i Core Study Participants:    
Alfred I. DuPont Hospital for Children – Nemours 
Wilmington  
All Children’s Hospital  
Ann and Robert H. Lurie Children’s Hospital of 
Chicago  
Baylor College of Medicine  
British Columbia Children’s Hospital – Vancouver  
CancerCare Manitoba  
Children’s Healthcare of Atlanta  
Children’s Hospital & Research Center, Oakland  
Children’s Mercy Hospital and Clinics  
Children’s National Medical Center  
Cincinnati Children’s Hospital Medical Center  
City of Hope National  Medical Center  
Cleveland Clinic  Foundation  
Cook Children’s Medical Center  
DFCI/Brigham & Women’s Hospital  
DFCI/Children’s Hospital of Boston  
Duke University Medical Center  
Fred Hutchinson Cancer Research Center  
Hackensack University Medica l Center  
Johns Hopkins/SKCCC  
Karmanos Cancer Institute – Children’s Hospital 
of Michigan  
Medical College of Wisconsin  
Memorial -Sloan Kettering Cancer Center  
Nemours Children’s Clinic  - Jacksonville  
Oregon Health & Science University  
Penn State College of M edicine – The Milton S. 
Hershey Medical Center  
Phoenix Children’s Hospital  
Primary Children’s Medical Center  – Utah BMT  
Riley Hospital for Children – Indiana University  
Roswell Park Cancer Institute  
UCLA – Mattel Children’s Hospital  
University of Alabama at Birmingham  
University of Florida  College of Medicine 
(Shands)  
University of Iowa Hospital s and Clinics  
University of Louisville – Kosair Children’s 
Hospital  
University of Michigan  Medical Center  
University of Minnesota  
University of North Caroli na Hospital at Chapel 
Hill  University of Rochester Medical Center  
University of Texas Southwestern Medical 
Center  
University of Texas/MD Anderson Cancer 
Research Center  
University of Wisconsin Hospital and 
Clinics  
Virginia Commonwealth University  
Washington University in St. Louis – St. 
Louis Children’s Hospital  
 
 
 
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
ii  
PROTOCOL SYNOPSIS - BMT CTN PROTOCOL # 1204   
 
Reduced -Intensity Conditioning f or Children and Adults with Hemophagocytic Syndromes  
or Selected Primary Immune Deficiencies  (RICH I) 
 
Study Chairpersons:  Carl Allen , MD , PhD  and Michael Pulsipher , MD  
 
Primary Objective:  To prospectively determine the 1 -year overall survival in subjects 
treated for hemophagocytic syndromes or primary immune 
deficiencies (CGD, HIGM1 , IPEX, and severe LAD -I) using a 
standardized, reduced -intensity conditioning protocol consisting of 
fludarabine, melphalan and intermediate timing of alemtuzumab 
(Day -14).  
 
Secondary Objective s:  Secondary objectives for the study include measurement o f 
sustained  engraftment, incidence of HLH and CAEBV reactivation 
and death from disease, immune reconstitution and functional 
immune recovery  at 1-year, cumulative incidence ( CI) of grade II -
IV and III -IV acute GVHD  and chronic GVHD , transplant -related 
complications  (VOD, CNS toxicity) , infectious complications 
including reactivation of CMV, adenovirus, EBV, invasive fungal 
infection or bacterial sepsis , and overall survival and rate of 
sustained engraftment of specific disease subsets . 
 
Study Design:  This study is designed as a Phase II multi -center trial. The study 
population includes  patients with HLH , HLH -related disorders, 
and selected primary immune deficiencies:  CGD, HyperIgM  
Syndrome (HIGM1), IPEX Syndrome, or severe LAD -I with 
indications for HCT receiving a bone marrow transplant from a 
related or unrelated donor (see HLA typing requirements in 
eligibility criteria below).  
 
Accrual Objective:  The trial will accrue a minimum  of 35 HLH patients.  
 
Accrual Period:   The estimated accrual period is 3 years.  
 
Eligibility Criteria:  Eligible patients are > 3 months and ≤ 45 years of age with 
Lansky/Karnofsky performance status ≥ 50% who have HLH or 
related disorders or selected immune deficiencies with an 
indication for HCT. Patients must have adequate organ  function  
(cardiac, renal, hepatic, pulmonary) .  Only bone marrow donors 
are allowed on this study. The donor must be:  
• An unaff ected sibling  donor  who is  a 6/6 match at HLA –A 
and –B (intermediate or higher resolution ) and –DRB1 (at 
high resolution using DNA -based typing ) OR  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
iii • An unaffected related donor (other than sibling) who is a  
7/8 or 8/8 match for HLA –A, –B, –C (at intermediate or 
higher resolution) , and –DRB1 (at high resolution using 
DNA -based typing ) OR  
• An u nrelated donor who is a 7/8 or 8/8 match at HLA –A, –
B, –C, and –DRB1 (at high resolution using DNA -based 
typing).  
 
Treatment Description:  All eligible pat ients undergoing bone marrow HCT will receive 
reduced -intensity conditioning (RIC) with fludarabine, melphalan 
and alemtuzumab beginning on Day -14. 
 
Study Duration:  Patients will be followed for  1 year post -HCT .  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
iv TABLE OF CONTENTS  
 
1. BACKGROUND AND RATIONALE  ................................ ................................ .........  1-1 
1.1. Background  ................................ ................................ ................................ ....................  1-1 
1.1.1.  An Op portunity to Improve Survival of Patients with HLH and Selected Primary 
Immune Deficiencies (PID)  ................................ ................................ ........................  1-1 
1.1.2.  Challenges with Rejec tion of Cord Blood in Patients with HLH/PID  ........................  1-1 
1.2. Hemophagocytic Lymphohistiocytosis  ................................ ................................ .........  1-2 
1.2.1.  Diagnostic Criteria for HLH  ................................ ................................ .......................  1-2 
1.2.2.  Initial Therapy for HLH  ................................ ................................ ..............................  1-3 
1.2.3.  Salvage Strategies for Recurrent/Refractory HLH  ................................ .....................  1-3 
1.2.4.  Fully Ablative Conditioning with Hematopoietic Cell Transplant and HLH  .............  1-4 
1.2.5.  Reduced Intensity Conditioning Hematopoietic Cell Transplantation for HLH  ........  1-4 
1.2.6.  Optimizing RIC HCT for HLH Syndromes  ................................ ................................  1-5 
1.2.7.  HLH -Related Syndrome:  Chronic Active EBV Disease  ................................ ...........  1-5 
1.2.8.  Diagnosis of CAEBV  ................................ ................................ ................................ .. 1-5 
1.2.9.  CAEBV and HCT  ................................ ................................ ................................ ....... 1-6 
1.3. Selected Primary Immune Deficiencies  ................................ ................................ ....... 1-6 
1.3.1.  Chronic Granulomatous Disease  ................................ ................................ .................  1-6 
1.3.2.  Hyperimmunoglobulin M Syndrome  ................................ ................................ ..........  1-8 
1.3.3.  IPEX Syndrome  ................................ ................................ ................................ ..........  1-8 
1.3.4.  Leukocyte Adhesion Deficiency  ................................ ................................ .................  1-9 
1.4. Summary  ................................ ................................ ................................ .......................  1-10 
2. STUDY DESIGN  ................................ ................................ ................................ ............  2-1 
2.1. Study Overview  ................................ ................................ ................................ ..............  2-1 
2.2. Hypothesis and Study Objectives  ................................ ................................ .................  2-1 
2.2.1.  Primary Hypothesis  ................................ ................................ ................................ ..... 2-1 
2.2.2.  Primary Objective  ................................ ................................ ................................ ....... 2-1 
2.2.3.  Secondary Objectives  ................................ ................................ ................................ .. 2-2 
2.3. Patient Eligibility  ................................ ................................ ................................ ...........  2-2 
2.3.1.  Patient Inclusion Criteria ................................ ................................ .............................  2-2 
2.3.2.  Patient Exclusion Criteria  ................................ ................................ ...........................  2-4 
2.3.3.  Donor Selection Criteria  ................................ ................................ .............................  2-5 
2.3.4.  Donor Exclusion Criteria  ................................ ................................ ............................  2-5 
2.4. Treatment Plan ................................ ................................ ................................ ...............  2-6 
2.4.1.  Alemtuzumab (Campath -1H) ................................ ................................ ......................  2-7 
2.4.2.  Fludarabine  ................................ ................................ ................................ ..................  2-8 
2.4.3.  Melphalan  ................................ ................................ ................................ ....................  2-8 
2.4.4.  Infusion of Hematopoietic Stem Cells  ................................ ................................ ........  2-9 
2.5. GVHD Prophylaxis  ................................ ................................ ................................ ........  2-9 
2.5.1.  Cyclosporine (CSA)  ................................ ................................ ................................ .... 2-9 
2.5.2. Methylprednisolone/Prednisone  ................................ ................................ ................  2-10 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
v 2.6. Managing Chimerism  ................................ ................................ ................................ .. 2-10 
2.7. Supportive Care (Recommended)  ................................ ................................ ..............  2-11 
2.7.1.  Engraftment Syndrome  ................................ ................................ .............................  2-11 
2.7.2.  Venous Access  ................................ ................................ ................................ ..........  2-11 
2.7.3.  Growth Factor  ................................ ................................ ................................ ...........  2-11 
2.7.4.  Blood Products  ................................ ................................ ................................ ..........  2-11 
2.7.5.  Treatment of Fever/Infections  ................................ ................................ ...................  2-12 
2.7.6.  Blood Pressure Monitoring and Control  ................................ ................................ ... 2-12 
2.7.7.  Infection Surveillance and Prophylaxis  ................................ ................................ .... 2-12 
2.8. Toxicities  ................................ ................................ ................................ .......................  2-14 
2.8.1.  Conditioning: Pancytopenia  ................................ ................................ ......................  2-14 
2.8.2.  Alemtuzumab  ................................ ................................ ................................ ............  2-14 
2.8.3.  Fludarabine  ................................ ................................ ................................ ................  2-14 
2.8.4.  Melphalan  ................................ ................................ ................................ ..................  2-15 
2.8.5.  Hematopoietic Cell Infusion  ................................ ................................ .....................  2-15 
2.8.6.  Cyclosporine  ................................ ................................ ................................ .............  2-15 
2.8.7.  Tacrolimus ................................ ................................ ................................ .................  2-15 
2.8.8.  Dexamethasone, Methylprednisolone and Prednisone  ................................ .............  2-15 
2.8.9.  Filgrastim (G -CSF)  ................................ ................................ ................................ ... 2-15 
3. STUDY ENDPOINTS  ................................ ................................ ................................ .... 3-1 
3.1. Primary Endpoint  ................................ ................................ ................................ ..........  3-1 
3.2. Secondary Endpoints  ................................ ................................ ................................ ..... 3-1 
3.2.1.  Sustained Engraftment (sustained donor lymphoid and myeloid chimerism)  ............  3-1 
3.2.2.  HLH and CAEBV Reactivation  ................................ ................................ ..................  3-1 
3.2.3.  Immune Reconstitution and Functiona l Immune Recovery ................................ ........  3-2 
3.2.4.  Cumulative Incidence of Neutrophil and Platelet Engraftment  ................................ .. 3-2 
3.2.5.  Grade II -IV and Grade III -IV Acute GVHD ................................ ...............................  3-3 
3.2.6.  Chronic GVHD  ................................ ................................ ................................ ...........  3-3 
3.2.7.  Frequency of Transplant -related Complications  ................................ .........................  3-3 
3.3. Correlative Biology Studies  ................................ ................................ ...........................  3-3 
4. PATIENT ENROLLMENT AND EVALUATION  ................................ ....................  4-1 
4.1. Enrollment Procedures  ................................ ................................ ................................ .. 4-1 
4.1.1.  Screening and Eligibility Procedures  ................................ ................................ ..........  4-1 
4.2. Study Monitoring  ................................ ................................ ................................ ...........  4-1 
4.2.1.  Follow -up Schedule  ................................ ................................ ................................ .... 4-1 
4.2.2. Adverse Event Reporting  ................................ ................................ ............................  4-3 
4.2.3.  Patient Evaluations Prior to Enrollment  ................................ ................................ ...... 4-3 
4.2.4.  Patient Evaluations Prior to Conditioning  ................................ ................................ .. 4-6 
4.2.5.  Required Post -Transplant Evaluations (Follow evaluation windows listed in Table 
4.2.3)  ................................ ................................ ................................ ...........................  4-6 
5. STATISTICAL CONSIDERATIONS  ................................ ................................ .........  5-1 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
vi 5.1. Study Design  ................................ ................................ ................................ ...................  5-1 
5.2. Accrual  ................................ ................................ ................................ ............................  5-1 
5.3. Study Duration  ................................ ................................ ................................ ...............  5-1 
5.4. Randomization  ................................ ................................ ................................ ...............  5-1 
5.5. Primary Objective  ................................ ................................ ................................ ..........  5-1 
5.6. Sample Size and Power Considerations  ................................ ................................ ....... 5-1 
5.7. Interim Analysis and Stopping Guidelines  ................................ ................................ .. 5-2 
5.8. Demographic and Baseline Characteristics  ................................ ................................ . 5-4 
5.9. Analysis of Primary Endpoint  ................................ ................................ ......................  5-4 
5.10.  Analysis of Secondary Endpoints  ................................ ................................ .................  5-4 
5.11.  Safety Analysis  ................................ ................................ ................................ ...............  5-5 
 
 
LIST OF APPENDICES  
 
APPENDIX A  HUMAN SUBJECTS  
APPENDIX B  CONSENT FORM  
APPENDIX C  LABORATORY PROCEDURES  
APPENDIX D  LANSKY PERFORMANCE STATUS SCALE  
APPENDIX E  RECOMMENDATIONS FOR HLH THERAPY PRIOR TO HCT 
FOR HLH SALVAGE THERAPY , AND FOR HLH CNS THERAPY  
APPENDIX F  DERIVATION OF A SEQUENTIAL TEST STATISTIC FOR 
CENSORED EXPONENTIAL DATA  
APPENDIX G  BLOOD PRESSURE LEVELS BY AGE AND HEIGHT 
PERCENTILE  
APPENDIX H REFERENCES  
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-1 CHAPTER 1  
 
 
1. BACKGROUND AND RATIONALE  
 
1.1. Background  
 
Hematopoietic  cell transplant ( HCT ) is required for long -term survival in many patients with 
primary defects of the immune system.  The major obstacles to long -term survival with high 
quality  of life in these patients, many of whom have significant morbidities at the time of 
transplant, ar e treatment -related mortality  (TRM)  and durable immune reconstitution .  Reduced -
intensity conditioning protocols have significantly improved outcomes in patients with immune 
deficiencies such as hemophagocytic lymphohistiocytosis (HLH)  (Marsh et al., 2011) .  However, 
the decrease in treatment -related morbidity and mortality comes with increased risk of 
inadequate durable engra ftment, though a portion of patients with unstable chimerism  or graft 
loss may be rescued with subsequent lymphocyte infusions or repeat HCT  (Marsh et al., 2010) .  
In an institutional case series of patients with HLH and related disorders, “intermediate” (Day  
-14) timing of alemtuzumab adm inistration maintained excellent survival rates with improved 
stable engraftment  (Marsh et al., 2013b) .  In this study, we will test the efficacy of Intermediate -
Timed Alemtuzumab  Reduced Intensity Conditioning (Intermediate RIC) in a multi -center 
setting in patients with HLH and other primary immunodeficiencies.  
 
1.1.1.  An Opportunity to Improve Survival of Patients with HLH and  Selected  Primary Immune 
Deficiencies  (PID)  
 
Although outcom es after related and unrelated donor HCT have  improved dramatically in the 
past decade, survival in patients with diseases  of immune dysfunction has lagged behind.  
Myeloablative (MA) approaches  have been plagued with high rates of early treatment related -
mortality (section 1. 2.4), but even patients transplanted with RIC approaches have not had ideal 
outcomes.  A review of CIBMTR data between 2008 and 2010 illustrates this challenge.  A total 
of 77 HLH patients received unrelated  BM/PBSC , 22 related  BM/PBSC , and 57 unrelated cord 
blood  (CB)  transplants  during this three -year period.  One third received various RIC approaches 
and 2/3 MA approaches.  O verall survival (OS)  at 1-year was 70% in  those who  received either 
related or unrelated BM/PBSC  and 67% in re cipients of unrelated CB.  One -year OS of patients 
with immune deficiencies included in this protocol (XLP, Chediak -Higashi, CGD, HIGM1, 
IPEX, and LAD -I) receiving URD RIC approaches was similarly poor at 74% (personal 
communication, Mary Eapen, CIBMTR).  Single -center experiences with fludarabine, 
melphalan, and alemtuzumab describe overall survival as high as  90% in HLH patients, 
demonstrating  a clear opportunity to improve survival in this patient population  (Cooper et al., 
2008; Marsh et al., 2010) . 
 
1.1.2.  Challenges with Rejection of Cord Blood in Patients with HLH/PID  
 
Very little data on outcomes of cord blood transplantation in this population has been published.  
Early exper ience with use of  cord blood following the Flu/Mel/Alem approach led to a high 
number of rejections.  This anecdotal experience is born e out by CIBMTR data.  Between 2008 -
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-2 2010, of the 56 who underwent cord blood transplantation for HLH (2/3 MA, 1/3 RIC), 13 had 
primary and  7 had secondary graft failure for an overall graft failure rate of 36%.  One -year 
survival was poor, at 67%.  Patients with immune deficiencies undergoing cord blood procedures 
during these three years rejected 35 % and 34% of the time with RIC (n= 31) and MA (n=68)  
approaches, respectively.  Over the same time period, rejection occurred in 5% of MA 
procedures for immune deficiencies who received unrelated BM/PBSC  (personal 
communication, Mary Eapen, CIBMTR) .  There is clearly a major problem with cord bloo d 
engraftment in these non -malignant disorders that will need to be addressed by a different 
approach.   Relative delay in immune recons titution with cord grafts and difficulty generating 
cytotoxic T cell therapy from donor cells are also challenges in this  population with frequent 
infectious complications.  With these data in mind, most  investigators will choose a 7/8 or 8/8 
HLA matched unrelated donor over a cord blood  for these disorders .  For patients who do not 
have a 7 -8/8 matched unrelated donor avail able, enrollment on pilot studies aimed at improving 
engraftment using UCB or haploidentical donors is encouraged.    
 
1.2. Hemophagocytic Lymphohistiocytosis  
 
Hemophagocytic lymphohistio cytosis  (HLH) is a syndrome of pathologic immune activation 
characterized by clinical signs and symptoms of extreme inflammation caused by dysregulation 
of immune effector function.  Without prompt initiation of immunochemotherapy, active familial 
HLH is almost u niversally fatal  (Janka, 1983) .  “Primary” inherited and presumed “secondary” 
acquired HLH are imp ossible to differentiate in the acute clinical setting, and distinctions 
between these groups are becoming increasingly blurred.  In the last Histiocyte Society trial, 
HLH -94, there was no significant difference in outcomes between patients with presumed 
familial or presumed secondary HLH with overall 3 -year survival of 55%  (Henter et al., 2002) .  
 
1.2.1.  Diagnostic Criteria for HLH  
 
The current resource most clinicians use to define HLH is the Histiocyte Society HLH -2004 
research protocol that requires either identification of recognized mutations in HLH -associated 
genes (including PRF1, MUNC13 -4, STX11, STXBP2  (Munc18 -2), SH2D1A (XLP1) , BIRC4 
(XLP2) , LYST (Chediak -Higashi Syndrome) , or RAB27a (Griscelli Syndrome ))  or five out of  
eight clinical criteria: fever; splenomegaly;  cytopenias in  2/3 lineages;  hypertriglyceri demia 
and/or hypofibrinogenemia;  hemophagocytosis in bone  marrow/spleen/lymph no de/liver; 
decreased NK -cell activity; elevated ferritin;  and elevated soluble CD25 (also called soluble IL -2 
receptor alpha)  (Henter et al., 2007) . (See Table 1 .2.) 
 
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-3 TABLE 1 .2: DIAGNOSTIC CRITERIA FOR HLH USED IN THE HLH -2004 TRIAL*  
 
The diagnosis of HLH may be established by: **  
A.   A molecular diagnosis consistent with HLH:  Pathologic mutations of PRF1 , UNC13D  (MUNC13 -2), 
STXBP2 ( Munc18 -2), Rab27a , STX11 , SH2D1A , or BIRC4  
-OR- 
 B. Five out of the eight  criteria listed below are fulfilled:  
1. Fever ≥  38.3°C 
2. Splenomegaly  
3. Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood):  
Hemoglobin <  9 g/dL (in infants <  4 weeks: hemoglobin <  10 g/ dL)  
Platelets <  100X103/mL 
Neutrophils <  1X103/mL 
4. Hypertriglyceridemia (fasting, > 265 mg/ dL) and/or  
    hypofibrinogenemia (< 150 mg/ dL)  
5. Hemophagocytosis in bone marrow or spleen or lymph nodes or liver  
6. Low or absent NK -cell activity  
7. Ferritin > 500 ng/ mL 
8. Elevated Soluble CD25 (soluble IL -2 receptor alpha)***  
 
Notes:  
*  Adapted from Henter et al. 2007  
**  Additionally, in the case of familial HLH, no evidence of malignancy should be apparent.  
*** Elevations above age -adjusted, laboratory -specific normal levels (defined as > 2 SD from the mean) appear more 
meaningful than the original designation of ‘>  2,400 U/ mL’, because of variations between laboratories  and 
age groups . 
 
1.2.2.  Initial Therapy for HLH  
 
Without therapy, survival of patients with active familial HLH is approximately 2 months  
(Henter et al., 1991) . The first international treatment protocol for HLH was organized by the 
Histiocyte Society in 1994 and led to reported survival of 55%, with a median follow -up of 3.1 
years  (Henter et al., 2002) .  The HLH -94 protocol included an 8 week induction therapy with 
dexamethasone, etoposide, and intrathecal methotrexate in patients with CNS inflammation.  The 
principal goal of induction therapy is to suppress the life -threatening inflammatory process that 
underlie s HLH.  At the end of 8 weeks, patients who can be weaned off of dexamethasone an d 
etoposide without recurrence, recover normal immune function, and have no identified HLH -
associated gene defects may stop therapy.  HCT is generally recommended in patients with CNS 
involvement, recurrent/refractory disease, persistent NK cell dysfunctio n or proven 
familial/genetic disease  (Jordan et al., 2011) .  
 
1.2.3.  Salvage Strategies for Recurrent/Refractory HLH  
 
A significant number of patients with HLH will either fail to respond adequately to current 
therapies or have disease recurrence prior to HC T.  Approximately 50% of patients treated on the 
HLH -94 study experienced a complete resolution of HLH, while 30% experienced a partial 
resolution, and approximately 20% died prior to HCT  (Henter et al., 2002) .  Notably, most 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-4 deaths occurred during the first few weeks of treatment and may reflect either pre -existing 
morbidities or primary refractory disease.  While it is hoped that some pa tients will fare better 
with more prompt diagnosis of HLH, others remain unresponsive to standard therapy. Initial 
treatment with anti -thymocyte globulin (Thymoglobulin, rabbit ATG) has been reported to give 
higher complete response rates, but due in part to higher recurrence rates, long term outcomes do 
not appear superior  (Ouachee -Chardin et al., 2006) .  
 
At present there is little data regarding potential second line therapies. Case reports exist 
describing the use of infliximab, daclizumab, alemtuzumab, anakinra, vincristine, and other 
agents as salvage therapies for HLH  (Bruck et al., 2011; Henzan et al., 2006; Imashuku et al., 
1999; Kobayashi et al., 2007; Olin et al., 2008; Strout et al., 2010; Tomaske et al., 2002) .  Due to 
the increasing recognition of the critical r ole of T cells in driving HLH pathogenesis, 
alemtuzumab has been increasingly used as a salvage therapy.  A recent retrospective analysis of 
25 patients found that alemtuzumab has significant activity against refractory HLH  (Marsh et al., 
2013a) .  Tho ugh refractory HLH typically has a dismal prognosis, approximately 70% of 
patients in this series survived.  In contrast to refractory patients, those patients who initially 
respond well to standard therapy but then recur as treatment is tapered or withdra wn often 
respond to reintensification of therapy with standard agents.  
 
1.2.4.  Fully Ablative Conditioning with Hematopoietic Cell Transplant and HLH  
 
For patients with refractory or inherited HLH, HCT is the only curative therapy  currently 
available .  In the HLH -94 protocol, consisting primarily of matched related and matched 
unrelated donors, 3 -year survival was 64%  (Horne et al., 2005) .  A retrospective evaluation of 
HLH patients undergoing HCT with unrelated matched do nors through the National Marrow 
Donor Program  (Baker et al., 2008)  and a single -institution study from Necker Hospital which 
included many haploidentical donors  (Ouachee -Chardin et al., 2006)  both reported similar 
outcomes with long -term survival for patients receiving ablative co nditioning for HLH at  ~55%.  
Most of the patients in these reports treated with ablative conditioning received busulfan, 
cytoxan and etoposide with  or without ATG.  A significant finding in all of these studies is  a 
very high rate of TRM  > 30%  (Baker e t al., 2008; Horne et al., 2005; Ouachee -Chardin et al., 
2006) .  Causes of death were multifactoral, including infection, veno -occlusive disease, 
hemorrhage, and multi -system organ failure.  Primary graft failure was reported in 9 -22%.  
Ouachee -Chardin et al . attributed 50% of the TRM to r eactivation of HLH, and Horne et al. 
correlated active disease at the time of transplant with primary graft failure.   These poor Day 
+100 outcomes with standard myeloablative conditioning reg imens highlight the need for an 
alternative approach to transplan tation for these patients, many of whom come to transplant with 
pre-existing organ dysfunction, infection and persistent pathologic inflammation.  
 
1.2.5.  Reduced Intensity Conditioning Hematopoietic Cell Transplantation for HLH   
 
Several recent series have demonstrated decreased TRM and improved overall survival with 
reduced -intensity conditioning strategies that include alemtuzumab  (Cooper et al., 2006; Cooper 
et al., 2008; Marsh et al., 2010) . In the long -term, protection from HLH reactivation requires 
stable donor chimerism greater than 10 -20% (Ouachee -Chardin et al., 2006) , and donor T cells 
alone may be sufficient to protect against HLH reactivation  (Cooper et al., 2008) .  The immune 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-5 deficiencies described below  require similar levels of chimerism for disease correction.  In a 
single -institution study, survival for HLH patients receiving RIC was significantly superior to 
survival for patients receiving myeloablative conditioning (92% vs . 43%)  (Marsh et al., 2010) .  
There were no deaths before Day  +100 in the RIC group.  However, while survival was 
significantly improved, patients undergoing RIC HCT in this series had extremely high rates of 
post transplantation mixed chimerism (65%).  Other series also report high rates of mixed 
chimerism in patients treated wit h alemtuzumab -based RIC for HLH  (Cooper et al., 2008) .   
 
1.2.6.  Optimizing RIC HCT for HLH  Syndromes  
 
The improved survival reported for RIC strategies for HCT for HLH may be due to decreased 
toxicity of fludarabine/melphalan compared to myeloablative busulf an/cyclophosphamide.  
Additionally, it is possible that alemtuzumab -mediated depletion of T cells and antigen -
presenting cells ameliorates inflammation prior to transplant.  Investigators from Cincinnati 
Children’s Hospital reported that the timing of alem tuzumab administration appeared to 
influence sustained engraftment  with 65% of patients having mixed chimerism : 29% of patients 
who received “distal” alemtuzumab (start ing Day -22) and 79% of patients who received 
“proximal” alemtuzumab (start day range -12 to -8).  Most of the patients with mixed chimerism 
in this study ultimately received lymphocyte infusion or second stem cell infusion.  
Alemtuzumab persists at cytotoxic levels in patients following RIC for up to 60 days  (Morris et 
al., 2003) , with an estimated half -life of 15-21 days  (Rebello et al., 2001) .  While a RIC 
approach for HLH appears to be  effective, the optimal dose and timing of alemtuzumab and 
other therapeutic agents used in conditioning to achieve maximum survival with improved 
engraftment remains to be defined.    
 
Recent data from Cincinnati Children’s Hospital suggests that intermediate timing ( starting Day  
-14) of alemtuzumab significantly improved engraftment rates (8 7% Day +100 stable 
engraftment without donor lymphocyte infusion ( DLI)) while maintaining improved  overall 
surviv al (90% at one year).  The cumulative incidence of mixed chimerism was also significantly 
better in the Intermediate RIC (31%) compared to patients who received “proximal” 
alemtuzumab (72%)  (Marsh et al., 2013b) . 
 
1.2.7.  HLH -Related Syndrome:  Chronic Active EBV Disease  
 
While over 90% of the adult population is infected  with EBV, rare individuals develop a life -
threatening condition of chronic active EBV disease (CAEBV) , characterized by highly elevated 
EBV levels in blood and tissue and often associated with hemophagocytic syndrome .  EBV 
typically infects B cells and CAEBV may arise as a B -cell lymphoproliferation .  However, in 
most cases of CAEBV in Asians or Native Americans, very high levels of EBV are detected in T 
or NK cells (Reviewed in (Cohen et al., 2011) ).   
 
1.2.8.  Diagnosis of CAEBV  
 
CAEBV is defined as prolonged systemic symptoms of inflammation associated with 
uncontrolled EBV infection of B, T or NK cells.  Unlike post -transplant lym phoproliferative 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-6 disorder, CAEB V arises in people without known immune dysfunction or iatrogenic immune 
suppression.  Clinical Definition of CAEBV  requires all of the following  (Cohen et al., 2011) :  
1. Severe progressive illne ss of > 6 months duration, usually with fever, lymphadenopathy 
and splenomegaly that either began as primary EBV infection or was associated with 
markedly elevated antibody titers to EBV viral capsid antibody (≥ 1:5120) or early 
antigen (≥ 1:640), or marke dly elevated EBV DNA in the blood;  
2. Infiltration of tissues (e.g., lymph nodes, liver, lungs, CNS, bone marrow, eye, skin) with 
lymphocytes;  
3. Elevated EBV DNA, RNA or proteins in affected tissues; and,  
4. The absence of any other immunosuppressive condition.  
 
1.2.9.  CAEBV and HCT  
 
CAEBV is infrequently reported in North America.  In a 28 -year series at the NIH and Baylor 
College of Medicine, 19 patients with EBV were evaluated.  In this North American cohort, 
immunosuppressive agents, rituximab, autologous cytotoxic T cells, cytotoxic chemotherapy or 
autologous HCT achieved only short -term responses.  The only cures were achieved with 
allogeneic HCT, with 5/8 alive 2 -11 years after transplantation, including 2 of 3 who underwent 
subablative HCT (Cohen et al., 2011) .  From 57 othe r cases of CAEBV who underwent HCT 
reported in the literature, overall survival was 72%.  Factors associated with survival from these 
cases include younger age (14.4 years vs . 21.2 years), shorter time to transplant from onset of 
disease (3.5 years vs . 6.5 years), and non -myeloablative conditioning (69% vs . 38%) (Cohen et 
al., 2011) . 
 
1.3. Selected Primary Immune Deficiencies  
 
HLH is caused by defects in effector immune function resulting in uncontro lled immune 
activation and pathologic inflammation.  Defects in other regu latory pathways also cause 
diseases due to dysfunctional immune mechanisms , including chronic granulomatous disease, 
hyper IgM syndrome, IPEX syndrome, and leukocyte adhesion deficie ncy.  HCT corrects defects 
in all of these primary immune deficiencies and sustained partial chimerism may be sufficient for 
cure.   HCT with myeloablative conditioning is associated with high rates of TRM in these 
patients due to pre -existing infections an d organ dysfunction in many patients at the time of 
transplant  (Filipovich, 2008) . 
 
1.3.1.  Chronic Granulomatous Disease  
 
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by ineffective 
function of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, resulting in 
impaired microbicidal activity of reactive oxygen in neutrophils, macrophages and eosinophils.  
Patients with NADPH oxidase  deficiency are susceptible to recurrent, life -threatening  infections 
by bacteria and fungi ( reviewed in (Kang et al., 2011; Seger, 2010b) ).  CGD is a heterogeneous 
disease with significant phenotypic variability.  The production of residual oxygen intermediates 
(ROIs) is determined  by the specific NADPH mutation, and is a predictor of sur vival in patients 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-7 with CGD  (Kuhns et al., 2010) .  However, even among patients with similar NADPH muta tions, 
there is variability in clinical outcomes.  Therefore, the specific genetic defect, the patient’s 
infection history, the presence of active inflammation or infection and other co -morbidities are 
important clinical variables  in risk/benefit considera tions for different therapeutic options .  
 
1.3.1.1.  Diagnosis of CGD  
 
CGD is diagnosed by clinical history of recurrent infections, classically including 
Staphylococcus aureus (lymphadenitis, liver abscess), Burkhoderia  (necrotizing pneumonia, 
sepsis), Serratia ma rcescens  (sepsis, skin ulcers, osteomyelitis), Nocardia  and Aspergillus  spp. 
(pneumonia, brain, bone infections), Actinomyces  spp. (cervicofacial, pulmonary or abdominal 
infections), Granulibacter bethesdensis  (lymphadenitis), Mycobacterium tuberculosis  
(pulmonary and extrapulmonary infections), and Leishmania infantum  (intracellular protozoal 
infection) (Reviewed in (Seger, 2010a) ).  Front -line diagnostic tests are based  on measurement 
of phagocyte NADP H oxidase (Phox) activity.  The flow -cytometry -based dihydrorhodamine -
1,2,3 (DHR) test measures the ability of stimulated phagocytes to oxidize DHR interacellularly, 
and is a  sensitive  screening study  (Vowells et al., 1995) .  Definitive  diagnosis is made by 
protein - or DNA -based study of the five Phox components: gp91phox (X-linked) , p47phox, p67phox, 
p22phox and p40phox (Rada and Leto, 2008) . 
 
1.3.1.2.  HCT  for CGD  
 
While survival has improved with the use of prophylactic antimicrobials and earlier diagnosis, 
the only cure for CGD currently available is allogeneic hematopoietic cell transplantation.   To 
date, fewer than 200  transplants  have been reported, with most data as case reports.  A survey of 
European centers (n=27 patients) reported 85% survival with myeloablative conditioning and 
primarily matched -sibling donors  (Seger et al., 2002) .  Two series  including  matched unrelated 
donor  (MUD ) transplants for CGD (n= 19) with ablative conditioning reported cumulative 84% 
survival  (Schuetz et al., 2009; Soncini et al., 2009) . Reduced intensity conditioning strategies for 
HCT  in CGD are feasible.  One study from the NIH reported 70% survival (n=10 patients) with 
allogeneic matched related donor ( MRD ) transplants with non -myeloablative condition ing 
(cyclophosphamide/fludarabine/ATG) (Horwitz et al., 2001) .  Similarly , a European consortium 
reported successful  MRD/MUD transplant s with non-myeloablative busulfan - and fludarabine -
based  conditioning regimen with ATG , with durable engraftment, survival to 1 year, and 
normalized superoxide production in all three patients  (Gungor et al., 2005) .  A CIBMTR survey 
(through 2009) found 59 patients who ha d undergone allogeneic transplant for CGD with 71% 
overall survival  (Seger, 2010b) .  In CGD, patients with stable mixed chimerism recover 
neutrophil Phox function  (Martinez et al., 2012; Ho rwitz et al., 2001) .  To date, the limited data 
available make it difficult to determine what the most optimal conditioning regimen is for this 
disease, however, a  reduced -intensity conditioning transp lant strategy is particularly attractive in 
CGD, where many patients have significant co -morbidities including severe infections at the 
time of transplant.  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-8 1.3.2.  Hyperimmunoglobulin M Syndrome  
 
Hyper -IgM syndrome includes a heterogeneous group of conditions c haracterized by defects in 
class -switch recombination (CSR).  As a result, serum IgM accumulates with reduced or absent 
levels of IgG, IgA and IgE.  The most common genetic form of hyper -IgM syndrome , HIGM1,  is 
caused by defects in the gene encoding CD40 l igand (CD40L)  on the X chromosome .  In 
addition to defective humoral immunity and lack of germinal centers in peripheral lymphoid 
tissue, patients with hyper -IgM may also have neutropenia, anemia, impaired delayed -type 
hypersensitivity  reactions to recall antigens, and decreased T cell proliferation in vitro  
(Reviewed in (Davies a nd Thrasher, 2010) ).  More than 50% of boys with HIGM1  develop 
symptoms by one year, and more than 90% are symptomatic by four years  (Winkelstein et al., 
2003) .  Symptoms include recurrent respiratory tract bacterial infections, opportunistic 
infections, chronic diarrhea, neutropenia, thrombocytopen ia and anemia.  Opportunistic 
infections from Pneumocystis  jeroveci  and Cryptosporidium parvum  are also common  (Lee et 
al., 2005) .  The median survival of patients with HIGM1 without HCT  is less tha n 25 years  
(Levy et al., 1997; Winkelstein et al., 2003) . 
 
1.3.2.1.  Diagnosis of HIGM1  
 
HIGM1  should be considered in boys with recurrent bacterial and opportunistic infections.  Lab 
criteria include decreased serum IgG (2 or more SD below normal for age) with a mutation in 
CD40LG  or a family history of maternally related males with HIGM1 [ESID Working Party 
2005 : http://www.esid.o rg/workingparty.php?party=3&sub=2&id=73#Q16 ]. 
 
1.3.2.2.  HCT  for HIGM1  
 
Allogeneic HCT  is the only curative treatment currently available for HIGM1.  The largest 
published case series is a European survey which reported HCT  for 38 patients, with 68% long -
term survi val and immune reconstitution  with cure in 58%.   Pre-existing lung disease correlated 
with poor outcome and all deaths in this series were associated with infection (Gennery et al., 
2004) .  Outco mes for MRD and MUD were not statistically different.  There were some patients 
conditioned with non -ablative strategies but too few to analyze separately  (Gennery et al., 2004) .  
However, the cases included in the survey by Gennery et al. as well as other case series  support 
feasibility of reduced -intensity conditioning strategies  (Kikuta et al., 2006; Jasinska et al., 2013; 
Gennery et al., 2004) .  The co -morbidi ties of this population prior to transplant and associated 
risks of TRM also support investigation of a RIC approach in patients with  HIGM1.  
 
1.3.3.  IPEX Syndrome  
 
IPEX refers to immune dysregulation, polyendo crinopathy, enteropathy, and X-linked 
inheritance.  The syndrome is a rare X -linked disorder that typically presents with a triad of 
enteropathy, autoimmune polyendocrinopathy and dermatitis  (Powell et al., 1982) .  Most patients 
present with the characteristic constellation of symptoms in early infancy.  IPEX  is caused by 
defects in the inhibitory reg ulatory helper T cells (Tregs) due to dysfunctional or absent FOXP3 
transcription factor  (Wildin et al., 2001; Chatila et al., 2000) .  Disease manifestations are due to 
immune dysregulation from absent or dysfunctional Tregs .  Disease -causing mutations in FoxP3  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-9 have been described in each of the main coding regions of the gene, as well as in some non-
coding regions  (Campbell and Ziegler, 2007) .    
 
1.3.3.1.  Diagnosis of IPEX Syndrome  
 
IPEX should be considered in male infants with chronic diarrhea, failure to thrive and/or onset  of 
type 1 diabetes in infancy.  The other clinical manifestation s discussed above are also supportive.  
Definitive diagnosis is established by absent or functionally defective FOXP3+ CD4+ T cells or 
by mutational analysis of FoxP3  (Hannibal and Torgerson, 1993) .     
 
1.3.3.2.  HCT  for IPEX Syndrome  
 
HCT  is the only curative therapy for IPEX  currently available .  Infections and co -morbidities are 
common in patients at the start of transp lant.  Literature is limited to case reports, including 
examples demonstrating feasibility of reduced intensity conditioning strategies  and resolution of 
disease symptoms even with mixed chimerism (Burroughs et al., 2010; Dorsey et al., 2009; Rao 
et al., 2007; Seidel et al., 2009; Zhan et al., 2008) . 
 
1.3.4.  Leukocyte Adhesion Deficiency  
 
Leukocyte adhesion deficiency  is a primary immune disorder caused by defects in migration of  
immune cells.  It typically presents in infancy with delayed umbilical cord separation with 
omphalitis, deep tissue infections , impaired pus formation, and poor wound healing.  LAD -I is an 
autosomal recessive disorder caused by mutations in the common chain (CD18) of the  -
integrin family, resulting in deficiency of 3 integrins with functions in leukocyte function: 
lymphocyte function associated antigen -1 (LFA -1, CD11a/CD18), Mac -1 (CD11b/CD1 8), and 
gp 150/95 (CD11c/CD18) (Reviewed in (Etzioni, 2010) ).  The severity of LAD -I is related to the 
degree of CD18 deficiency: severe deficiency is observed in patients with less than 2% of normal 
surface expression of CD18; mild to moderate deficiency is observed in patients with greate r 
than 2 -30% of normal surface expression of CD18  (Fischer et al., 1988) .  Clinical management 
of LAD -I depends on clinical severity .  Mild to moderate disease can usually be managed with 
antibiotic  therapy while this is generally inadequate  for patients with severe disease  (Etzioni, 
2010) . 
 
1.3.4.1.  Diagnosis of LAD -I 
 
Definitive diagnosis of s evere LAD -I can be made  in male or female patients with decreased 
intensity of expre ssion of CD18 on neutrophils (<  5% of normal for age) with mutation of the 2 
integrin gene and/or absence of 2 integrin mRNA in leukocytes  (Conley et al., 1999) . 
 
1.3.4.2.  HCT  for LAD -I 
 
HCT  is the only curative therapy for patients with severe LAD -I currently available .  The largest 
published series reported 36 children who underwent HSC transplant with 75% overall survival  
(Qasim et al., 2009) .  Reduced -intensity conditioning was used in 8 patients, with no deaths in 
this sub -group, and mixed -donor chimerism was suffici ent to correct the symptoms of LAD.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
1-10  
1.4. Summary  
 
HLH , HLH -related disorders , CGD, H IGM1, IPEX and severe LAD -I represent primary immune 
disorders that are typically fatal without HCT .  However, transplant is often complicated by 
inflammation, infection and other co -morbidities.  In addition, these disorders have been shown 
to be cured with  partial chimerism, making them an ideal target for the use of reduced intensity 
approaches, where a portion of patients may not achieve full donor chimerism, but instead 
achieve stable mixed chimerism.  Reduced -intensity conditioning strategies have demon strated 
improved survival with decreased TRM in institutional series for patients with HLH  (Cooper et 
al., 2006; Marsh et al., 2010; Marsh et al., 2011) .  However, graft loss and unstable chimerism 
remain challenges.  An ins titutional case series from Cincinnati Children’s Hospital 
demonstrate d full or high -level chimerism and improved durable engraftment using intermediate 
(Day -14) timing alemtuzumab  (Marsh et al., 2013b) .  This study aims to test the efficacy of the 
Intermediate RIC strategy in a prospective multi -center study including HLH as well as other 
primary immunodeficiencies where allogeneic transplant with RIC has been shown to be feasible 
and stable  chimerism is curative.  
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-1 CHAPTER 2  
 
 
2. STUDY DESIGN  
 
2.1. Study Overview  
 
The primary goal of this Phase II clinical trial is to determine the one -year overall survival of 
patients treated for immune deficiencies including HLH , HLH -like disorders , CGD, HIGM1, 
IPEX syndrome, and severe LAD -I with MRD /MUD bone marrow transplant using a reduced -
intensity conditioning strategy including intermediate -timing of alemtuzumab .  The patient’s 
donor must be willing  and able  to give bone marrow stem cells and be:  
• An unaffected sibling donor who is a 6/6 match at  HLA -A and –B (intermediate or higher 
resolution) and –DRB1 (at high resolution using DNA -based typing) OR 
• An unaffected  related donor (other than  a sibling) who is a 7/8 or 8/8 match for HLA -A,  
-B, -C (at intermediate or higher  resolution ) and –DRB1 (at high resolution  using DNA -
based typing ) OR 
• An unrelated donor who is a 7/8 or 8/8 match at HLA -A, -B, -C, and –DRB1 (at high 
resolution using DNA -based typing).  
 
The transplant conditioning regimen will include fludarabine, melphalan , and alemtuzumab  
starting at Day -14 (Flu/Mel/Alem) .  GVHD prophylaxis will consist of cyclosporine and 
corticosteroids through engraftment.  Post -transplant supportive care will include infection 
surveillance and prophylaxis, and disease -specific supportive care.  
 
2.2. Hypothesis and Study Objectives  
 
2.2.1.  Primary Hypothesis  
 
Allogeneic HCT with MRD/MUD  using  RIC conditioning ( fludarabine, melphalan ) and 
intermediate timing of alemtuzumab (Day -14) in patients with hemophagocytic syndromes or 
selected primary immune deficiencies including CGD, HIGM1, IPEX syndrome, and severe 
LAD -I will result in  a one year overall survival rate of  90%.   
 
2.2.2.  Primary Objective  
 
To prospectively determine  the one year overall survival  in subjects treated for hemophagocytic 
syndromes  or selected primary immune deficiencies (CGD, HIGM1, IPEX, and severe LAD -I) 
using  a standardized, reduced -intensity conditioning protocol consisting of fludarabine, 
melphalan and intermediate timing of alemtuzumab (Day -14).  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-2 2.2.3.  Secondary Objecti ves 
 
Secondary objectives are to determine the impact of HCT on clinical and laboratory 
manifestations of hemophagocytic syndromes and selected primary immune deficiencies  and the 
incidence of HCT complications.  Secondary clinical outcomes to be collected  include:  
1. Rates of sustained engraftment: Donor engraftment >  5% (unfractionated blood and T 
cells) at one year without infusion of stem cell products after the original transplant.  
Incidence and timing of primary graft failure  (< 5% donor cells by Day  +42) , infusion of 
second stem cell product, or graft loss (<  5% donor cells  at any time from initial 
engraft ment through Day  +365 ), all of which are considered failures of sustained 
engraftment, will be analyzed.  
2. Incidence  of HLH and CAEBV reactivation  and death from disease.  
3. Immune reconstitution and functional immune recovery.  
4. The cumulative incidence of neutr ophil and platelet engraftment.  
5. The cumulative incidence of grade II -IV and III -IV acute GVHD and chronic GVHD . 
6. Transplant -related complications including hepatic veno -occlusive disease (VOD) and 
CNS toxicity.  
7. Rates of reactivation of CMV and EBV and infection with adenovirus, invasive fungal 
infection, or bacterial sepsis.  Prospective collection of peripheral blood at specific time -
points, in order to study pharmacokinetics of alemtuzumab, engraftment, and immune 
reconstitution with clinical correlati on in a companion biology study.  
8. Overall survival and rate of sustained engraftment at one year of specific disease subsets 
(HLH -related diseases and selected immune deficiencies).  
 
2.3. Patient Eligibility  
 
2.3.1.  Patient Inclusion Criteria  
1. Patient is ≥ 3 months and ≤ 45 years of age at time of enrollment.  
2. Meets criteria for one of the following immune disorders  (2A-2F) requiring HCT:  
2A.  HLH or related disorder with indication for HCT :  
a. Inherited gene mutation associated with HLH: PRF1 , UNC13D  (MUNC13 -2), 
STXBP2 ( MUNC18 -2), STX11 , RAB27A  (Griscelli syndrome, type 2), SH2D1A  
(XLP1), XIAP  (XLP2), LYST  (Chediak -Higashi syndrome).   
– OR – 
b. Meets clinical criteria for HLH (Table 1 .2), refractory to therapy according to HLH -
94 or HLH -2004 (dexamethasone/etoposide), or recurrent episodes of hyper -
inflammation.    
– OR – 
c. Meets clinical criteria for HLH (Table 1 .2), without identified gene defects, with 
affected sibling  – OR – decreased or absent NK cell function  at the last evaluation ,  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-3 – OR – a history of CNS inflammation as evidenced by pleocytosis in CSF or MRI 
evidence of hyper -inflammation in the CNS.  
2B. CAEBV: Patients with chronic EBV infection (CAEBV) with or without associated 
lymphoma (in complete remission) or active HLH.  No te that this diagnosis is distinct 
from post -transplant lymphoproliferative disorder/ EBV -associated 
lymp hoproliferative disease (PTLD/LPD).  Patients must meet all of the following:  
a. Severe progressive illness, usually with fever, lymphadenopathy and splen omegaly 
that either began as primary EBV infection or was associated with markedly elevated 
antibody titers to EBV viral capsid antibody (≥ 1:5120) or early antigen (≥ 1:640), or 
markedly elevated EBV DNA in the blood;  
– AND – 
b. Infiltration of tissues (e.g., lymph nodes, liver, lungs, CNS, bone marrow, eye, skin) 
with lymphocytes;  
– AND – 
c. Elevated EBV DNA, RNA or proteins in affected tissues;  
– AND – 
d. The absence of HIV or post -transplant lymphoprolifer ative disorder.  
2C. Chronic granulomatous disease with indication for HCT:  
a. Oxidative burst <  10% normal with dihydrorhodamine ( DHR ) assay   
– AND –  
b. Documented CGD mutation(s)  in gp91phox , p47phox, p67phox, p22phox or p40phox   
– AND –  
c. Severe disease as evidenced by  one or more of the following:  
i. history  of one or more potentially life -threatening  infection s 
ii. inflammatory bowel disease  
iii. failure to thrive  with height <10% for age (unless parent(s) height <10%)   
iv. autoimmune compli cation felt to be linked to CGD  
2D. X-linked Hyper IgM Syndrome (HIGM1):  
a. Decreased serum IgG (more than 2 standard deviations below normal for age)  
– AND –  
b. Mutation in CD40LG – OR – family history of maternally related males with HIGM1.  
2E. IPEX Syndrome : 
a. Absent FOXP3+ CD4+ T cells – OR – abnormal function of  FOXP3+CD4+ T cells   
– AND  – 
b. Disease -associated mutation in FoxP3 (bi-allelic in females)  – OR – family history of 
maternally related males with clinical diagnosis of IPEX.  
2F. Severe Leukocyte Adhesion Deficiency, type I ( LAD -I): 
a. Decreased CD18 expression on neutrophils (<5% normal for age)  
– AND  – 
b. Mutation of ITGB2  – OR – absence of ITGB2  mRNA in leukocytes  
3. Lansky or Karnofsky performance status ≥ 50%. 
4. The patient’s donor must be willing and able to give bone marrow stem cells and be:  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-4 • An unaffected sibling donor who is a 6/6 match at HLA -A and –B (intermediate or 
higher resolution) and –DRB1 (at high resolution using DNA -based typing) OR 
• An unaffected related donor (other than sibling) who is a 7/8 or 8/8 match for HLA -
A, -B, -C (at intermediate or higher resolution) and –DRB1 (at high resolution using 
DNA -based typing) OR 
• An unrelated donor who is a 7/8 or 8/8 match at HLA -A, -B, -C, and –DRB1 (at high 
resolution using DNA -based typing).  
5. Patient must have adequate organ function as measured by:  
a. Cardiac: Left ventricular ejection fraction (LVEF)  > 40%; or LV shortening fraction 
(LVSF)  > 26% by echocardiogram.  
b. Renal: Calculated  or radioisotope GFR  > 50 mL/min/1.73m2 
c. Hepatic: Adequate liver function: s erum conjugated (direct) bilirubin < 2 x upper limit 
of normal for age as per local laboratory  (with the exceptions of isolated 
hyperbilirubinemia due to Gilbert’s syndr ome, or hyperbilirubinemia as the result of 
liver inflammation in the setting of persistent, active  HLH) ; ALT and AST < 10x 
upper limit of normal as per local laboratory  (with the exception of elevated 
transaminase levels as the result of liver inflammatio n in the setting of persistent, 
active  HLH) .   
d. Pulmonary: Patient may not be on mechanical ventilation support or have progressive 
pulmonary infection at the time of transplant ; Pulmonary Function Testing (PFT) 
with FEV1 > 50% of normal  and DLCO corrected for Hgb >  50% of normal.  Patients 
unable to undergo PFTs should have stable respiratory status  with SaO2  > 90% on a 
maximum of 2L/min supplemental oxygen.  
6. Signed informed con sent. 
 
2.3.2.  Patient Exclusion Criteria  
1. Hematopoietic  stem cell transplant within 6 months of enrollment.  
2. Uncontrolled bacterial, viral or fungal infection (currently receiving appropriate 
antimicrobials  and experiencing  progression or no clinical improve ment)  at time of 
enrollment .  We recognize that patients with CAEBV may have ongoing EBV viremia at 
the time of initiating transplant therapy, but other patients should have no uncontrolled 
bacterial, viral or fungal infections at the time of enrollment  (or prior to initiating the 
preparative regimen) .  
3. Pregnant or breastfeeding . 
4. Seropositive for h uman immunodeficiency virus (HIV) . 
5. Alemtuzumab within 2 weeks of enrollment.  
6. History of prior or current malignancy, especially malignancies with a likelihood of 
relapse and progression, with the exception of (1) EBV -associated lymphomas related to 
immune deficiency or lymphomas associated with X -linked LPD in a good remission, as 
they are unlikely to relapse after treatment; (2) Resected basal cell carcinoma or treated 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-5 cervical carcinoma in situ. Cancer treated with curative intent will not be allowed unless 
approved by the Protocol Officer or one of the Protocol Chairs.  
 
2.3.3.  Donor Sel ection Criteria  
1. Related donors will be identified according to institutional guidelines . 
2. HLA typing of a sibling  donor must be  a 6/6 match for HLA –A and –B (intermediate or 
higher  resolution ) and –DRB1 (at high resolution using DNA -based typing ). 
3. HLA typing of a related donor other than a sibling must be a 7/8 or 8/8 match for HLA -
A, -B, -C (at intermediate or higher resolution) and –DRB1 (at high resolution using 
DNA -based typing).   
4. Unrelated donors will be identified through the National Marrow Donor  Program 
(NMDP)  or equivalent donor search organization . 
5. HLA typing of an unrelated donor must be  a 7/8 or 8/8 match for HLA –A, –B, –C and 
DRB –1 (at high resolution using DNA -based typing ). 
6. Donors must be willing and able to donate bone marrow stem cells.  
7. For HLH  or related disorders : If donor is a relative of a recipient with known HLH -
associated gene mutations , the donor must not have  the same HLH -causing gene 
mutations as the recipient  (a sibling with a heterozygous mutation of an autosomal 
recess ive HLH -associated gene would be acceptable , as would a female sibling or other 
female relative who is a carrier of an X -linked HLH -associated gene mutation ). If donor 
is a relative of a recipient with unknown genetic cause of HLH, the donor must not have 
medical history concerning for HLH  or laboratory values suggestive of significant 
immune dysfunction (for example, highly elevated ferritin or  absent NK cell function ). 
8. For CGD, HIGM1, IPEX Syndrome, and LAD -I: If donor is a sibling, the donor must no t 
meet diagnostic criteria for the immune deficiency for which the patient is receiving 
HCT.  
9. A donor who is EBV IgG positive is recommended for recipients with history of EBV 
exposure, and strongly recommended for patients with CAEBV.  Similarly, a donor w ho 
is CMV IgG positive is recommended for recipients with history of CMV exposure.  
 
2.3.4.  Donor Exclusion Criteria  
1. Donors will be excluded if they are an identical twin of the recipient.  
2. Females who are pregnant (positive serum β -HCG) or uninterrupt edly breastfeeding will 
be excluded.  
3. HIV seropositive donors will be excluded.  
4. Donors receiving experimental therapy or investigational agents will be excluded unless 
approved by the protocol chairs and protocol officer.  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-6 2.4. Treatment Plan  
 
If an infection occurs  or a pre -existing infection worsens between the day of enrollment and the 
day the  preparative  regimen is scheduled to begin, the infection must be controlled and the 
patient clinically improved prior to initiating the preparative regimen. We recognize tha t patients 
with CAEBV may have ongoing EBV viremia at the time of initiating pre-transplant therapy, but 
other patients should have no uncontrolled bacterial, viral or fungal infections at the time of 
initiation of the transplant preparative regimen.  
 
Patients will receive Intermediate RIC  with Flu/Mel/Alem  (Table 2.4). The experimental design 
is outlined in Figure 2.4.  
 
 
 
Figure 2.4: Trial Design  
 
 
TABLE 2. 4: Flu/Mel/Alem( -14) 
Day Treatment  
(adults and children > 15kg)  Treatment  
(children 10 to 15 kg) Treatment  
(children < 10 kg)  
-14 Alemtuzumab * 3mg  test dose  Alemtuzumab 0.2 mg/kg  Alemtuzumab 0.2 mg/kg  
-13 Alemtuzumab *  (max 21.75 mg)  Alemtuzumab 0.2 mg/kg  Alemtuzumab 0.2 mg/kg  
-12 Alemtuzumab *  (max 21.75 mg)  Alemtuzumab 0.2 mg/kg  Alemtuzumab 0.2 mg/kg  
-11 Alemtuzumab *  (max 21.75 mg)  Alemtuzumab 0.2 mg/kg  Alemtuzumab 0.2 mg/kg  
-10 Alemtuzumab *  (max 21.75 mg)  Alemtuzumab 0.2 mg/kg  Alemtuzumab 0.2 mg/kg  
-9 Rest Rest Rest 
-8 Fludarabine 30 mg/m2 Fludarabine 30 mg/m2 Fludarabine 1 mg/kg   
-7 Fludarabine 30 mg/m2 Fludarabine 30 mg/m2 Fludarabine 1 mg/kg  
-6 Fludarabine 30 mg/m2 Fludarabine 30 mg/m2 Fludarabine 1 mg/kg  
-5 Fludarabine 30 mg/m2 Fludarabine 30 mg/m2 Fludarabine 1 mg/kg  
-4 Fludarabine 30 mg/m2 Fludarabine 30 mg/m2 Fludarabine 1 mg/kg  
-3 Melphalan 140 mg/m2 Melphalan 140 mg/m2 Melphalan 4.7 mg/kg  
-2 Rest Rest Rest 
-1 Rest Rest Rest 
0 Stem cell infusion  Stem cell infusion  Stem cell infusion  
 Alemtuzumab dose is 1 mg/kg for the entire treatment course (including the test dose on Day -14) in adults 
and children > 15 kg.  
 Calculation for Alemtuzumab daily dose for Day -13, Day -12, Day -11, Day -10 for a patient 15kg -90kg:  
((1mg/kg x (patient weight in kg)) – 3mg)/4  
 The maximum cumulative Alemtuzumab dose for any patient is 90 mg, making the maximum daily dose of 
Alemtuzumab from Day -13 to Day -10, 21.75 mg = (90mg – 3mg)/4  

BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-7 2.4.1.  Alemtuzumab (Ca mpath-1H) 
 
If a patient cannot receive the complete dose  due to  intolerance , the choice of conditioning 
regimen  modifications (if any)  will be left to the institution; however, the patient will be 
followed per protocol.  
 
For information about the Campath Distribution Program and how to procure Campath, please 
visit th e following website: http://www.campath.com/index.html  
 
2.4.1.1.  Premedication  
 
Premedication should be commenced 30 minutes prior to each infusion of alemtuzumab, 
including the first dose,  and should be continued as needed for at least 48 hours after the last 
dose of alemtuzumab.  
 
Recommended pre -medication includes the following combination of medications:  
Acetaminophen : 15 mg/kg PO pre -therapy, then as needed every 6 hours for signs of 
allergic reaction (maximum 4 gram s per day) 
Diphenhydramine : 1 mg/kg IV or PO pre -medication, then every 6 hours as needed for 
signs of allergic reaction (maximum 50 mg/dose)  
Meperidine : 0.5 mg/kg IV every 6 hours as needed for rigors  
Hydrocortisone : 1 mg/kg IV pre -medicati on, then 1-2 mg/kg IV as needed for signs of 
allergic reaction . For patients on scheduled corticosteroids for control of HLH, 
dexamethasone or methylprednisolone may substitute for hydrocortisone.  
 
2.4.1.2.  Alemtuzumab administration  
 
First day:  test dose : 
Day -14:  The first day children ≤  15kg will receive a dose of 0.2  mg/kg subcutaneously.  
Children or adults >  15 kg will receive a maximum of 3  mg subcutaneously.   Subcutaneous route 
of administration for alemtuzumab is required on this protocol.  
 
If the firs t dose is not tolerated:  
If the patient has a severe , life-threatening or fatal adverse reaction to alemtuzumab (e.g., severe 
hypotension, severe bronchospasm) , the adverse event meets the expedited reporting 
requirements (within 24 hours  for life -threatening  or fatal events or within 3 days for severe 
events ) through the expedited AE  reporting system via Advantage EDCSM (see Section 4.2.2 ).   
 
If the first dose is tolerated:  
Alemtuzumab will be given  subcutaneously  each day  for the next four days ( -13 to -10).  The 
total dose will be 1  mg/kg with a maximum cumulative dose of 90  mg.  For children ≤ 15 kg, the 
dose will be 0.2  mg/kg each day.  For children or adults >  15kg the dose will be the total dose 
(1mg/kg) minus the 3  mg test dose divi ded evenly over the four days.  For example , if the 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-8 patient weighs 40  kg, the y will receive 3  mg on Day -14 and 40  mg (total dose) – 3 mg (test 
dose) = 37  mg/4 daily doses or 9.25  mg daily Day -13 to Day -10. (Table2.4)  
 
Day -13 to Day -10: (total dose (1 mg/kg) – test dose  (3 mg))/4 mg  given daily  subcutaneous ly 
(max cumulative dose: 90 mg, max daily dose (90  mg – 3 mg)/4 or 21.75  mg for any patient ≥  
90kg) . (Table 2.4)  
 
Alemtuzumab dilution guidelines:   For ≤ 3 mg, drug is diluted to 3 mg/mL concentrat ion. For 
doses > 3 mg undiluted 30 mg/mL concentration is used.  
 
2.4.2.  Fludarabine  
 
Fludarabine will be administered IV, on Day -8 to Day -4 (for a total of 5 days) given over a 
minimum of 30 minutes daily.  (Table 2.4) The infusion can take longer per institutional 
guidelines.  
 
 For patients ≥ 10kg, Dose :  30 mg/m2/day IV (cumulative dos e 150 mg/ m2) 
For children < 10kg, Dose:  1 mg/kg/day IV (cumulative dose 5 mg/kg)  
 
Preparation, administration and monitoring will be according to institutional standard practice.  
 
Dose Adjustment of Fludarabine  for Patients Whose Weight Exceeds > 125% IBW  
Fludarabine will be dosed based on actual weight for patients ≤ 125% IBW. Those > 125% IBW 
will be dosed based upon adjusted ideal body weight as follows:  
 
Adjusted ideal body weight = IBW + 0.25(Actual weight – IBW)  
 
The following formulas for pediatric and adult IBW calculations are recommended, but IBW 
may be calculated according to institutional SOPs.  
 
Recommended Ideal Body Weight Calculation for Children Age 1 -17 years  
IBW = (Height (cm)2 x 1.65)/1000  
 
Recommended Ideal Body Weight Calculation for Adults  
IBW (females) = (cm ÷ 2.54 – 60) x 2.3 kg + 45.5 kg  
IBW (males) = (cm ÷ 2.54 – 60) x 2.3 kg + 50 kg  
 
2.4.3.  Melphalan  
 
Melphalan will be given IV on Day -3 (Table 2.4). It is recommended to be given  over a 
minimum of 30 minutes ; however , the infusion can be shorter or longer per institutional 
guidelines.  
 
 For patients ≥ 10kg, Dose :  140 mg/m2 IV 
 For children < 10 kg, Dose:   4.7 mg/kg IV  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-9 2.4.4.  Infusion of Hematopoietic Stem Cells  
 
Under no circumstances is the stem cell product to be irradiated.  Vital signs should be 
monitored before beginning the infusion and periodically during administration.  Pre -
medications and hydration prior to stem cell infusion will be administered per institutional 
procedure s.   
 
2.5. GVHD Prophylaxis  
 
Patients will receive the regimen as described in Table 2. 5 
 
TABLE 2. 5: GVHD PROPHYLAXIS REGIMEN  
 
Day Dosage  (HLH Patients)  Dosage (Non -HLH Patients)  
-3 Cyclosporine  dosed to maintain appropriate 
level.  Given through Day +100, then taper 
to Day +180. Cyclosporine dosed to maintain 
appropriate level.  Given through Day 
+100, then taper to Day +180.  
-2 Methylprednisolone 2 mg/kg/day IV  
(if patient is already on cortic osteroids for 
HLH control, adjust to this amount)  -- 
-1 Methylprednisolone 2 mg/kg /day IV  -- 
0 Stem cell infusion  
Methylprednisolone 1 mg/kg/day  
(ongoing  through Day +28, then taper  over 
1 month ; may substitute PO Prednisone 1.2 
mg/kg/day)  Stem cell infusion  
Methylprednisolone 1 mg/kg/day  
(ongoing  through Day +28, then taper  
over 1 month ; may substitute PO 
Prednisone 1.2 mg/kg/day)  
 
2.5.1.  Cyclosporine (CSA)  
 
Cyclosporine administration will commence on Day -3 and dos ing per institutional standard  will 
be adjusted to maintain a level of 250 -500 ng/mL by TDX method (or 200-350 ng/mL by 
Tandem MS or equivalent level for other CSA testing methods).  CSA can be administered by 
continuous or intermittent infusion per institutional guidelines.   Patients who are on CSA at the 
time of starting conditioning will continue on the pre -HCT  dose, with adjustment to goal levels 
beginning on Day -3. Either brand name (Sandimmune) or generic cyclosporine will be allowed.  
 
Dose adjustments will be made on the basis o f toxicity and CSA levels.  Once the patient can 
tolerate oral medications and has a normal gastro -intestinal transit time, CSA will be converted 
to an oral form per institutional standards .  CSA dosing will be monitored and altered as 
clinically appropria te.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-10 Patients will receive CSA until Day +100 and CSA will be tapered between Days +100 to +180.  
If there is no GVHD, the dose will be tapered by approximately 10% per week beginning on Day 
+100. 
 
In the event of toxicity, tacrolimus may be substituted for cyclosporine. Tacrolimus 
administration will commence on Day –3, and doses will be adjusted to maintain a level of 8 -12 
ng/mL by the IMx immunoassay technique (Abbott Diagnostics) or a level of 5 -8 ng/mL if 
measured by a LC -tandem mass -spectrometric assay.  If using another method to measure levels 
then dose should be adjusted to maintain appropriate levels  per institutional standards .  
Tacrolimus can be administered by intermittent infusion or by continuous infusion to maintain 
therapeutic levels per institutional guidelines.   
 
Dose adjustments will be made on the basis of toxicity and tacrolimus levels.  Once the patient 
can tolerate oral medications and has a normal gastro -intestinal transit time , tacrolimus will be 
converted to an oral form. Tacrolimus dosing will be monitored and altered as clinically 
appropriate.  
 
From Day +100 to +180, tacrolimus will be gradually tapered in patients without significant 
acute or chronic GVHD (taper approximately 10% per week).  
 
2.5.2.  Methylprednisolone/ Prednisone  
 
On Day -2, methylprednisolone 2 mg/kg/day IV in two divided doses will be started as GVH D 
prophylaxis as well as prophylaxis against reactivation of HLH and adrenal insufficiency  for 
patients wit h HLH .  For patients who remain on corticosteroids for HLH control, this will be 
continued and unchanged through conditioning until Day  -2, when previous corticosteroids will 
be replaced with  methylprednisolone .  On Day 0, the methylprednisolone dose will decrease to 1 
mg/kg/day  for patients with HLH  and continue at that dose until Day +28. For patients without 
HLH, they will start methylprednisolone at Day 0 at 1mg/kg/day.  All patients will  continue at 
that dose until Day +28.  In the absence of GVHD, meth ylprednisolone will be tapered and 
discontinued over 1 month .  Oral prednisone may substitute for methylprednisolone at 1.2 
mg/kg/day after Day 0.  
 
2.6. Managing Chimerism   
1. Donor c himerism studies (T cell and whole blood) are required monthly starting at Day 
+28 through Day +100, then at Day +180 and Day +365.  An option al chimerism study at 
Day +21 is recommended if neutrophil engraftment occurs before Day +28.  
Additionally, donor chimerism studies are  required at D ay +42 if prior chimerism results 
are equ ivocal (donor chimerism < 20%).  Additional donor chimerism studies are 
recommended at Day +70. Monitoring chimerism outside of the required studies can be 
performed by whole blood or T -cell chimerism or both, by center preference.    
Recommendation: If chim erism falls by > 25% after engraftment, we recommend that  
immune suppression be rapidly tapered (over 0 -14 days) with more frequent (weekly)  
chimerism monitoring.  If chimerism continues to fall despite withdrawal of immune 
suppression, DLI can be given ac cording to center preference.  If the patient has falling 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-11 chimerism in the face of clinically active, significant GVHD, full withdrawal of immune 
suppression may not be clinically feasible.  
2. Patients with donor engraftment <  5% by Day +42 will be considered primary graft 
failure s.   
Recommendation :  It is recommended that these patients undergo a second transplant.   
 
2.7. Supportive Care  (Recommended)  
 
Institutional standard care practice guidelines will be followed after transplantation for 
nutritional support, treatment of infections, and blood product support.  Supportive guidelines are 
detailed below.  
 
2.7.1.  Engraftment Syndrome  
 
Engraftment syndrome is a clinical diagnosis.  The most frequently reported manifestations are 
transient fever, rash,  and respiratory symptoms not attributable to infection or GVHD.  The 
pathophysiology is multifactoral mediated by cellular, complement and cytokine components.  
Diagnostic criteria include fever (temperature >  38.5o C) without an identifiable infectious c ause 
within 4 days of the start of neutrophil recovery and/or an erythematous rash not attributable to 
GVHD or medications and/or capillary leak (weight gain, edema, ascites, effusions) or 
respiratory symptoms not attributable to IPS.  Mild symptoms may no t require therapy due to the 
self-limiting nature of this syndrome.  For progressive symptoms, methylprednisolone at  
2 mg/kg/day is recommended for 2-5 days.  If recurrent, prolonged, or unusually severe, 
investigation for HLH reactivation and GVHD is rec ommended.  
 
2.7.2.  Venous Access  
 
Recipients will have appropriate long -term central venous access placed, per institutional 
standard practice, prior to beginning the conditioning regimen.  The placement of a double lumen 
tunneled catheter is recommended.  
 
2.7.3.  Growth Factor  
 
Granulocyte colony stimulating factor (G -CSF) may be used at the treating physician’s 
discretion.  Granulocyte -monocyte colony stimulating factor (GM -CSF) is generally not 
recommended for patients with HLH.  
 
2.7.4.  Blood Products  
 
The hemoglobin level is recommended to be maintained over 8.0 g/dL for at least 100 days post -
transplant.  Due to specific bleeding risks in HLH patients, the platelet count should be 
maintained >  50,000/ul , and transfused per institutional guidelines  in pati ents with other immune 
defects .  Irradiated blood products should be administered universally.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-12 2.7.5.  Treatment of Fever/Infections  
 
Patients should be monitored closely for clinical manifestations of infection and treated per 
institutional guidelines with broad  spectrum antibacterial, antiviral and antifungal agents.  Since 
patients receive alemtuzumab, they are especially susceptible to bacterial and viral infections in 
the early post -transplant period.  
 
2.7.6.  Blood Pressure Monitoring and Control  
 
Blood pressure should be strictly controlled to prevent CNS toxicity. Patients with HLH often 
have experienced renal toxicity prior to HSCT. This in combination with high doses of steroids 
and Calcineurin inhibitors used both before and after HSCT puts these pat ients at risk for 
posterior reversible encephalopathy syndrome (PRES). Blood pressure should be monitored 
closely and elevations in systolic and/or diastolic pressure(s) should be treated promptly to 
maintain blood pressure within 10% above the baseline ag e-related median systolic and diastolic 
pressure (see Appendix G).  
 
PRES is characterized by headache, seizures, and visual loss, as well as an abrupt increase in 
blood pressure.  If PRES is suspected or diagnosed, symptom -directed treatment should be 
main tained until the condition is reversed by control of hypertension or other instigating factors. 
A negative MRI is required to exclude PRES.  
 
2.7.7.  Infection Surveillance and Prophylaxis  
 
2.7.7.1.  HSV prophylaxis  
 
Valacyclovir or a cyclovir prophylaxis is recommended for 6 months for patients who are 
seropositive for HSV or VZV.  
 
2.7.7.2.  Pneumocystis jirovecii pneumonia (PJP) prophylaxis  
 
Trimethoprim -sulfamethoxazole  or an equivalent drug should be administered beginning after 
neutrophil recovery and continued post -transplant for 1 year . 
 
2.7.7.3.  Fungal prophylaxis  
 
Due to the level of prolonged immune suppression, anti -fungal prophylaxis against Aspergillus 
sp. is recommend ed with agents such as itraconazole, voriconazole, posaconazole  or other 
appropriate agents  until Day +180.   
 
2.7.7.4.  Bacterial prophylaxis  
 
May consider bacterial prophylaxis per institutional guidelines.  
 
2.7.7.5.  CMV surveillance  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-13 All recipients must be tested weekly  for CMV from plasma using the PCR method beginning a 
week after commencing alemtuzumab (starting Day -7) until Day +100 , then at Day +180 and 
Day +365 .  Antiviral therapy for CMV reactivation should commence if CMV testing reveals a 
high or rising viral l oad, according to institutional practice guidelines.  
 
2.7.7.6.  EBV surveillance  
 
Patients will have EBV DNA quantitative PCR testing on plasma or peripheral blood cells every 
week after commencing alemtuzumab  (starting Day -7) until Day +100 , then at Day +180 and 
Day +365 . In the event of persistent EBV viremia or signs/symptoms consis tent with EBV -
related PTLD, therapy is recommended according to institutional practice guidelines.  
 
2.7.7.7.  Adenovirus surveillance  
 
Testing for adenovirus infection in the blood by PCR is recommended in the event of symptoms 
suspicious for an infection, includin g diarrhea, hepatic dysfunction or respiratory symptoms.  If 
an active systemic infection is diagnosed, therapy should be instituted according to institutional 
practice guidelines.  
 
2.7.7.8.  Intravenous immune globulin  
 
Intravenous immune globulin may be administe red according to institutional practice guidelines.  
 
2.7.7.9.  HLH surveillance   
a. HLH recurrence should be evaluated in patients who develop unexplained fever (>  2 
days) or organ dysfunction.  Markers of inflammation include sIL2R α, ferritin, LDH and 
d-dimers.  Recommendations for pre -transplant management of inflammation in HLH are 
discussed in Appendix E.  Patients with HLH may have exaggerated engraftment 
syndrome.  However, systemic HLH typically does not recur in the absence of graft loss.  
b. All patients with history of CNS involvement  by HLH (pleocytosis, elevated protein, 
abnormal MRI, or hemophagocytosis in CSF) should  undergo diagnostic LP prior to 
transplant, at Day + 28 (+ 3 days) , at Day  +100  (+ 14 days)  or at any time of mental status 
change.  Brain MRI may be substituted for LP if patients are not able to tolerate the 
procedure.  CNS reactivation of HLH (as evidenced by pleocytosis or hemophagocytosis 
in CSF, or MRI consistent with HLH -associated inflamm ation) pre - or post -transplant 
may be treated with intrathecal therapy.  Isolated CNS inflammation may be seen despite 
engraftment in patients without systemic symptoms of inflammation.  
c. Patients who have reactivation of HLH, either isolated CNS or systemic  (fever, highly 
elevated ferritin and soluble IL2R , end -organ damage) may receive salvage therapy per 
treating physician.  Stable engraftment >  20% is typically sufficient to prevent symptoms 
of HLH , though isolated CNS inflammation is occasionally observ ed (Jordan et al., 
2011) .  See Appendix E for recommendations for HLH salvage therapy.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-14 2.7.7.10.  Guidelines for infusing a second stem cell product or donor cellular infusion  
 
Refer to Section 2.6 for guidelines for managing unstable chimerism and graft loss.   
 
2.8. Toxicities  
 
2.8.1.  Conditioning: Pancytopenia  
 
The administration of Flu/Mel/Alem  is expected to produce pancytopenia for at least a week in 
most patients.  Most patients will require transfusions of red blood cells and platelets during this 
period. In addition, many patients will develop fever and approximately 30% will develop a 
docu mented infection during the period of neutropenia.  Complications related to pancytopenia 
may be life -threatening or fatal.  
 
2.8.2.  Alemtuzumab  
 
Administration can cause fevers, rigors, nausea, vomiting, bleeding, hypotension, fatigue, rash,  
local irritation at injection site,  urticaria, arrhythmias, dyspnea, headache, cough, pruritis,  throat 
inflammation,  diarrhea, pain, anorexia, increased perspiration , sepsis, myalgia, asthenia, 
hypertension, pharyngitis, abdominal pain, back pain, dizziness, anemia, infection s, neutropenia 
and thrombocytopenia.  
 
Fever and chills : These are regularly observed, particularly during initial doses .  They 
probably result from breakdown of cells binding the antibody.  
 
Skin rash and itching : A complication that is probably due to allergic reactions to the 
antibodies.  These symptoms will usually be prevented by or controlled with anti -histamines 
as well as with concomitant administration of corticosteroids.  
 
Anaphylaxis : A rare but severe allergic reaction which may cause a life -threatening drop in 
blood pressure, wheezing and difficulty breathing and severe hives or skin exfoliation.  This 
complication may be treated with anti -histamines and steroids.  
 
Platelet and white cell count depression : These are frequently observed and are probably 
caused by the binding of the antibody to human blood elements.  Platelet transfusions should  
be administered to reduce the chance of bleeding or life -threatening hemorrhage.  
 
2.8.3.  Fludarabine  
 
Administration can cause hemolytic anemia, neutropenia, thr ombocytopenia, low blood counts 
secondary to bone marrow suppression,  bleeding,  infection, pneumonia, nausea, vomiting, 
anorexia, diarrhea, oral ulcers, stomatitis, pain, skin rash, pne umonitis, edema, fever, rigors , 
fatigue,  weakness,  blurred vision, peri pheral neuropathy, agitation/nervousness, confusion, 
difficulty breathing, coma, renal damage, decreased immunity and rarely encephalopathy (in 
very high doses).  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
2-15 2.8.4.  Melphalan  
 
Administration can cause neutropenia, thrombocytopenia , anemia, infection,  bleeding, nausea, 
vomiting, anorexia , weakness, weight loss, hypotension, diarrhea, oral ulcers, decreased 
immunity, sterility, interstitial pneumonitis, lung fibrosis, allergic reactions , skin breakdown (if 
drug leaks from vein), tempo rary hair loss, excessive perspiration, cancer of bone marrow cells, 
hepatic damage, cardiac arrest  and rarely seizures (with very high doses).  
 
2.8.5.  Hematopoietic Cell Infusion  
 
Infusion of allogeneic BM cells can result in shortness of breath, fever, hemolysi s with renal 
dysfunction and back pain or anaphylaxis.  To reduce the risk of reactions to product infusion, 
patients will be hydrated before and after administration of allogeneic BM, and will be 
monitored closely before, during and after infusion  as per institutional practice . 
 
2.8.6.  Cyclosporin e 
 
Administration may cause nephrotoxicity, seizures,  tremors, headaches, abdominal  pain or 
indigestion, edema, confus ion, muscle cramps, dizziness, hemolytic anemia,  hypertension, 
hirsutism, thrombotic microangiopathy, electrolyte imbalances, paresthesia/neuropathy, gingival 
hyperplasia,  hypertrygliceridemia, diarrhea,  transient blindness , renal dysfunction  and hepatic 
dysfunction.  
 
2.8.7.  Tacrolimus  
 
Administration may cause hypertension, hyperglycemia, anemia, hyperkalemia, hypokalemia, 
hypomagnesemia, hypocalcemia, anorexia , diarrhea, nausea, fever, headache, hair loss, vomiting, 
peripheral neuropathy, pruritis , rash, abdominal pain, confusion, joint pain, increased light 
sensitivity, changes in vision, insomnia, infection, jaundice, renal injury, and seizures.  
 
2.8.8.  Dexamethasone, Methylprednisolone and Prednisone  
 
Corticosteroids can cause predisposition to infection, overeating, abnormal hormone production, 
hyperglycemia, slowe d growth, decreased bone density, headaches, poor wound healing, 
hypertension, stomach ulcers, muscle weakness, cataracts, increased intraocular pressure, 
worsening of diabetes, pancreatitis, disturbance of bone calcium, electrolyte disturbances, 
gastritis , GI bleeding, insomnia and mental status changes, fluid retention, edema, fat 
accumulation causing a change in facial appearance, and aseptic necrosis.  
 
2.8.9.  Filgrastim (G -CSF)  
 
Administration can cause bone pain, increased levels of liver enzymes and uric acid in the blood, 
thrombocytopenia, headaches, fatigue, local irritation at injection site, nausea, bleeding, fever, 
allergic reaction, splenomegaly or rupture of the spleen, worsening of pre -existing skin rashes, 
temporary hair loss, and  inflammation of a blood vessel in the skin.
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
3-1 CHAPTER 3  
 
 
3. STUDY ENDPOINTS  
 
3.1. Primary Endpoint  
 
The primary endpoint will be overall survival at one year post-transplant in patients who receive 
at least one dose of the preparative regimen . 
 
3.2. Secondary Endpoints  
 
Secondary endpoints are evaluations of the effects of HCT on clinical and laboratory 
manifestations of immune deficiency at one year and evaluatio n of other transplant -related 
outcomes.  T hese will include the followin g: 
 
3.2.1.  Sustained Engraftment (sustained donor lymphoid and myeloid chimerism)  
 
Sustained engraftment will be considered to have occurred in the absence of:  
1. Primary graft failure: <  5% donor chimerism by Day +42  
2. Second stem cell infusion: DLI (except in the case of donor CTLs given for infection 
control) or second HCT following original HCT  
3. Secondary graft failure: <  5% donor chimerism following original engraftment  
 
Overall as well as T  cell (CD3+) chimerism will be evaluated at least every month  following 
engraftment  until Day +100 , then at Day +180 and Day +365, as well as when clinically 
indicated.  
 
3.2.2.  HLH and CAEBV Reactivation  
 
3.2.2.1.  Systemic HLH reactivation  
 
HLH reactivation s are difficult to define since the transplant process alters many of the 
diagnostic criteria  (Henter et al., 2007) .  Post -transplant HLH reactivation is defined by clinical 
and lab evidence of pathologic inflammation (persistent fever, progressive cytopenias, rising 
ferritin and soluble IL2R α, decreasing fibrinogen, hepatosplenomegaly , end -organ damage ) not 
attributable to other causes.    
 
3.2.2.2.  CNS HLH reactivation  
 
Reactivation of CNS inflammation in patients with HLH may present with or without altered 
mental status and is defined by pleocytosis in CSF or an MRI consistent with CNS inflammation 
not attributable to other causes.   
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
3-2 3.2.2.3.  CAEBV reactivation  
 
In a patient w ith known CAEBV, CAEBV reactivation is defined as detection of recipient  EBV+ 
lymphocytes in tissue (peripheral blood lymphocytes or tissue biopsy) following engraftment.  
 
3.2.3.  Immune Reconstitution  and Functional Immune Recovery  
 
3.2.3.1.  Recovery of l ymphocyte subpop ulations  
 
Absolute number of CD3, C D4, CD8, CD16+56 and CD19 cells  will be measured by flow 
cytometry.  Immunoglobulin levels (IgG, IgA and IgM) will also be quantified (at baseline prior 
to conditioning, Day +100  and Day +365).  B cell reconstitution is de fined as an IgG of > 500 
mg/dL more than 12 weeks from the last IVIg infusion.  
 
3.2.3.2.  Correction of Immune Defects  
 
The following will be tested prior to conditioning, on Day +100 and Day +365, per underlying 
diagnosis.  
Disease -specific studies:  
i. HLH: NK cell function  
ii. HLH ( with PRF1 mutation): Perforin expression by flow cytometry  
iii. XLP: SAP expression by flow cytometry  
iv. CAEBV: EBV qPCR  
v. HIGM: CD40L expression on activated CD4+ T cells by flow cytometry (if available)  
vi. CGD: DHR assay  
vii. IPEX: Quantitative Treg analysis by flow cytometry; Functional Treg assay (if 
available)  
viii. LAD: CD18 expression on granulocytes by flow cytometry  
 
3.2.4.  Cumulative Incidence of Neutrophil and Platelet Engraftment  
 
Neutrophil Engraftment:  Time to ANC engraftment is  defined as the first of three measurements 
on different days that the patient has an absolute neutrophil count of ≥ 500/uL following 
conditioning regimen induced nadir.  
 
Platelet Engraftment : Platelet engraftment is defined as  the first day of a minimum o f three 
measurements on different days that the patient has achieved a platelet count >  20,000 AND the 
patient is platelet transfusion independent for a minimum of seven days following conditioning 
regimen induced nadir.  
 
Subjects must not have had platele t transfusions during the preceding 7 days after the day of 
engraftment, unless the platelet transfusion is being given specifically to achieve a platelet 
threshold to allow an elective invasive procedure.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
3-3 3.2.5.  Grade II -IV and Grade III -IV Acute GVHD  
 
The cumu lative  incidence of grade II -IV and grade III -IV acute GVHD will be assessed  
according to the BMT CTN Manual of Procedures (MOP).  
 
3.2.6.  Chronic GVHD  
 
Incidence and severity of chronic GVHD will be scored according to the BMT CTN MOP.  
 
3.2.7.  Frequency of Transplant -related Complications  
 
3.2.7.1.  Veno -occlusive disease  
 
Veno -occlusive disease (VOD) is diagnosed by the presence of two or more of the following 
with no other identifiable cause for liver disease  (McDonald et al., 1993) : 
1. Jaundice (direct bilirubin > 2  mg/dL or > 34 umol/L ) 
2. Hepatomegaly with right upper quadrant pain  
3. Ascites and/or weight gain (>  5% over baseline)  
 
3.2.7.2.  CNS toxicity  
 
CNS toxicity is defined as a patient experiencing  seizures, CNS hemorrhage , or posterior 
reversible encephalopathy syndrome (PRES ). 
 
3.2.7.3.  Infection  
 
Infection is defined as documented infection with or reactivat ion of viruses, including CMV 
reactivation, adenovirus infection, or EBV reactivation ; invasive fu ngal infections ; and systemic 
bacterial infections.   CMV and EBV will be followed by PCR weekly.  Other pathogens will be 
evaluated as clinically indicated.  
 
3.2.7.4 . Disease Group Specific Outcomes  
 
The above endpoints will be analyzed within disease subgroups, specifically HLH patients 
versus patients ent ering with other primary immune deficiencies.   
 
3.3. Correlative Biology Studies  
 
Optional peripheral blood samples will be collected for correlative biology studies and shipped 
to the BMT CTN Research Sample Repository  within 14 days prior to start of conditioning  (Day 
-28 to Day -14), on Day -7, Day -1, Day +1, Day +14 , Day +28, Day +42, Day +7 0, Day +100 , 
Day +180  and Day  +365 . As samples must be collected and shipped the same day and only on 
Monday through Thursday, there is some flexibility in these  specific days as shown below 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
3-4 (Table  3.3).  Blood samples will be used in correlative biology studies, including correlation of 
clinical variables with alemtuzumab pharmacokinetics, engra ftment, and immune reconstitution.  
 
TABLE 3.3: OPTIONAL PERIPHERAL BL OOD SAMPLES  FOLLOW -UP SCHEDULE  
Visit  Window  
Prior to start of conditioning  Day -28 to Day -14 
Day -7 Day -8 to Day -6 
Day -1 Day -2 to Day 0  
Day +1  Day +1 to Day +3  
Day +14  Day +12 to Day +16  
Day +28  Day +26 to Day +30  
Day +42  Day +39 to Day +45  
Day +70  Day +60 to Day +80  
Day +100  Day +90 to Day + 110 
Day +180  Day +160 to Day +200  
Day +365  Day + 335 to Day +395  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-1 CHAPTER 4  
 
 
4. PATIENT ENROLLMENT AND EVALUATION  
 
4.1. Enrollment Procedures  
 
4.1.1.  Screening and Eligibility Procedures  
 
Patients will be registered using the BMT CTN Electronic Data Capture System 
(AdvantageEDCSM).  The following procedures should be followed:  
1. The transplant coordinator at the transplant center should proceed with their institution’s 
standard pr ocedure to identify a sibling donor, if applicable.  If an unrelated donor search 
is to be pursued, then the coordinator should inform the transplant center’s assigned 
NMDP (or other appropriate donor search organization) coordinator through the standard 
procedure for any unrelated donor . 
2. Within the 14 days prior to initiation of the conditioning regimen, an authorized user at 
the transplant center should enter the patient demographics and complete  the Segment 0 
Enrollment Form in AdvantageEDC.  The Segment  0 form includes a question 
confirming that the patient (or legally authorized representative) signed the informed 
consent.  The patient will be assigned a study number at this time.  Additionally, Segment 
0 requires completion of the HLA -typing form (pati ent and donor) to confirm that the 
HLA -typing meets protocol criteria.  Upon successful completion of the two Segment 0 
forms, the authorized user will proceed to Segment A and complete the Segment A 
enrollment form to verify eligibility and capture propos ed start date of conditioning.  The 
Segment A enrollment form must be completed prior to initiation of conditioning 
regimen . 
 
4.2. Study Monitoring  
 
4.2.1.  Follow -up Schedule  
 
The follow -up schedule for scheduled study visits is outlined in Table 4.2.1.  A detailed 
description of each of the forms and the procedures required for forms completion and 
submission can be found in the Data Management Handbook and User’s Guide.  The Data 
Management Handbook, including the Forms Submission Schedule, is available on the 
homepa ge of the Internet data entry system.  
 
4.2.1.1.  Follow -up visits 
 
Follow -up visits will begin as soon as patients are enrolled onto the study.  The follow -up period 
is 12 months . 
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-2 TABLE 4.2.1: FOLLOW -UP SCHEDULE  
Study Visit  Target Day  
(+ 3 Days to Day +42 Post-HCT ) 
(+ 7 Days to Day + 60) 
(+ 14 Days to Day +100)  
(+ 28 Days After Day +100) 
1 week  7 days  
2 week  14 days  
3 week  21 days  
4 week  28 days  
5 week  35 days  
6 week  42 days  
7 week  49 days  
8 week 56 days  
9 week  63 days  
10 week  70 days 
11 week  77 days  
12 week  84 days  
13 week  91 days  
100 day  100 days  
6 month  180 days  
12 month  365 days  
 
4.2.1.2.  Criteria for forms submission  
 
Criteria for timeliness of submission for all study forms are detailed in the Data Management 
Handbook and User’s Guide.  Forms that are not entered into AdvantageEDCSM within the 
specified time will be considered delinquent.  A missing form will continue to be requested 
either until the form is entered into AdvantageEDCSM and integrated into the Data and 
Coord inating Center’s (DCC) master database or until an exception is granted and entered into 
the Missing Form Exception File, as detailed in the Data Management Handbook.  
 
4.2.1.3.  Reporting patient deaths  
 
Recipient Death Information must  be entered into AdvantageEDCSM within 24 hours of 
knowledge of the patient’s death  on the Death Form  and the Unexpected, Grade 3 -5 Adverse 
Event Form .  If the cause of death is unknown at that time,  the cause of death field may be left 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-3 blank .  However, once the cause of death is dete rmined, the form must be updated in 
AdvantageEDCSM.   
 
4.2.1.4.  CIBMTR data reporting  
 
Centers participating in BMT CTN trials must register pre - and post -transplant outcomes on all 
consecutive hematopoietic stem transplants done at their institution during their time of 
participation to the Center for International Blood and Marrow Transplant Research (CIBMTR).  
Registration is done using procedur es and forms of the Stem Cell Transplant Outcomes Database 
(SCTOD) (Note: Federal legislation requires submission of these forms for all US allotransplant 
recipients) .  Enrollment of BMT CTN # 1204 must be indicated on the SCTOD pre -transplant 
registration form.  Additionally, CIBMTR pre - and post -transplant Report Forms must also be 
submitted for all patients enrolled on this trial.  CIBMTR forms will be submitted directly to the 
CIBMTR at the times specified on the Form Submission Schedule.   
 
4.2.1.5.  Weekly GVHD  monitoring  
 
GVHD should be monitored in accordance with BMT CTN guidelines as specified in the Manual 
of Procedures.  Patients should be assessed weekly until Day +100 post-transplant for GVHD.  
After Day +100, patients will be assessed at each follow -up visit for the  presence of GVHD  
through 12 months .  For scheduling, a target day range has been provided in Table 4.2.1.  
 
4.2.2.  Adverse Event Reporting  
 
Unexpected, grade 3 -5 adverse events (AE) and all deaths will be reported through an expedited 
AE reporting system via Adva ntageEDCSM.  Additionally, any occurrence of posterior reversible 
encephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome 
(RPLS) requires reporting through the AE reporting system. Unexpected, grade 4 -5 AEs must be 
reported with in 24 hours of knowledge of the event.  Unexpected, grade 3 AEs must be reported 
within three business days of knowledge of the event.  Expected AEs will be reported using 
NCI’s Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 at regular 
intervals as defined on the Form Submission Schedule.  
 
4.2.3.  Patient Evaluations Prior to Enrollment  
 
Table 4.2. 3 summarize s patient clinical assessments over the course of the study.  
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-4 TABLE 4.2.3 : CLINICAL STUDIES AND RESEARCH LABS  
Week  Pre-
Conditioning9 -1 -1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 26 52 
Day2 -7 -1 0 1 7 14 21 28 35 42 49 56 63 70 77 84 91 100 180 365 
PE with performance status  x x   x x x x x x x x x x x x x x x x x 
CBC, chem10, LDH, AST, ALT, GGT, 
AP, bilirubin, INR, PTT, d -dimer, 
fibrinogen, triglycerides  
(See 4.2.4. 9 for recommendations to screen for 
reactivation in patients with HLH)  x                     
Bone marrow aspirate5 x                     
GFR  x                     
HLA typing, ABO/Rh typing  x                     
PFT/oxygen saturation  x                     
Chest x -ray or CT scan  x                     
EKG/Echo  x                     
beta-HCG4 x                     
Bone marrow graft - total nucleated cells 
and CD34+ count     x                  
Ferritin  x                     
Hepatitis, HSV, syphilis, HIV, HTLV1, 
VZV tests  x                     
CMV and EBV qPCR  x x   x x x x x x x x x x x x x x x x x 
Infection evaluation  x                     
HLH: LP and/or brain MRI1 x        x          x   
Immune reconstitution  x                  x  x 
Immunoglobulin levels  x                  x  x 
Chimerism (unfractionated  and CD3+)8 x       x3 x  x7  x  x1  x  x x x 
Optional r esearch blood  x10 x x  x  x  x  x    x    x x x 
HLH & related disorders : NK function, 
Perforin expression5, SAP expression5 x                  x  x 
CGD: DHR assay  x                  x  x 
HIGM: CD40L expression6 x                  x  x 
IPEX: Treg analysis  x                  x  x 
LAD: CD18 expression  x                  x  x 
Notes:     1 Recommended but not required       6 If available  
2 Please follow the same windows as listed for follow -up visits in Table 4.2.1    7 Required if prior chimerism results are equivocal (donor chimerism < 20%)  
3 If neutrophil engraftment achieved before Day +28      8 Monthly chimerism studies are standard of care  
4 If patient is of childbearing potential       9 < 30 days  prior to enrollment (unless noted otherwise)  
5 As indicated (perforin  study for PRF1 familial HLH; SAP expression for XLP1)   10 Within 14 days prior to onset of conditioning (Day -28 to Day -14) 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-5 The following observations must  be performed within 30 days prior to  enrollment  (unless noted 
otherwise) : 
 
1. History, physical examination, height and weight . 
2. Lansky/Karnofsky performance  status.  
3. Blood count with differential, c hemistries (sodium, potassium,  carbon dioxide, chloride, 
magnesium, calcium, phosphorous, BUN, creatinine ), lactate dehydrogenase, AST, ALT, 
GGT, alkaline phosphatase, bilirubin (conjugated and unconjugated), INR, PTT, d -dimer, 
fibrinogen, triglycerides, ferritin, soluble IL2R  (recomm ended  for HLH patients ), 
soluble CD163  (recommended  for HLH patients ). 
4. Bone marrow aspirate (recommended in patients with cytopenias or other concerns for  
abnormal hem atopoiesis). 
5. Disease -specific studies:  
i. HLH: NK cell function, diagnostic lumbar puncture and/or brain MRI   
ii. HLH: (with PRF1 mutation): Perforin expression by flow cytometry * 
iii. XLP: SAP expression by flow cytometry * 
iv. CAEBV: EBV qPCR , NK cell function  (if available) , diagnostic lumbar puncture 
and/or brain MRI   
v. HIGM: CD40L expression on activated CD4+ T cells by flow cytometry (if 
available) * 
vi. CGD: DHR assay * 
vii. IPEX: Quantitative Treg analysis by flow cytometry ; Functional Treg assay (if 
available) * 
viii. LAD: CD18 expression on granulocytes by flow cytometry * 
*May be performed at any time prior to enrollment  
6. Calculated or r adionuclide  GFR.  
7. EBV antibody test and PCR, CMV antibody test  and PCR , hepatitis panel (HepA Ab, 
HepB sAb, HepB sAg, HepB Core Ab, HepC Ab), herpes simplex, syphilis, HIV and 
HTLV1 I/II antibody, and varicella zoster virus antibody.  
8. HLA typing, ABO and Rh typing, if not already performed. For sibling  donor s: 6/6 match 
for HLA –A, –B (intermediate  or higher resolution) and –DRB1  (at high resolution using 
DNA -based typing) ; for related donor s other than  a sibling: 7/8 or 8/8 match for HLA –A, 
–B, –C (at intermediate or higher resolution),  and –DRB1 (at high resolution using DNA -
based typing ). For unrelated donor s: 7/8 or 8/8 match for HLA –A, –B, –C, and –DRB1 
(at high resolution using DNA -based typing ).   
9. Baseline peripheral blood samples for chimerism analysis by molecular methods 
(STR/VNTR).  
10. Baseline EKG . 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-6 11. Baseline echocardiography for left ventricular ejection fraction (LVEF)  or left ventricular 
shortening fraction . If tricuspid regurgita tion is present, it is recommended to evaluate 
presence of pulmonary hypertension.   It is strongly recommended that these tests be 
performed ≤ 2 weeks  prior to enrollment .  However, they can be done up to 6 weeks  prior 
to enrollment , provided the patient h as been asymptomatic since the time of the tests.  
12. Pulmonary function testing: FEV1 and DLCO  if patient is able to undergo PFT testing . If 
not; record oxygen saturation by pulse oxymetry.   It is strongly recommended that these 
tests be performed ≤ 2 weeks  prior to enrollment .  However they can be done up to 6 
weeks  prior to enrollment , provided the patient has been asymptomatic since the time of 
the tests.  
13. β-HCG serum pregnancy test for females of childbearing potential.  
14. Chest X -ray or CT scan :  It is strong ly recommended that the X -ray or scan be performed 
≤ 2 weeks  prior to enrollment  in symptomatic patients .   
15. Baseline immune profile:  Absolute lymphocyte numbers by flow cytometry for 
lymphocyte subpopulations (CD3, CD4, CD8, CD19 and CD1 6+56 cell subsets), 
immunoglobulin levels ( IgG, IgA and IgM). 
16. Optional samples for correlative research studies: Peripheral blood 20 mL in Sodium 
Heparin tubes at three time points: within 14 days prior to start of conditioning (Day -28 
to Day -14); Day -7 and Day -1. For patients that weigh less than 6.7 kg, 3 mL/kg will be 
collected at each time point.  
17. Total nucleated cell count and CD34+ count of the infused product on Day 0.  
 
4.2.4.  Patient Evaluations Prior to Conditioning  
 
If an infection occurs or a previously c ontrolled infection worsens between the day of enrollment 
and the day the preparative regimen is scheduled to begin, the infection must be controlled and 
the patient clinically improved prior to initiating the preparative regimen. We recognize that 
patient s with CAEBV may have ongoing EBV viremia at the time of initiating pre-transplant 
therapy, but other patients should have no uncontrolled bacterial, viral or fungal infections at the 
time of initiation of the transplant preparative regimen.  
 
4.2.5.  Required Post -Transplant Evaluations (Follow evaluation windows listed in Table 4.2.3)  
1. History and physical exam to assess GVHD and other morbidity weekly until Day +100 
post-transplant, then at Day +180  and Day +365 .  GVHD evaluation and grading to be in 
keeping with BMT CTN MOP.  
2. Peripheral blood sample for post -transplant chimerism assay (unfractionated and CD3+) 
by molecular methods monthly beginning at Day +28, and at Day +42  if prior chimeris m 
results are equivocal ( donor chimerism < 20%), then at leas t month ly (recommended 
every 2 weeks) through Day +100, then at Day +180 and Day  +365.  An optional 
chimerism study at Day +21 is recommended if neutrophil engraftment occurs before 
Day +28.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
4-7 3. EBV qPCR on plasma or blood cells weekly from Day  +1 through Day  +100, then at Day 
+180 and Day  +365.  
4. CMV qPCR on plasma weekly from Day  +1 through Day  +100, then at Day +180 and 
Day +365.  
5. Immune reconstitution (absolute lymphocyte numbers) by flow cytometry for 
lymphocyte subpopulations (CD3, CD4, CD8, CD19 and CD16+56 cell subsets), 
immunoglobulin levels (IgG, IgA and IgM) at Day +100 and Day +365.  
6. Disease -specific studies (Pre -therapy, Day  +100, Day  +365) : 
i. HLH: NK cell function  
ii. HLH ( PRF1 mutation): Perforin  expression by flow cytometry  
iii. XLP: SAP expression by flow cytometry  
iv. CAEBV: EBV qPCR , NK cell function  (if available) , diagnostic lumbar puncture 
and/or brain MRI   
v. HIGM: CD40L expression on activated CD4+ T cells by flow cytometry (if 
available)  
vi. CGD: DHR as say 
vii. IPEX: Quantitative Treg analysis by flow cytometry ; Functional Treg assay (if 
available)  
viii. LAD: CD18 expression on granulocytes by flow cytometry  
8. Optional samples for correlative research studies: Peripheral blood 20 mL in Sodium 
Heparin tubes  collected on Day +1, Day +14, Day +28, Day +42, Day +70, Day +100, 
Day +180, and Day  +365. For patients less than 6.7 kg, 3 mL/kg will be collected at each 
time point . 
9.  HLH Reactivation: For patients with HLH  or hemophagocytic syndromes , regular surveillance 
labs ( blood counts, ferritin, soluble IL2R α, soluble CD163, d-dimer, fibrinogen, triglyercerides, 
LDH, AST/ALT/GGT  and bilirubin) are recommended.  If patients develop persistent fever of 
uncertain etiology, HLH reactivation should be re-evaluated  completely according to the 
diagnostic criteria (Table 1.2), along wi th chimerism studies including CD3+ fraction 
chimerism.   Resources to manage HLH reactivation (systemic or CNS) are outlined in 
Appendix E.
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
5-1 CHAPTER 5   
 
 
5. STATISTICAL CONSIDERATIONS  
 
5.1. Study Design  
 
The study is a Phase II, non -randomized, multi -center trial. It is designed to assess overall 
survival 365 days after patients undergo reduced -intensity conditioning (RIC) HCT with 
fludarabine, melphalan , and intermediate timing of alemtuzumab for HLH or r elated conditions .  
The sample size is a minimum of 35 HLH patients.   
 
5.2. Accrual  
 
It is estimated that three years of accrual will be necessary to enroll the targeted sample size.  
Accrual will be reported by race, ethnicity, gender, and age.  
 
5.3. Study Durati on 
 
Patients will be followed for one year post -transplant.  
 
5.4. Randomization  
 
There is no randomization in this trial.  
 
5.5. Primary Objective  
 
The primary endpoint is the proportion of patients who survive for one year after transplantation.  
The choice of this  endpoint is based on CIBMTR registry data for patients receiving HCT for the 
above diseases between 2008 and 2010.  In these data, the probability of one year survival was 
70% for HLH patients .  Recent single center data with the RIC strategy used in this  protocol 
have shown survival probabilities closer to 90%.  The primary analysis will include all patients  
who receive at least one dose of the preparative regimen .  Death from any cause is the event for 
this endpoint.  The study is designed to rule out su rvival percentages below 70%.  
 
5.6. Sample Size and Power Considerations  
 
Sample size calculations were based on an original sample size of 35 patients. After rapid 
accrual, the protocol was amended to include a minimum of 35 HLH patients to improve the 
precis ion of both the overall estimate and the secondary disease specific su bgroup analysis.  
 
Table 5.6.1 provides 90% confidence intervals for a variety of observed proportions.  For 
example if 28 of the 35 patients survive (80% observed survival percentage) , the length of the 
confidence interval is 22.2%.  The percentages above and below 80% are intended to represent 
other plausible survival rates.   
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
5-2  
The probability to rule out survival percentages of a certain size is known as “power .”  Table 
5.6.2 provides the probability (or power) that the lower bound of a 90% two -sided confidence 
interval for the overall survival probability will be greater than a threshold of 65%, 70%, 75%, or 
80%.  Based on the table below, there is 87% power at a one -sided   = .05 to reject the null of 
70% survival if the true percentage is 90%.  
 
TABLE 5.6.1:  CONFIDENCE INTERVAL LENGTHS AND POSSIBLE  
CONFIDENCE INTERVALS FOR VARIOUS OBSERVED  
OVERALL SURVIVAL PROBABILITIES  
 
N Overall Survival 
(OS) %  Length of 90% 
Confidence Interval  Possible 90% Confidence Intervals  
35 70 25.4 (57.3,  82.7)  
35 75 24 (63.0,  87.0)  
35 80 22.2 (68.9,  91.1)  
35 85 19.8 (75.1,  94.9)  
35 90 16.6 (81.7,  98.3)  
 
 
TABLE 5.6.2:  PROBABILITY OF RULING OUT A THRESHOLD OF SIZE  
T FOR VARIOUS TRUE UNDERLYING OVERALL  
SURVIVAL PERCENTAGES  
 
 
 
N True 
Overall 
Survival 
%  
Probability of Ruling Out Overall Survival Percentages  
of Size T  
  T=80%  T=75%  T=70%  T=65%  
35 90 0.31 0.73 0.87 0.98 
35 85 0.09 0.38 0.57 0.86 
35 80  0.14 0.27 0.60 
35 75   0.10 0.32 
35 70    0.13 
 
 
5.7. Interim Analysis and Stopping Guidelines  
 
Interim analyses for safety will be conducted at times specified in the power and sample size 
calculations. Monitoring of a key safety endpoint ( overall  mortality ) will be conducted monthly, 
and if rate significantly exceed s pre-set thresholds, the NHLBI will be notified in order tha t the 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
5-3 DSMB can be advised.  Policies and composition of the DSMB are described in the BMT CTN's 
Manual of Procedures.  The stopping guidelines serve as a trigger for consultation with the 
DSMB for additional review, and are not formal “stopping rules” that  would mandate automatic 
closure of study enrollment.  
The rate of overall mortality  will be monitored up to 100 days post -transplant.  Monitoring will 
be performed monthly beginning after the third month of enrollment until enrollment is closed.  
At least three events must be observed in order to trigger review.  Each month, the null 
hypothesis that the 100 -day overall mortality  rate is less than or equal to 15% is tested.  An 
extension of the sequential probability ratio test (SPRT) will be used to monitor  overall 
mortality .  A description of the SPRT is provided below.  
 
The SPRT can be represented graphically.  At each monthly interim analysis, the total time on 
study is plotted against the total number of patient  deaths .  The continuation region of the SP RT 
is defined by two parallel lines.  Only the lower boundary will be used for monitoring to protect 
against excessive 100 -day overall mortality .  If the graph falls below the lower boundary, the 
SPRT rejects the null hypothesis, and concludes that there a re more events than predicted by the 
observed time on study.  Otherwise, the SPRT continues until enrollment reaches the maximum 
sample size.  
 
This procedure assumes an exponential distribution for the time until death  during the first 100 
days, but censor s follow -up time after 100 days.  Only events that occur on or before the patient 
has been followed for 100 days are counted.  Total time on study is computed as time from 
registration to event, or to 100 days, whichever comes first, summed for all evaluab le patients.  
 
The usual measures of performance of an SPRT are the error probabilities  and  of rejecting 
H0 when  = 0 and of accepting H 1 when  = 1, respectively, and the expected sample size 
E(N|i).  The test to be used in this protocol was developed from the following SPRTs:  A SPRT 
contrasting 15% versus 35% 100 -day rate of overall mortality  results in a common slope of 0.99 
and the intercepts are -2.18 and 1.83.  
 
The actual operating characteris tics of the truncated test, shown in Table 5.7.1, were determined 
in a simulation study that assumed uniform accrual of 35 individuals over a 3 year time period 
and exponential time to failure after registration.  Since 100,000 replications were used, the 
estimates have two digits of precision.  
 
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
5-4 TABLE 5.7.1:  OPERATING CHARACTERISTICS OF SEQUENTIAL TESTING 
PROCEDURE FROM A SIMULATION STUDY WITH 100,000 REPLICATIONS  
FOR OVERALL  MORTALITY  
 
True 100 -Day Rate  15% 25% 30% 35% 
Probability Reject Null  0.07 0.42 0.65 0.83 
Mean Month Stopped  15.8 17.8 17.1 15.7 
Mean # Endpoints in 100 Days  5.7 6.2 6.1 5.8 
Mean # Patients Enrolled  16 18 17 16 
 
 
The testing procedure for overall mortality  rejects the null hypothesis in favor of the alternative 
7% of the time when the true 100 -day overall mortality  rate for a treatment is 15%, and 83% of 
the time when the rate is 35%.  This corresponds to a type I error rate of  = 0.07 and a type II 
error rate of  = 0.17.  When the true 100 -day overall mortality  rate is 35%, on average, the 
DSMB will be consulted 15.7 months after the opening, when approximately 6 events have been 
observed in 16 patients.  
 
5.8. Demographic and Baseline Characteristics  
 
Demograp hics and baseline characteristics will be summarized for all patients.  Characteristics to 
be examined are: age, gender, race/ethnicity, performance status, HLA match, disease stage, 
serum bilirubin level, serum creatinine level, donor age, donor gender, a nd donor ethnicity.  
 
5.9. Analysis of Primary Endpoint  
 
The primary analysis will consist of estimating the one year overall survival probability based on 
the Kaplan -Meier product limit estimator.  The one year overall survival probability and 
confidence interval will be calculated using Greenwood’s Formula for the variance.  All patients  
who receive at least one do se of the preparative regimen  will be considered for this analysis.  
 
5.10. Analysis of Secondary Endpoints  
• Rate of Sustained Engraftment:  The proportion of patients achieving sustained 
engraftment at one year will be estimated along with 95% confidence intervals.  
• Graft Failure:  To assess the incidence of primary and secondary graft failure (as 
outlined in Chapter 3), the proportion of subjects experiencing primarily graft failure will 
be estimated and the  cumulative incidence of secondary graft failure  will be computed 
along with 95% confidence interval s. Death prior to graft failure will be considered as a 
competing risk   
• HLH and CAEBV Reactivation :  To assess the incidence of reactivation , cumulative 
incidence curve s will be computed along with 95% confidence interval s. Death prior to 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
5-5 reactivation  will be considered as a competing risk.   Death due to reactivation  will be 
noted.  
• Immune Reconstitution:  Summary statistics for absolute number of CD3, CD4, CD8, 
CD16+56, and CD19 cells and immunoglobulin levels IgG, IgA and IgM will be reported 
at baseline, Day +100 and Day +365.  Further proportion of subjects experiencing B cell 
reconstitution as defined in  Chapter 3 will be estimated along with a 95% confidence 
interval.  
• Correction of Immune Defects: Descriptive statistics for disease -specific immune 
measures will be reported by underlying disease for  measurements at baseline, Day +100 
and Day +365 . 
• Neutrop hil Engraftment:  To assess the incidence of neutrophil engraftment from day of 
transplant, a cumulative incidence curve will be computed along with a 95% confidence 
interval. Death prior to neutrophil engraftment will be considered as a competing risk.   
• Platelet Engraftment:  To assess the incidence of platelet engraftment (> 20,000) from 
day of transplant, a cumulative incidence curve will be computed along with a 95% 
confidence interval. Death prior to platelet engraftment will be considered as a competin g 
risk.   
• Acute GVHD:   To assess the incidence and severity of grades II -IV and grades III -IV 
acute GVHD from day of transplant , the first day of acute GVHD onset at a certain grade 
will be used to calculate a cumulative incidence curve for that acute GVHD  grade.  An 
overall cumulative incidence curve will be computed along with a 95% confidence 
interval at one year post -transplant with death considered as a competing risk.   
• First Clinical Onset of Chronic GVHD:  To assess the incidence and severity of chro nic 
GVHD from day of transplant, a cumulative incidence curve will be computed along with 
a 95% confidence interval at one year post -transplant. Death prior to occurrence of 
chronic GVHD will be considered as a competing risk.  
• Transplant -Related Complicati ons:  The frequencies of  transplant -related 
complications ( veno-occlusive disease (VOD), CNS toxicity, and infection) will be 
described using proportions  (95% confidence interval ). 
• Disease Group Specific Outcomes:  In addition to the overall analysis of the primary and 
secondary endpoints, endpoints will be analyzed within disease subgroups, specifically 
HLH patients versus patients entering with primary immune deficiencies. Note that due 
to the small sample size no  formal comparisons between the groups will be made.  
 
5.11. Safety Analysis  
 
The reporting of serious adverse events will be consistent with standard BMT CTN procedures.  
The type and severity of adverse events will be analyzed.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
A-1 APPENDIX A  
 
HUMAN SUBJECTS  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
A-2 APPENDIX A  
 
HUMAN SUBJECTS  
 
 
1. Subject Consent  
 
A conference will be held with the patient and family to discuss this study and alternative 
treatments available for the treatment of the underlying disease.  The Principal Investigator or 
another designated physician will conduct the conference.  Potentia l risks associated with HCT 
should be discussed as objectively as possible.   
 
The consent document should be reviewed with the patient and family prior to proceeding to 
ablative therapy.  
 
Informed consent from the patient will be obtained using a form app roved by the Institutional 
Review Board of the institution enrolling the patient.  
 
2. Confidentiality  
 
Confidentiality will be maintained by masking of individual names and assignment of a patient 
identifier code.  The identifier code representing the patient’s identity will be kept separately 
from the research file at the center.  The ID code will be transmitted to the BMT CTN Data and 
Coordinating Center upon enrollment.  
 
3. Participation of Women and Minorities and Other Populations  
 
Women, ethnic minorities , and other populations will be included in this study.  Accrual of 
women and minorities at each center will be monitored to determine whether their rates of 
enrollment are reflective of the distribution of potentially eligible women and minorities 
expected from data reported to the CIBMTR and from published data on the incidence of HLH, 
HLH -related disorders and the selected primary immunodeficiencies (CGD, hyper -IgM, IPEX, 
LAD -I).  Centers will be notified if their rates differ signi ficantly from those expected and asked 
to develop appropriate recruitment strategies.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-1  
APPENDIX B  
 
INFORMED CONSENT AND ASSENT  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-2 Informed Consent to Participate in Research  
 
 
 
 
 
 
 
 
 
Your Name:   ________________________________  
 
Study Title:   Reduced -Intensity Conditioning for Children and Adults With 
Hemophagocytic Syndromes or Selected Primary Immune Deficiencies 
(RICHI)  
 
Protocol :  BMT CTN # 1204  
 
Principal  
Co-Investigator :  Carl Allen , MD , PhD  
   ceallen@txch.org  
Texas Children’s  Hospital  
1102 Bates St., Suite 750  
Houston, TX 77030  
(832) 824-4312  
 
Principal  
Co-Investigator:  Michael Pulsipher, MD  
 michael.pulsipher@hsc.utah.edu  
Primary  Children’s  Medical  Center  
100 North Mario Capecchi Dr.  
Salt Lake City, UT 84113  
(801) 662 -4732  
 
Transplant Center  
Investigator:   ________________________  
(Insert contact information for PI at your site)  
 
Sponsor:   The National Institutes of Health (NIH) is sponsoring this study by 
providing financial support through the Blood and Marrow Transplant 
Clinical Trials Network (BMT CTN).  
 
 
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-3  
1. Introduction  
 
We invite you to join this clinical trial, also 
known as a research study. We are doing 
this study because we want to learn if 
reduced -intensity transplants  are safe and 
work well  for people with hemophagocytic 
syndrome s or immune disorder s. A 
reduced -intensity transplant uses lower 
doses of chemotherapy. This type of 
transplant is also called a non -
myelo ablative, or ‘mini’ transplant.  
An allogeneic transplant  uses cells from a 
family member or an unrelated donor to 
remove and replace your disea sed cells. 
An allogeneic transplant generally uses 
higher levels of chemotherapy and 
radiation (also known as h igh intensity 
treatments or myeloablative conditioning 
regimens) to destroy the diseased cells 
before receiving the donor cells. However, 
high in tensity transplants can have more 
side effects during and after transplant. A 
reduced -intensity transplant can have fewer 
side effects, but may have more problems 
with engraftment . Engraftment is the 
ability of the donor cells to replace the 
patient’s cells.   
Your study participation will last for 1 year  
post-transplant . This study will take about 3 
years total and will include 35 HLH 
patients in addition to patients with other 
hemophagocytic syndromes or immune 
disorders from around the Unite d States  and 
Canada .  
To be part of the study , you must:  • Be between the ages of 3 months and 
45 years  
• Have a hemophagocytic syndrome or 
an immune disorder including:  
• Hemophagocytic 
lymphohistiocytosis (HLH)  
• Griscelli syndrome  
• Chediak -Higashi syndrome  
• X-linked lymphoproliferative 
disease  
• Chronic active EBV (CAEBV), 
which is typically associated 
with HLH  
• Chronic granulomatous disease 
(CGD)  
• X-linked hyper IgM syndrome 
(HIGM1)  
• IPEX syndrome  
• Severe leukocyte adhesion 
deficiency (LAD -I)  
• Have a matc hed related marrow 
donor or unrelated marrow donor 
available. The unrelated donor needs 
to be a close tissue match.  
• Provide a signed consent for 
participation in the study  
This Consent Form tells you about the 
purpose of the study, the possible risks and 
benefits, other treatment options available 
to you, and your rights as a participant in 
the study. Please take your time to make 
your decision.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-4 Everyone who takes part in research at 
[insert facility name ] should know that:  
• Being in any research study is  
voluntary.  
• You may or may not benefit from 
being in the study.  Knowledge we 
gain from this study may benefit 
others.  
• If you join the study, you can quit 
the study at any time.   
• If you decide to quit the study, it will 
not affect your care at [ insert nam e 
of facility or institution ].  
• Please ask the study staff questions 
about anything that you don’t understand, or if you would like to 
have more information.  
• You can ask questions now or any 
time during the study.  
• Please take the time you need to talk 
about the study with your doctor, 
study staff, and your family and 
friends.  It is your decision to be in 
the study.  If you decide to join, 
please sign and date the end of the 
Consent Form.  
You and your doctor will discuss other 
treatment options  if you don’t want to 
participate in this study . 
 
 
2. Study Background  
The National Institutes of Health  (NIH), 
through the Blood and Marrow Transplant 
Clinical Trials Network (BMT CTN), are 
providing staff support and money for this 
research study. The BMT CTN will direct 
the research study. The BMT CTN and the 
NIH will make decisions about how to 
manage the  study together.  
Some of the immune system disorders 
included in this study are: Hemophagocytic 
lymphohistiocytosis, Griscelli syndrome, 
Chediak -Higashi syndrome, X -linked 
lymphoproliferative disease, chronic active 
EBV, chronic granulomatous disease, hyp er 
IgM syndrome, IPEX syndrome, and severe 
leukocyte adhesion deficiency. These disorders prevent the immune system from 
working well. Your immune system fights 
off infections, so people with these disorders 
might develop deadly infections.  
One way to trea t these disorders is through a 
blood and bone marrow transplant. A 
transplant replaces your unhealthy blood 
cells with bone marrow  cells from  a family 
member or an unrelated donor .  It requires a 
close tissue m atch between you and the 
donor. Your donor cou ld be a sibling (a 
sister or brother) or an unrelated person. In 
the United States , we use  the Be The 
Match® Registry to find unrelated donors.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-5 A transplant first uses chemotherapy  to 
destroy the unhealthy blood cells  or stop 
them from growing . Then, we re place the 
destroyed cells with the new cells from your 
donor . In this study, doctors want to use 
lower doses of chemotherapy. This type of transplant is called a reduced -intensity  
transplant.  
Your disease can be treated in other ways 
too. You and your doctor will decide on the 
best treatment for you.  
 
 
3. Study Purpose  
We are inviting you to join this study 
because you have an immune system 
disorder, a matched bone marrow donor, and 
a reduced -intensity transplant is a treatment 
option for you. The goal of this study is to learn if a reduced -intensity transplant is safe 
and works well to treat your disease. We 
also want to know how well your immune 
system  responds to the transplant.  
 
 
4. Right to Ask Questions and/or Withdraw  
You have the right to ask questions about 
the study at any time. If you have questions 
about the study  or you want to leave the 
study, please contact:  
[insert contact info  for site PI ] 
Being in this study is voluntary. You can 
choose not to be in this study or leave this study at any time.  If you choose not to take 
part or to leave this study, it will not affect 
your regular medical care in any way.    
Your study doctor and study staff will be 
available to answer any questions you may 
have about taking  part in or leaving  this study .
 
 
5. Study Treatment and Tests  
We will check your health before your 
transplant. We will also check your health 
several times after your transplant for up to 
1 year.   
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-6 ______________________________________________________________________________
Before Your Transpl ant: 
You will be admitted to the hospital 14 days 
before your transplant. Your doctor  will put 
an intravenous (IV) catheter (a thin tube) in 
a large vein in your neck  or chest . This is 
done to make giving you drugs and blood 
transfusions easier and less pa inful. This is 
also known as a central venous catheter.  
When you are ready to get your catheter, 
your doctor will explain what will happen in 
more detail. Your anesthesiologist   
(the doctor who will give you pain 
medicine) will describe the risks and 
bene fits of the pain medicine.     
When the catheter is in your chest, it will 
need to be cleaned and flushed regularly to 
prevent infection and blood clots. Your  
nurse or caregiver will help you clean your 
catheter.
________________________________ _____________________________________________ _ 
Reduced -Intensity Transplant:  
To prepare your body for transplant and 
destroy the diseased cells, you will be 
treated with chemotherapy and other 
medicines. Your chemotherapy will start the 
day you are admitted to the hospital (14 days 
before your transplant) . 
Study c hemotherapy drugs  
The study drugs that will be used for your 
chemotherapy are called alemtuzumab , 
fludarabine , and melphalan .  
We will start giving you alemtuzumab 14 
days before your transplant. It will be given 
as a shot. You will get a dose of 
alemtuzumab once a day for 5 days. The 
first day will be a small test dose. The test 
dose is given to make sure you will not have 
a bad reaction to the full dose. If you have a 
bad reaction, your doctor will talk with you 
about other drug options to prepare for 
transplant.  The risk s of alemtuzumab are listed in 
Section 6: Risks and Discomforts. These 
risks include serious allergic reactions. 
Patients are usually admitted to the hospital 
for their first dose of alemtuzumab. Your 
doctor will decide if you need to stay in the 
hospital for the other doses of alemtuzumab 
or if you can receive them as an outpatient.  
If you stay in the hospital for all of the 
alemtuzumab shots, your doctor might 
discharge you after the shots are done if you 
respond well. If you are discharged, you will 
return to the hospital 8 days before your 
transplant to start receiving the other 
chemotherapy drugs (fludarabine and 
melphalan).   
Fludarabine will be given through your 
central venous catheter , once a day for 5 
days. A central venous catheter is a thin tube 
that is placed in a large vein in your neck  or 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-7 chest . We will give you one dose of 
melphalan 3 days before the transplant. It 
will also be given through your  central 
venous catheter .  
You will have 2 days to rest before your 
transplant. We won’t give you any 
chemotherapy drugs on these days.  
Table 1 shows the timeline for the 
chemotherapy drugs and blood tests. This 
timeline does not show the drugs we will  
give you to help prevent Graft Versus Host 
Disease  (below) .  
Drugs to prevent Graft -Versus -Host Disease 
(GVHD):  
We will give you immune suppressing drugs  
3 days before your transplant . We will 
continue to give you t hese drugs  after your 
transplant. These drugs are important  
because they  allow the donor cells  to 
perform their new rol e in your body. They can also lower your chance s of developing 
GVHD. GVHD happens when the donor 
cells attac k your body  (GVHD is discussed 
in more  detail below ).   
You will receive 1 or more standard drugs  
(drugs that are not part of the study)  to lower 
your chances of developing  GVHD . We will 
give you these drugs  for at least 6 months 
after the transplant.  They are cyclosporine 
(also called Gengraf® or Neoral®) or 
tacrolimus (also called FK 506 or Prograf®). 
We will give them to you with  
methylprednisolone or prednisone  daily 
starting 2 days prior to transplant and 
continuing until 28 days after transplant 
(both of these drugs work the same) . 
Donated marrow cells : 
The donated marrow cells will come from a 
related donor or unrel ated donor. The donor 
cells will be given through your catheter, 
just like a blood transfusion.
______________________________________________________________________________  
After Your  Transplant:  
The chemotherapy drugs will destroy  the 
cells i n your bone marrow that produce your 
blood and immune cells . The donor cells 
will produce new blood cells in your body. 
To speed up this process, we may give you a 
drug called Filgrastim (also called G -CSF or 
Neupogen). This drug helps protect against 
infections. It is given as a shot or IV.    
Check -up appointments:  
You will stay in the hospital after your 
transplant until your doctor feels you’re well 
enough to go home. When you’re in the 
hospital, we will watch you carefully for 
signs of infection and ot her problems. A physical exam and blood tests will be done 
every day  to know how you’re doing.  Your 
doctor may need to give you other drugs, 
tests and treatments if you have problems.  
After you leave the hospital, you will need 
to visit the transplant clin ic at least once a 
week  for check -ups to make sure you’re still 
doing well. You will also need to visit us 
100 days (3 months), 6 months, and 1 year 
after your transplant so we can check your 
progress and treat any problems. You will 
check in with us less and less over time.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-8 At these visits, we will take 2 – 6 teaspoons 
of your blood (10  – 30 mL) from your 
catheter or from a vein in your arm if your 
catheter has been removed. We will test 
your blood to see how well your body is 
responding to the chemotherapy drugs and 
the donated cells.  
 
Health Evaluations : 
 
We will test (evaluate) your health during 
the study. These tests and how often they are 
scheduled are standard care for patients 
receiving an allogeneic transplant. They 
would be done even if you were not part of 
this study.  
 
Health evaluations after treatment : 
 
1) Physical exam to assess toxicities, and 
infections weekly until Day +56 and then at 
Days +180 and +365. 
 2) Physical exam to assess GVHD weekly 
until Day +100  and then at Day s +180 and 
+365. 
 
3) Routine blood tests (cell counts and liver 
and kidney function) weekly until Day +56 
and then at Days +180 and +365. 
 
4) Blood or bone marrow tests to find the 
amount of donor cells in your body monthly 
until Day +100 and then at Days +180 and 
+365. This is also called chimerism . 
 
5) Disease -specific tests to see how much 
disease you have before treatment and after 
treatment on Days +100 and +365. 
 
6) Optional  blood samples for future 
research (see Section 17: Blood Samples 
for Future R esearch ). 
 
Your doctor may decide that you need other 
tests and treatments that are not part of this 
research study, but are necessary to take care 
of you.  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
 
B-9  
*Legend for Chemotherapy Drugs  
A Alemtuzumab test dose  
B Alemtuzumab  
C Fludarabine  
D Melphalan  Table 1: Timeline for Chemotherapy Drugs and Blood Tests  
Day:  Before transplant  Transplant  
Day After transplant  
After 
you 
consent  14 13 12 11 10 9 8 7 6 5 4 3 2 1 0  
 
1 
 
 14 28 42 70 100 
(3 mths)  180 
(6 mths)  365 
(1 yr)  
Optional  
Blood 
Tests:  ✓        ✓      ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Drugs*:   A B B B B  C C C C C D            
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-10  
6. Risks and Discomforts  
You will have side effects while on the 
study. Side effects can range from mild to 
very serious.  
The risks listed in this section might happen 
from transplant. These risks might happen if 
you have a transplant as part of this study or 
standard care. The chances of developing 
GVHD and infections are the same if you 
have a reduced -intensity or standard 
transplant.  Your doctor will give you drugs to help 
lower the side effects, such as feeling sick to 
your stomach (nausea). In some cases, side 
effects can be long lasting or may never go 
away.  
The chemotherapy drugs can cause leukemia 
years later, but th is is rare. These “s econdary 
cancers” are often very hard to treat and can 
cause death.  
 
Risks of Study Treatments and Drugs   
 
Possible Side Effects of Study Drugs  
The most common side effects of the 
treatments used in this study are listed 
below. There is also the risk of very uncommon or unknown side effects.  All 
chemotherapy drugs  in this study  are 
commonly used in transplant.
 Likely  What it means: This type of side effect is expected to occur in more than 
20% of patients . This means that 21 o r more patients out of 100 might get 
this side effect.  
Less Likel y What it means: This type of side effect is expected to occur in 20% of 
patients or fewer . This means that 20 patients or fewer out of 100 might get 
this side effect.  
Rare , but 
Serious  What it means: This type of side effect does not occur very often – in fewer 
than 2% of patients  – but is serious when it occurs. This means that 1 or 2 
patients (or fewer) out of 100 might get this side effect.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-11   Alemtuzumab  
Likely  Less Likely   
Rare, but Serious  
 
• Fever  
• Chills  
• Anemia (decreased 
number of red cells)  
• Infection  
• Bleeding  
• Weakened immune system  
• Local irritation (skin) at 
injection site  
• Low number of white 
blood cells  
• Low number of platelets in 
the blood  
 • Nausea  
• Vomiting  
• Diarrhea  
• Rash 
• Headache  
• Sweating  
• Back pain  
• Severe itching  
• Allergic reaction of skin 
and blood vessels  
• Tiredness  
• Loss of appetite  
• Low blood pressure  
• Irregular heartbeat  
• Shortness of breath  
• Sore throat  
• Pain 
• Cough  • Abdominal pain  
• Dizziness  
• High blood pressure  
• Blisters  
• Pain in the muscles  
• Herpes simplex infection  
• Swelling of the throat  
• Bacterial infection in the 
bloodstream  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-12 Fludarabine  
Likely   
 
Less Likely  
 
  
Rare, but Serious  
 
▪ Infection  
▪ Anemia  (low red blood 
cell count ) 
▪ Tiredness  
▪ Nausea  
▪ Vomiting  
▪ Pneumonia  
▪ Mouth sores  
▪ Fever  
▪ Swelling of hands and feet  
▪ Weakened immune system  
▪ Pain 
▪ Low number of white 
blood cells  
▪ Low number of platelets in 
the blood  
▪ Electrolyte imbalances  ▪ Diarrhea  
▪ Numbness and tingling in 
hands and/or feet  
▪ Changes in vision  
▪ Skin rash  
▪ Cough  
▪ Changes in heartbeat  
▪ Loss of appetite  
▪ Chills  
▪ Lung inflammation  
 ▪ Changes in vision  
▪ Agitation/nervousness  
▪ Confusion  
▪ Difficulty breathing  
▪ Weakness  
▪ Severe brain injury and death  
▪ Bleeding due to decreased 
numbers of platelets   
▪ Kidney damage that could 
require dialysis  
▪ Coma  
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-13 Melphalan  
 
Likely  
  
Less Likely  
 Rare, but Serious  
▪ Loss of appetite  
▪ Nausea  
▪ Vomiting  
▪ Skin breakdown (if drug 
leaks from vein)  
▪ Anemia (low red blood 
cell count)  
▪ Infection  
▪ Bleeding  
▪ Mouth sores  
▪ Temporary hair loss  
▪ Decreased immunity  
▪ Low number of white 
blood cells  
▪ Low number of platelets in 
the blood  ▪ Diarrhea  
▪ Inflammation of the lung  
▪ Weakness  
▪ Weight loss  
 
 
 ▪ Low blood pressure  
▪ Excessive perspiration  
▪ Allergic reaction  
▪ Damage/scarring of lung 
tissue  
▪ Sterility  
▪ Seizure  
▪ Cancer of bone marrow cells  
▪ Heart stops beating  
▪ Liver damage  
 
Side Effects of Drugs Used To Prevent G VHD  
The side effects of the GVHD drugs (listed below) usually stop when you’re done taking them.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-14 Cyclosporine ( Gengraf® or Neoral®). 
This drug may be used for all patients  
 
Likely  
  
Less Likely  
  
Rare, but Serious  
 
▪ Tremors  
▪ High blood pressure  
▪ Kidney problems  
▪ Headaches  
▪ Nausea  
▪ Vomiting  
▪ Stomach pain or 
indigestion  
▪ Swelling of the hands or 
feet  
▪ Increased hair growth  
▪ Electrolyte imbalances  ▪ Confusion  
▪ High levels of 
triglycerides in the blood  
▪ Diarrhea  
▪ Gum enlargement  
▪ Liver dysfunction  
▪ RPLS/PRES1 
 
 ▪ Muscle cramps  
▪ Numbness and tingling of the 
hands or feet  
▪ Seizures  
▪ Dizziness  
▪ Red blood cell destruction  
▪ Temporary blindness  
     1 Reversible posterior leukoencephalopathy syndrome (RPLS) also known as posterior reversible                   
encephalopathy syndrome (PRES) – See text below for description    
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-15 Tacrolimus  (Prograf or FK-506) 
 This drug may be used for all patients. 
 
Likely  
   
Less Likely  
  
Rare, but Serious  
 
▪ High blood pressure  
▪ High blood sugar  
▪ Anemia (low red blood 
cell count)  
▪ High or low potassium 
levels  
▪ Low magnesium and 
calcium  levels  
▪ Loss of appetite  
▪ Diarrhea  
▪ Nausea  
▪ Fever  
▪ Headache  ▪ Hair loss  
▪ Vomiting  
▪ Tingling sensation in the 
extremities  
▪ Itching  
▪ Rash  
▪ Abdominal pain  
▪ RPLS/PRES1 
 
 
 ▪ Confusion  
▪ Painful joint s 
▪ Increased sensitivity to light  
▪ Change in vision  
▪ Insomnia (trouble sleeping)  
▪ Infection  
▪ Jaundice (skin yellowing)  
▪ Kidney injury  
▪ Seizures  
1 Reversible posterior leukoencephalopathy syndrome (RPLS) also known as posterior reversible 
encephalopathy syndrome (PRES) – See text below for description  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-16 Methylprednisolone  and Prednisone  
This drug will be used as part of GVHD prophylaxis for bone marrow recipients.  
 
Likely  
   
Less Likely  
  
Rare, but Serious  
 
▪ Water retention  (storing of 
extra water)  
▪ Overeating  
▪ Weake r immune system  
▪ Temporary personality 
changes  
▪ Abnormal hormone 
production  
▪ High blood sugar  
▪ Slowed growth  
▪ Decreased bone density  
▪ Fat accumulation causing 
a change in facial 
appearance  ▪ Headaches  
▪ Poor wound healing  
▪ Stomach swelling or pain  
▪ Tissue swelling  
▪ High blood pressure  
▪ Stomach ulcer  
▪ Muscle weakness  
▪ Cataracts  
▪ Bone cell death  
▪ RPLS/PRES1 
 
 ▪ Difficulty falling asleep  
▪ Worsening of diabetes  
▪ Inflammation of pancreas  
▪ Personality disturbances  
▪ Bleeding in the stomach and 
intestines  
▪ Increased pressure within the 
eye 
▪ Disturbance of bone calcium 
(might lead to possible 
broken bones or permanent 
bone damage)  
1 Reversible posterior leukoencephalopathy syndrome (RPLS) also known as posterior reversible  
encephalopathy syndrome (PRES) – See text below for description    
 
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-17  
Potential Risk of RPLS/PRES  
The Data Safety and Monitoring Board (DSMB) of the Blood and Marrow Transplant Clinical 
Trials Network is a group of transplant, HLH and immune deficiency disease and other experts that 
ensure the safety of patients treated on this and other trials. This g roup carefully monitors the 
experience of patients to make sure that the side effects that they experience are not unusual or 
more frequent or more severe than would be expected.  
 
The DSMB has noted that patients transplanted on the clinical trial BMT CTN  1204 have a higher 
than expected occurrence of a usually uncommon (<5%) complication called reversible posterior 
leukoencephalopathy syndrome (RPLS) also known as posterior reversible encephalopathy 
syndrome (PRES). Patients with RPLS/PRES have confusion and other changes in their ability to 
think. Sometimes, they experience seizures, sleepiness or, rarely, loss of consciousness.  RPLS is 
diagnosed with an MRI of the brain. In transplant patients, it is usually caused by some of the 
drugs used to prevent o r treat graft versus host disease. It can often, but not always, be prevented 
by very careful control of blood pressure. It is treated by changing graft versus host disease drugs, 
controlling blood pressure and/or giving anti -seizure medicines. Three out o f thirty -five patients on 
BMT CTN 1204 have developed RPLS/PRES; all were successfully treated for this complication. 
Thus far, no RPLS/PRES has been observed in any patient more than 6 months from their date of 
transplant. We believe that children who are  on prednisone or other corticosteroids, or 
immunosuppressive drugs such as cyclosporine or tacrolimus or have high blood pressure are more 
likely to develop RPLS/PRES.  Filgrastim  (G-CSF)  
 
Likely  
   
Less Likely  
  
Rare, but Serious  
 
▪ Ache or pain inside the 
bones  
▪ Increased levels of liver 
enzymes and uric acid in 
the blood  
▪ Low number of platelets 
in the blood  
▪ Headache  
▪ Tiredness  ▪ Local irritation (skin) at 
injection site  
▪ Nausea BleedingFever  
 ▪ Allergic reaction  
▪ Enlargement or rupture of 
the spleen  
▪ Worsening of pre -existing 
skin rashes  
▪ Temporary hair loss  
▪ Inflammation of a blood 
vessel in the skin  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-18  
If you/your child experience any of these side effects or changes in mental status, yo u should 
contact your/your child’s transplant physician right away, since early treatment is 
important.  It is also important that any blood pressure medication be taken as prescribed to 
decrease the risk of RPLS/PRES.  
 
Risks of Transplant:  
The following problems might happen from 
your transplant. These problems might 
happen if you have a transplant as part of the 
study or standard care:  
Graft -versus -host disease (GVHD)   
GVHD develops  when the white blood cells, 
which are called T cells, in the donor’s cells 
attack your body. You are more likely to get 
GVHD if your donor’s tissue does not 
closely match your tissue.   
 
There are 2 kinds of GVHD: acute and 
chronic. Acute GVHD usually develops  in 
the first 3 months after transplant. Chronic 
GVHD  usually develops  later and lasts 
longer.  
You may experience these side effects  with 
acute GVHD :  
▪ Skin rash  
▪ Feel sick to your stomach (nausea)  
▪ Throw up (vomit)  
▪ Diarrhea  
▪ Abdominal (stomach area) pain  
▪ Problems with your liver (your 
doctor will run tests for this)  ▪ Infection  
You may experience these side effects with 
chronic GVHD :  
▪ Skin rashes  
▪ Hair loss  
▪ Thickened skin  
▪ Joint stiffness (knees, elbows, 
fingers)  
▪ Dry eyes  
▪ Dry mouth  
▪ Liver disease (your doctor will run 
tests for this)  
▪ Weight loss  
▪ Diarrhea  
▪ Infection  
We don’t know for sure if you will develop 
acute or chronic GVHD. The chance that 
you will get GVHD is 10 -30%. This means 
that 10 to 30 people out of 100 might 
develop it. We will watch you closely for 
GVHD and treat it if it happens.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-19 To know for sure if you have  acute or 
chronic GVHD, we may do a biopsy of your 
skin. A biopsy is where we take a small 
piece of your skin and look at it under a 
microscope for signs of GVHD. There’s a 
small chance that we might also do a biopsy 
of your intestine and l iver. Risks of biopsy 
may include pain, infection, or bleeding.  
In most cases, GVHD can be treated. If 
GVHD does not respond to the drugs, your 
doctor will talk with you about other 
treatment options. If you choose a different 
treatment option, we will giv e you 
information about the side effects.  
You may need to be treated for GVHD for 
many months or years. GVHD treatments 
can cause your immune system to become 
very weak if it goes on for a long time. This 
means you may develop more infections and 
need to be admitted to the hospital often. 
GVHD can be very serious and hard to treat. 
It might also cause death.   
Damage to your vital organs  
Your vital organs include your heart, lungs, 
liver, intestines, kidneys, bladder and brain. 
The chemotherapy and GVHD dr ugs may 
hurt these organs. You may develop lung 
problems from chemotherapy or an 
infection.  
Some patients can have veno -occlusive 
disease (VOD) of the liver even from a 
reduced -intensity transplant (lower doses of 
chemotherapy). Patients with VOD become 
jaundiced (yellow skin), have problems with 
their liver, retain too much water (feel 
swollen and uncomfortable), and have 
stomach swelling and pain.  If there is serious damage to  your vital 
organs, you may have to stay in the hospital 
longer or return to the hospital after your 
transplant. Many patients get better, but 
these complications can cause permanent 
damage to your organs or death.  
Serious infections  
It may take many months for your immune 
system to recover from the chemotherapy 
and GVHD drugs. There is an increased risk 
of infection during this time when your body 
is healing.  We will give you drugs to reduce 
the chance of infections, but they may not  
work. If you have an infection, you may 
have to stay in the hospital longer or return 
to the hospital after transplant.  Many 
patients get better, but some infections can 
cause death.  
Graft ( donor cells) rejection  
Some patients’ bodies reject the donor cells 
(graft) with a standard (non -reduced -
intensity) transplant. There is an increased 
risk of rejection with a reduced -intensity 
transplant. Also, a certain amount of your 
old blood and marrow cells will remain in 
your body.  
If your body rejects the don or cells, your 
doctor may need to give you a donor 
lymphocyte infusion (DLI). A DLI is an 
extra dose of the donor cells. You may also 
get another transplant, but this is rare. If you 
need a DLI or second transplant, your doctor 
will explain the risks and b enefits.  
Central venous catheter   
You may feel pain and bleed a little where 
the catheter is placed in your chest.  The 
most common risks of a catheter are blood 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-20 clots and infections. If you get a clot , we will 
give you a drug to break it up . If the drug 
doesn’t work, the catheter may need to be 
replaced. Infections will also be treated with  
drugs. S ometimes, the catheter has to be 
taken out and a new catheter put in. Also, t he 
catheter could puncture (create a hole) in 
your lung and cause serious bleeding, but 
this is very rare.  
We will do an X -ray or CT scan of your 
chest to make sure we know the best place 
to insert the catheter  and reduce the risks 
from happening as much as possible.  
Infertility and reduced sexual functioning   
Chemotherapy can cause infertility (inability 
to have children). It may decrease your 
sexual desire and cause female vaginal 
dryness.  
The chemotherapy doses used in this study 
are lower than what is used in standard 
transplants, so the risk of infertility may be 
lower. Som e patients who received reduced -
intensity transplants had children. It’s 
difficult to know the exact risk of infertility 
from reduced -intensity transplants. We don’t 
know for sure what your risk of infertility 
will be.  
Risk to the unborn  
The treatments in  this study have not been 
proven to be safe at any stage of pregnancy. 
Therefore, if you are pregnant or nursing, you 
are not eligible for this study. Women who 
can become pregnant must use two forms of 
effective birth control while receiving 
chemotherapy and drugs to prevent GVHD. 
Effective birth control is defined as the following:  
1. Refraining from all acts of vaginal 
sex (abstinence)  
2. Consistent use of birth control pills  
3. Injectable birth control methods 
(Depo -Provera, Norplant)  
4. Tubal steriliz ation or male partner 
who has undergone a vasectomy  
5. Placement of an IUD (intrauterine 
device)  
6. Use of a diaphragm with 
contraceptive jelly and/or condoms 
with contraceptive foam every ti me 
you have sex  
Reproductive Risks   
The drugs used in thi s research study may  
damage your reproductive organs,  affect 
your ability to have children  or possibly 
cause birth defects if you take them while 
you are pregnant. I t is important that a 
woman is  not pregnant or breast -feeding and 
does not become pregnant during the course 
of the study.  
If you are a woman and can become 
pregnant , you will need to take a pregnancy 
test before you start the study . You should 
discuss ways to prevent pregnancy while 
you are in the study.  Women who have gone  
through puberty may find that their 
menstrual cycle becomes irregular or stops 
permanently. This does not mean that you 
cannot become pregnant. You must still use 
an effective method of birth control during 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-21 your transplant and continue until you are 
finished with your GVHD prevention 
treatment.  
If you are a man, your body may not be able 
to produce sperm (become sterile). You 
should talk with your doctor about banking 
your sperm before having a transplant.  
Please check with your doctor to understand 
more a bout these risks.  Risk of death   
The side effects of a blood and bone marrow 
transplant might be very serious and cause 
death. Your doctor will do everything to 
make sure your transplant is as safe as 
possible, but there is still a risk of death.  
 
 
 
7. Alternative Treatments  
Participation in this study is optional . If you 
choose not to take part,  you may still receive 
a blood or marrow transplant to treat your 
disease . The treatment and evaluations you 
would receive could be very similar to what 
would receive  if you join this study .  
Your study doctor will talk with you about 
your options. If you decide not to participate 
in this study, your medical care will not be 
affected in any way.  
Your other choices may include:  
▪ Treatment with other drugs, 
radiation, or a combination of drugs 
and radiation without a transplant   
▪ A blood or marrow  transplant that is 
not part of the study , or another type 
of transplant  
▪ Participatio n in another clinical trial , 
if available (check with your doctor)  ▪ No treatment for  your blood disorder  
at this time  
▪ Comfort care : This can occur at any 
stage of a disease. The goal is to 
make you comfortable by treating 
symptoms of the disease and 
improvi ng your quality of life.  You 
may still be receiving treatment for 
your disease. This is different from 
hospice care.  
Every treatment option has benefits and 
risks . Talk with your doctor about your 
treatment choices before you decide if you 
will take part in this study.  
It is important that you talk to your doctor 
about treatment choices before you decide to 
participate in this study.  
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-22 8. Possible Benefits  
We don’t know if t aking part in this study 
will make your health better. If the 
transplant works well, you may not have any 
more symptoms of your disorder. The 
information from this study will help doctors learn if reduced -intensity transplant s are safe 
and work well  for people  with 
hemophagocytic s yndrome s or immune 
disorder s. 
 
 
9. New Information Available During the Study  
During this study, the study doctors may learn 
new information about the study drug or the 
risks and benefits of the study. If this happens, 
they will tell you  about the new information. 
The new information may mean that you can 
no longer take part in the study, or that you 
may not want to continue in the study.  If this happens, the study doctor will stop 
your participation and will offer you all 
available care to meet your needs and 
medical conditions.  
 
10. Privacy, Confidentiality and Use of Information  
Your confidentiality is one of our main 
concerns. We will do our best to make sure 
that the personal information in your 
medical record is kept private. However, we 
cannot guarantee total privacy. All your 
medical and demographic (such as race and 
ethnicit y, gender and household income) 
information will be kept private and 
confidential. (Name of Transplant Center)  
and the organizations listed below will not 
disclose your participation by any means of 
communication to any person or 
organization, except by yo ur written request 
or permission, or unless required by federal, 
state or local laws, or regulatory agencies.  
Individuals authorized by the organizations 
below will have access to your research and 
medical information. They may use this information for inspections or audits to 
study the outcomes of your treatment. In 
agreeing to participate, you consent to such 
inspections and to the copying of parts of 
your records, if required by these 
organizations.  
We may give out your personal information 
if required by law. If information from this 
study is published or presented at scientific 
meetings, your name and other pe rsonal 
information will not be used.  
Information about your transplant from your 
original medical records may be seen or sent 
to national and international transplant 
registries, including:  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-23 ▪ /Institution/  
▪ The National Institutes of Health (NIH)  
▪ The Nationa l Heart, Lung, and Blood 
Institute (NHLBI)  
▪ The National Cancer Institute (NCI)  
▪ Office of Human Research Protection 
(OHRP)  
▪ The Food and Drug Administration (FDA)  
▪ Institutional Review Boards (IRBs) 
responsible for this study  
▪ Data and Safety Monitoring Boar d 
(DSMB), not part of /Institution/  
▪ Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN), including 
the Center for International Blood and 
Marrow Transplant Research (CIBMTR), 
the National Marrow Donor Program 
(NMDP) and the EMMES Corporation who are coordinating the studies of the 
BMT CTN  
▪ Study investigators  
We will not identify you by name in any 
publications or reports that come from these 
organizations or groups.  
Information that does not include personally 
identifiable information about this s tudy has 
been or will be submitted, at the appropriate 
and required time, to the government -
operated clinical trial registry data bank, 
which contains registration, results, and 
other information about registered studies.  
This data bank can be accessed by  you and 
the general public at:  
www.ClinicalTrials.gov . Federal law 
requires study information for  certain 
studies to be submitted to the data bank.  
For questions about access to your medical 
records, please contact /name/  at /number /. 
11. Ending Your Participation  
The study doctor or the study sponsor may 
stop the study at any time, and we may ask 
you to leave the study. If we ask you to 
leave the study, the reasons will be 
discussed with you. Possible reasons to end 
your participation in this study include:  
▪ You do not meet the study 
requirements.  
▪ You need a medical treatment not 
allowed in thi s study.  ▪ The study doctor decides that it 
would be harmful to you to stay in 
the study.  
▪ You are having serious side effects.  
▪ You become pregnant . 
▪ You cannot keep appointments or 
take study drugs as directed.  
▪ The study is stopped for any reason . 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-24 You could h ave serious health risks if you 
stop treatment during the  conditioning 
process before you receive your transplant. 
If you stop taking the  immune suppressing 
drugs (see Section 6: Risks and 
Discomforts ) too soon after transplant, your 
body could reject the donor stem cells or 
you could develop serious complications 
and possibly die.  
We ask that you talk with the research 
doctor and your regular doctor before you leave the study. Your doctors will tell you 
how to stop safely and talk with you about 
other tre atment choices .  
If you decide to leave this study after the 
study, or your doctor asks you to leave the 
study for medical reasons, you will need to 
come back to the doctor’s office for tests for 
your safety. Even if you leave the study, the 
information co llected from your participation 
will be included in the study results.  
 
 
12. Physical Injury as a Result of Participation  
It is important to tell your study doctor, 
__________________ [investigator's 
name(s)] , or study staff if you feel that you 
have been injured from  taking part in this 
study. You can tell the doctor in person or 
call him/her at __________________ 
[telephone number] . 
You will get all available medical treatment 
if you are injured from taking p art in this study. You and/or your health plan will be 
charged for this treatment. The study will 
not pay for medical treatment.  
In case you are injur ed in  this study, you do 
not lose any of your legal rights to receive  
payment by signing this Consent F orm. 
 
13. Compensation or Payment
You will not be paid for taking part  in this 
study . You will not be compensat ed or 
reimburse d for any extra costs (for example, 
travel  and meals) from taking part  in this 
study.  
 
 
14. Costs and Reimbursement
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-25 Most of the tests for this study are standard 
medical care for your transplant and will be 
billed to your insurance company . You and/or 
your health plan/insurance company will need 
to pay for some or all of the costs of standard 
treatment in this study .  
You or your insurance will not be charged for 
tests that are only done  for research on this 
study.  You will not pay for any extra tests 
that are being done for the study.  
Some health plans will not pay the costs for 
people taking part in studies. Check with 
your health plan or insurance company to 
find out if they will pay.  For questions about your costs, financial 
responsibilities, and/or medical insurance 
coverage for yo ur transplant and this study, 
please contact /Center/ Financial Counselor 
at /Number/ . 
For more information on clinical trials and 
insurance coverage, you can visit the 
National Cancer Institute’s Web site at 
http://cancer.gov/clinicaltrials/understanding
/insurance -coverage . You can print a copy 
of the “Clinical Trials and Insurance 
Coverage” information from this Web site.  
Another way to get the information is to call 
1-800-4-CANCER (1 -800-422-6237) and 
ask them to send you a free copy.  
 
 
15. For More Information  
If you need more information about this 
study, or if you have problems while taking  
part in this study, you can contact the  study 
doctor or his/her staff . They can be reached at 
the telephone numbers listed here:    [Insert name and contact detail]
 
16. Contact Someone about Your Rights  
If you wish to speak to someone not directly 
involved in the study, or if you have any 
complaints about the project, or any questions 
about your rights as a research participant, 
then you may contact:  
[Insert appropriate contact details]  
The ethical aspec ts of this research study have 
been reviewed and approved by [name of 
IRB].  For questions about your rights while taking 
part in this study, call the __________[name 
of center]  Institutional Review Board (a 
group of people who review the resear ch to 
protect your rights) at __________________  
telephone number) .
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-26  
17. Blood Samples for Future Research (Optional)  
This section of the informed consent form is 
about future research studies that will use 
blood samples from people who are taking 
part i n the main study . You may choose to 
give blood samples for these future research 
studies if you want to. You can still b e a part 
of the main stud y even if you say 'no' to give  
blood samples for future research studies.  
Researchers are trying to learn more about 
how the human body processes the drugs 
used for transplant  and how the body 
recovers after transplant . This r esear ch is 
meant to gain knowledge that m ay help 
people in the future  and make transplants 
even more successful.   
If you agree to provide blood samples, 
here is what will happen:  
a) We will collect 11 extra blood samples 
from your catheter or by a vein in your 
arm at the same time you have routine 
blood tests done (Table 1) . We will take 
about 4 teaspoons  (20 mL) of your blood 
each time. If you weigh less than 6.7 kg, 
the amount of blood will be based on 
your weight (3 mL/kg).  
We will collect your blood on these 11 
days:  
▪ After you consent to giving 
blood samples, but before you 
start the chemotherapy drugs  
▪ 7 days and 1 day before  
transplant  ▪ 1, 14, 28, 42, 70, 100, 180, 365 
days after transplant  
b) The blood s amples for future research  
will be sent to the BMT CTN Repository 
for processing and  storage . A repository 
is a place that protects, stores and sends 
out samples for approved research 
studies. Only the repository will have the 
link between you and your res earch 
samples. All research samples will be 
given a bar code that cannot be linked to 
you by future researchers testing your 
samples.  
c) Samples  stored in the Repository will be 
used mainly by clinicians and 
researchers in the BMT CTN network. 
In the future, the unused  research 
samples and clinical data will be made 
available outside of this network.  
d) Researchers can apply to study the 
materials stored in the Repository. The 
BMT CTN Steering Committee and/or 
the BMT CTN Executive Committee 
must approve each request  before they 
will share samples or information with 
researchers. This is to make sure that the 
investigators requesting the samples are 
qualified, and that the research is of high 
quality . 
e) DNA from your stored blood samples 
might be used in genome -wide 
association (GWA) studies for a future 
project either done or supported by the 
National Institutes of Health (NIH). 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-27 Genome -wide association studies are a 
way for scientists to find genes that have 
a role  in human disease or treatment. 
Each study can look at hundreds of 
thousands of genetic changes at the same 
time. 
If your coded samples are used in 
such a study, the researcher is 
required to add your test results and 
sample information into a shared, 
public research database. This public 
database is called the NIH Genotype 
and Phenotype Database and it is 
managed by the National Center for 
Biotechnology Information (NCBI). 
The NCBI will never have any 
information that would identify you, 
or link you to you r information or 
research samples  although the results 
of genetic studies could theoretically 
include identifying information 
about you .  
Your name and other information that could 
directly identify you (such as address or 
social security number) will not be placed 
into any scientific database. However, 
because your genetic information is unique 
to you, there is a small chance that someone 
could trace it back to you. The risk of this 
happening is small, but may grow in the 
future. Researchers have a duty to  protect 
your privacy and to keep your information 
confidential.  
Some general things you should know about 
letting us store your blood for research are:  
▪ We will only store samples from  people 
who give us permission.  ▪ Research is meant to gain knowledge that 
may help people in the future. You will 
not get any direct benefit from taking part.  
Additionally, you  or your doctor will not 
be given results and they will not be 
added to your medical record . 
▪ A possible risk is the loss of 
confidentiality  about your medical 
information. We will use safety measures 
with both your samples and clinical 
information  to make sure that your 
personal information will be kept private. 
The chance that this information will be 
given to someone else is extremely  small .  
▪ Your blood will be used only for research 
and will not be sold. The research done 
with your blood may help to develop new 
products in the future.  You will not get 
paid for any samples or for any products 
that may be developed from current or 
future rese arch.  
You can change your mind at any time 
about allowing us to use your samples and 
health information for research .  
We ask that you contact [Principal 
Investigator]  in writing and let him/her 
know you do not want us to use your 
research samples or healt h information for 
research. His/her mailing address is on the 
first page of this form . However, samples 
and information that have already been 
shared with other researchers cannot be 
taken back or destroyed.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-28 Making Your Choice  
Please read each sentence b elow and think 
about your choice. After reading each 
sentence, please indicate your choice below. 
If you have any questions, please talk to your doctor or nurse, or call our research 
review board at ___________________ .  
No matter what you decide to do, it  will not 
affect your care.  
 
 
Statement of Consent for Future Research Samples  
The purpose of storing blood samples, the 
procedures involved, and the risks and 
benefits have been explained to me. I have 
asked all the questions I have at this time 
and I have been told whom to contact if I 
have more questions. I have been told that I 
will be given a signed copy of this consent 
form to keep.  
I understand that I do not have to allow the 
use of my blood for research. If I decide to 
not let you store research samples now or in 
the future, it will not affect my medical care 
in any way.  
I voluntarily agree that my blood and 
information can be stored indefinitely by the 
BMT CTN and/or NHLBI Repositories for 
research to learn about, preve nt, or treat health problems. I also understand that my 
DNA and health information may or may 
not be used in genome -wide association 
studies.  
The decision of whether to allow us to use 
the sample s for future research and for your 
genetic code to be release d onto a public 
database is completely up to you. There will 
be no penalty to you if you decide not to 
allow this, and your decision will in no way 
affect your participation in this research.  
If you agree to allow your sample s to be 
used for fut ure research you also agree to 
have your genetic code released to a public 
database and made accessible to other 
researchers .
 
❑ I agree to allow my blood samples to be stored for future research.  
❑ I do not  agree to allow my blood samples to be stored for future research.  
__________________________________________    __________________   
 Signature         Date 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-29 HIPAA1 authorization to use and disclose 
individual health information for 
research purposes:  
 
a. Purpose:   As a research participant, I 
authorize the Principal Investigator and 
the researcher’s staff to use and disclose 
my individual health information for the 
purpose of conducting the research study 
entitled Reduced Intensity Conditioning 
for Children and Ad ults with 
Hemophagocytic Syndromes or Selected 
Primary Immune Deficiencies.  
 
b. Individual Health Information to 
be Used or Disclosed:  My individual 
health information that may be used or 
disclosed to conduct this research 
includes: demographic information (e.g., 
age, date of birth, sex, weight), medical 
history (e.g., diagnosis, complications 
with prior treatment), physical 
examination findings, and laboratory test 
results obtained at the time of work -up 
and after transplantation (e.g. blood 
tests, biopsy results).   The identities of 
individuals such as names and addresses 
will not be shared or de -identified to 
make sure information cannot be linked 
to you.  
 
 
1 HIPAA is the Health Insurance Portability and 
Accountability Act of 1996, a federal law related to 
privacy of health  information  c. Parties Who May Disclose My 
Individual Health Information:  The 
researcher and the rese archer’s staff may 
obtain my child’s (my) individual health 
information from:  
(list: hospitals, clinics or providers from 
which health care information can be 
requested)  
 
 
 
 
d. Parties Who May Receive or Use My 
Individual Health Information:  The 
individual health information disclosed 
by parties listed in item c and 
information disclosed by my child (me) 
during the course of the research may be 
received and used by the following 
parties:  
• Members of the BMT CTN Data and 
Coordinating Center and BMT CTN 
#1204 Protocol Team  
• National Heart, Lung, and Blood 
Institute (NHLBI) and the National 
Cancer Institute (NCI), both of the 
National Institutes of Health (NIH), 
study sponsors  
• The National Marrow Donor 
Program (NMDP) and the Center for 
Internationa l Blood and Marrow 
Transplant Research  (CIBMTR)  
• U.S. government agencies that are 
responsible for overseeing research 
such as the Food and Drug 
Administration (FDA) and the Office 
of Human Research Protections 
(OHRP)  
• U.S. government agencies that are 
respo nsible for overseeing public 
health concerns such as the Centers 
for Disease Control (CDC) and 
federal, state and local health 
departments  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-30  
 
 
e. Right to Refuse to Sign this 
Authorization:  I do not have to sign this 
Authorization.  If I decide not to sign the 
Authorization, I will not be allowed to 
participate in this study or receive any 
research -related treatment that is 
provided through the study.  However, 
my decision not to sign this 
authorization will not affect any other 
treatment, payment, or enrollment in 
health plans or eligibility for benefits.   
 
f. Right to Revoke:   I can change my 
mind and withdraw this authorization at 
any time by sending a written notice to 
the Principal Investigator to inform the 
researcher of the decision.  If I withdraw 
this authorization, the researcher may 
only use and disclose the protected 
health information already collected for 
this research study.  No further health information about my child (me) will be 
collected by or disclosed to the 
researcher for this study.  
 
g. Potential for Re -disclosure:  My 
individual health information disclosed 
under this authorization may be subject 
to re-disclosure outside the research 
study and no longer protected.  
Examples include potential disclosures 
for law enforcement purposes, mandated 
reporting for abuse or neglect, judicial 
proceedings, health oversig ht activities 
and public health measures.  
 
h. This authorization does not have an 
expiration date.  However, you can 
elect at any time to withdraw your 
authorization to participate in the 
study.  
 
You will receive a copy of this form. If you 
need more infor mation about this study, ask 
the study doctor.  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-31 TITLE: Reduced -Intensity Conditioning for Children and Adults with Hemophagocytic 
Syndromes or Selected Primary Immune Deficiencies (RICHI)  
 
PROTOCOL NUMBER: BMT CTN # 1204  
PRINCIPAL INVESTIGA TOR (S):  
Name:  
Address:  
Email:  
Phone:  
Fax: 
 
I have read and understood this Consent 
Form . The nature and purpose of the 
research study has been explained to me.  
 
▪ I have had the chance to ask questions, 
and understand the answers I have been 
given . I understand that I may ask 
questions at any time during the study.  
▪ I freely agree to be a participant in the 
study.  
▪ I understand that I may not directly 
benefit from taking part in the study.  ▪ I understand that, while information 
gained du ring the study may be published, 
I will not be identified and my personal 
results will stay confidential.  
▪ I have had the chance to discuss my 
participation in this research study with a 
family member or friend.  
▪ I understand that I can leave this study at 
any time, and doing so will not affect my 
current care or prevent me from receiving 
future treatment.  
▪ I understand that I will be given a copy of 
this signed consent form.  
 
 
________________________________          
Participant Name       Date 
 
________________________________          
Signature        Date  
 
I certify that I have provided a verbal explanation of the details of the research study, including 
the procedures and risks . I believe the participant has understood the information provided.  
 
________________________________         
Name of Counseling Physician     Date  
 
________________________________          
Signature of Counseling Physician        Date  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-32 Pediatric Assent to Participate in Research  
For Children Ages 7 to 17 years old  
Study Title : Reduced -Intensity Conditioning for Children and Adults with Hemophagocytic 
Syndromes or Selected Primary Immune Deficiencies  
Protocol : BMT CTN  1204  
A. Why am I here ? 
We are inviting you to join our study because you will receive a bone marrow transplant to 
treat your disease. A transplant uses blood -making cells from another person (donor) to 
replace your cells that are not healthy. A donor is the name for a person who gives some of 
their blood -making cells for a transplan t. 
B. Why are you doing this study ? 
We want to learn if transplant works to cure your disease.  
C. What will happen to me?  
Before your transplant, you will have check -ups with the study doctors. Then, you will get a 
small tube put in your chest in the operating room (you will be asleep for this).  The small 
tube makes it easier for you to get your medicines. It will also make it easier and less painful 
for drawing blood for tests.  
We will give you medicines that will help make the cells from your donor grow in your body. 
These medicines might make you feel sick. You might throw up, lose your hair, or get sores 
in your mouth.  
After you’re done taking the medicines, you will get cells from your donor. This is your 
transplant. Your donor can be your sister or brother (related) or someone you don’t know 
(unrelated). Your new cells will come from your donor's bone marrow. The cells will make 
new and healthy cells in your body.  
Sometimes the donor cells can cause a problem called graft versus host disease ( GVHD ). 
GVHD happens when your body attacks the donor cells. It can give you diarrhea, a skin rash,  
make you feel sick and throw u p, or make you not feel hungry. Your doctors will give you 
medicines to try to make sure you don’t get GVHD.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-33 You will stay in the hospital for several days before your transplant and for about 4 weeks 
after your transplant. After you go home, you will nee d to go back to see your doctor often.  
It is possible that your disease will come back. If this happens, your doctor will find another 
way to treat you.  
D. Will it hurt?  
For your transplant,  we will put a small tube in your chest. It might hurt a little and you 
might bleed a little. Your doctor and nurses will make sure you feel as little pain as possible.  
E. Will the study help me?  
We don’t know if the study will help you or not.  
F. What if I have questi ons?  
You can ask any questions that you have about the study.  If you forget to ask a question and 
think of it later, you can call me [ insert office number ].  You can also ask your question the 
next time you see me.  
You can call the study office at any tim e to ask questions about the study.  
G. Do I have to be in this study?  
You don't have to be in this study. Your doctor and nurses will not be mad at you if you don't 
want to join. If you decide you don't want to be in this study, you should talk to your doctor, 
nurses and parents about other ways to treat your disease.  
You c an say yes now and change your mind later.  
Be sure to  talk this over with your parents before you decide if you want  be in the study. We 
will also ask your parents to give their permission for you to join this study.  
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
B-34  
Writing your name on this page me ans that you agree to be in the study and know what will 
happen to you.  If you decide to quit the study, all you have to do is tell your doctor.  
You and your parent or guardian will get a copy of this form after you sign it.  
 
________________________________ ______________   ______________________________  
Signature of Child       Date  
 
________________________________ ______________   ______________________________  
Print Name of Child  Age of Child  
 
Certification of Counseling Healthcare Professional: I certify that the nature and purpose, the 
potential benefits, and possible risks associated with participation in this study have been 
explained to the above individual and that any questions about this information have been 
answered.  
 
________________________________ ______________   ______________________________  
Counseling Healthcare Professional  Date  
 
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
 
 
C-1 APPENDIX C  
 
LABORATORY PROCEDURES  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
 Version 4.0 dated June 16, 2015  
 
 
C-2 APPENDIX C  
 
LABORATORY PROCEDURES  
 
 
Participants consenting to the optional future research will have samples collected for future 
research supporting the protocol.  All research sample aliquots  will be given unique bar code 
designations that generally cannot be linked back to the participant’s name or other identifying 
information , though participants  are given the opportunity to consent to research including 
genetic data, in which case the resu lts could theoretically include identifying information . 
Laboratory test results, clinical information, etc., associated with the coded samples may be 
provided to the Investigators to associate biological findings with clinical outcomes .  
Investigators wil l be able to link results from serial aliquots (for example: Pre -conditioning, Day 
+1, Day +30) plasma samples.  Similarly, investigators will be able to link data from different 
sample types (for example: protein data from plasma and gene expression data from peripheral 
mononuclear cells).  All research samples will be collected and shipped same -day to the BMT 
CTN Repository for processing and sample aliquot storage.   Priority for biological samples will 
be determined according to the BMT CTN # 1204 team, a long with the BMT CTN Biomarker 
Committee.  
 
The rationale for this sample collection strategy is to enable independently funded correlative 
biology studies.  The sample collection schedule is designed to allow development of studies to 
test the role of ear ly inflammation and alemtuzumab pharmacokinetics on clinical outcomes 
including immune reconstitution, engraftment and development of mixed chimerism, 
development and clearance of viral infections, and development of GVHD.  Endpoints may be 
determined by c linical reporting, with requirements outlined in the body of the protocol, and/or 
by specific research tests.  For example, chimerism (whole and CD3+ fractions) will be collected 
in clinical labs for all patients, though more refined lineage -specific chime rism may be tested on 
a research basis.  Samples at all time points will also be banked for unspecified future research.   
 
Biomarker 
Approach  Sample 
Type  Pre-
Conditioning  Day 
-7 Day 
-1 
-1 Day 
+1 Day 
+14 Day 
+28 Day 
+42 Day 
+70 Day 
+100  Day 
+180  Day 
+365  
Proteonomics  Plasma  X  X  X X X X X X X 
Gene 
Expression  PBMC  X  X  X X X X X X X 
Alemtuzumab 
Concentration  Plasma  X X X X X X X     
Clinical 
Endpoints  Sample 
Type  Pre-
Conditioning  Day 
-7 Day 
-1 
-1 Day 
+1 Day 
+14 Day 
+28 Day 
+42 Day 
+70 Day 
+100  Day 
+180  Day 
+365  
Early 
Inflammation   X X X         
Immune 
Reconstitution        X X X X X X 
Chimerism        X X X X X X 
Viral 
Infections   X X X X X X X X X X X 
GVHD        X X X X X X 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
 Version 4.0 dated June 16, 2015  
 
 
C-3  
Research sample collection and storage plan outlined below:  
 
Subjects  Research 
Sample Type  Peripheral Blood 
Collection Volume  Stored 
Material  Aliquots Stored  
Patients who 
consent to 
future 
research  Peripheral 
Blood  20 mL (Sodium 
Heparin Tubes)  
Maximum blood 
volume collection limit 
at each scheduled time 
point  
 
Pediatric patients (< 
6.7 kg):  3 mL/kg  Plasma  Maximum 12 aliquots  
~0.5 to 1.0 mL aliquots; stored at 
-80°C (If ≤ 2 mL plasma: stored 
in 0.25 mL aliquots)  
Viable PBMC  Maximum 6 aliquots  
1.0 mL aliquots containing ~2.5 -
5.0 x 106 PBMC; controlled -rate 
frozen and stored in LN  
(When PBMC recovery is low: 
stored in 1.0 mL aliquots 
containing ~1.0 x 106 PBMC)  
* All blood samples will be collected and shipped same -day for next -day processing and storage at the BMT CTN 
Research Sample Repository.  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
D-1 APPENDIX D 
 
LANSKY AND KARNOFSKY  
PERFORMANCE STATUS SCALE S 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
D-2 APPENDIX D  
 
LANSKY and KARNOFSKY PERFORMANCE STATUS SCALE S 
 
 
LANSKY SCALE (< 16 YEARS ) 
Percentage   
100 Fully active  
90 Minor restriction in physically strenuous play  
80 Restricted in strenuous play, tires more easily, otherwise active  
70 Both greater restrictions of, and less time spent in, active play  
60 Ambulatory up to 50% of time, limited active play with assistance/supervision  
50 Considerable assistance required for any active play; fully able to engage in quiet 
play 
40 Able to initiate quiet activities  
30 Needs considerable assistance for quiet activity  
20 Limited to very passive activity initiated by others (e.g., TV)  
10 Completely disabled, not even passive play  
0 Dead  
 
 
KARNOFSKY SCALE  (≥ 16 YEARS ) 
Percentage   
100 Normal health  
90 Minor symptoms  
80 Normal activity with some effort  
70 Unable to carry on normal activity but able to care for oneself  
60 Requires occasional help with personal needs  
50 Disabled  
40 Requires considerable assistance and medical care  
30 Severely disabled, in hospital  
20 Very sick, active support needed  
10 Moribund  
0 Dead  
 
REFERENCE  Karnofsky DA: Meaningful clinical classification of therapeutic responses to anti -cancer 
drugs.  Editorial: Clin Pharmacol Ther  2:709 -712, 1961.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
E-1 APPENDIX E 
 
RECOMMENDATIONS FOR HLH THERAPY PRIOR TO HCT 
AND  
FOR HLH SALVAGE THERAPY  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
E-2 APPENDIX E 
 
RECOMMENDATIONS FOR HLH THERAPY PRIOR TO HCT AND  
FOR HLH SALVAGE THERAPY  
 
1. Patients with active HLH should be treated according to  the Histiocyte Society HLH -94 
Protocol prior to HCT .1 
2. For patients with evidence of refractory HLH despite treatment per HLH -94 (As determined 
by clinician, but may include persistent fever; rising ferritin, rising soluble IL2R , rising 
LDH; clinical and lab evidence of organ damage/failure (Jordan et al., 2011 ) 
a. Re-escalate dexamethasone and etoposide to maximum of etoposide 150  mg/m2 twice 
weekly and dexamethasone 10 mg/m2/day, then  wean etoposide frequency and 
dexamethasone d ose as tolerated.   
b. If HLH is refractory despite maximum etoposide and dexamethasone, consider trial of 
alemtuzumab “salvage” therapy:  
­ Alemtuzumab: 0.1  mg/kg (IV  or subcutaneous ) x 1 day, then 0.3 mg/kg (IV  or 
subcutaneous ) x 3 days  
­ Continue dexametha sone at 10  mg/m2/day x 1 week, then wean as tolerated back to 
either “Induction” or “Continuation” per HLH -94 
­ Discontinue cyclosporine while patient has symptoms of active/refractory HLH  (Risk 
of PRES may be associated with cyclosporine and active HLH  (Thompson et al., 
2009) ) 
3. All patients with history of CNS involvement by HLH (pleocytosis, elevated protein, 
abnormal MRI, or hemophagocytosis  in CSF) should undergo diagnostic LP and/or at Day 
+30 ( + 1 week), or at any time of unexplained mental status change.  Brain MRI may be 
substituted for LP if patients are not able to tolerate the procedure.  Intrathecal therapy is 
recommended, when clini cally safe to administer in patients with pleocytosis or 
hemphagocytosis in CSF, or MRI consistent with HLH -associated inflammation.  
Recommended therapy for CNS inflammation in HLH: Weekly intrathecal therapy is 
generally continued until at least 1 week af ter resolution of CNS involvement (both clinical 
and CSF indices): age < 1 year: 6  mg  MTX/8 mg hydrocortisone; 1 -2 years, 8  mg MTX/10 
mg hydrocortisone; 2 -3 years, 10  mg MTX/12 mg hydrocortisone; > 3 years, 12 mg MTX/15 
mg hydrocortisone (Jordan et al.,  2011) .  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
F-1 APPENDIX F  
 
DERIVATION OF A SEQUENTIAL TEST STATISTIC FOR 
CENSORED EXPONENTIAL DATA  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
F-2 APPENDIX F 
 
DERIVATION OF A SEQUENTIAL TEST STATISTIC FOR CENSORED 
EXPONENTIAL DATA  
 
 
Background – The Sequential Probability Ratio Test  
 
Let 
) (.,f be the density function for random variable X.  According to Neyman  and Pearson, 
the most powerful test of 
o H  =:0  versus
1 1: = H  decides in favor of 
1H  or 
0H if 
c Ln  
or 
c Ln , respectively, where 
=n
ii i n x f x f L ) ; ( / ) ; (0 1   is the likelihood ratio, and 
c is 
determined to have the size 
 .  When the sample size is not fixed in advance, further 
improvement is possible by using Wald’s Sequential Probability Ratio Test (SPRT).  The SPRT 
continues to sample as long as 
A L Bn   for some constant 
A B 1 , stops sampling  and 
decides in favor of 
1H as soon as 
A Ln , and stops sampling and decides in favor of 
0H as soon 
as 
B Ln . 
 
The usual measures of performance of such a procedure are the error proba bilities 
 and
 of 
rejecting 
0H when 
0 = , and of accepting 
0H when 
1 = , respectively, and the expected 
sample size 
) ( ) | (N E N Ej j .  Wald and Wolfowitz showed that among all tests, sequential or 
not, for which 
) reject ( Pr0 0 H  and 
) reject ( Pr0 1 H , and for which 
) (N Ej  are finite, j=0,1, 
the SPRT with error probabilities 
  and 
 minimizes 
) (0N E  and 
) (1N E .  If, in addition, the 
,... 2 , 1x x
 are independent and identically distributed (i.i.d.) with density fun ction 
) , (x f , with 
monotone likelihood ratio in 
) (x , then any SPRT for testing 
0 against 
) (0 1   has non -
decreasing power function.  
 
For the SPRT with error probabilities 
 and
 , the SPRT boundaries are given approximately by 
 / ) 1 ( − = A
 and 
) 1 /( − = B .  The operating characteristics of the SPRT are given by 
) /() 1 ( ) , , , , () ( ) ( ) (
1 0      h h hB A A O − − =
 where 
) (h is the non -trivial solution to the equation 
=1 ) ; ( )), ( / ) ; ( () (
2 1 dxx f x f x fh  
.   
 
The formula 
) ; ( / ] log ) ( log )]( 1 [[() ; (     z E B O A O N E + − = provides the average sample number 
for an arbitrary 
 .  The sample size distribution is very highly skewed, 
2)]( [ ) (N E N Var  .  Thus 
we will consider a truncated test with maximum sample size of 
0N  and simulate to obtain the 
operating characteristics of the test.  
 
  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
F-3 Derivation of the SP RT for Censored Exponential Survival Times  
 
Suppose that we wish to construct a sequential test for the composite null hypothesis that the rate 
of overall mortality at an early time point t is less than or equal to p 0 versus the alternative 
hypothesis that  it is greater than or equal to p 0.  Let us assume that the survival times, 
nT T T,..., ,2 1 , 
are i.i.d. with exponential density function 
Te T f −=) , ( .  Although an exponential model may 
not fit well for overall mortality, it usually provi des a reasonable model over a short time frame 
for modeling toxicity, so in all discussion below we assume that exponential survival times are 
censored at time point t. In the exponential parameterization, a t -day survival rate of p 0 translates 
into a mean  survival of µ0=-t/ln(1 -p0) (rate parameter 
=0 -ln(1-p0)/t).  .  
 
The SPRT is derived with reference to a simple null and alternative hypothesis for the rate 
parameter, in this case, 
0:o H=   versus
1 1: = H  .  The log -likelihood ratio for the 
exponential in the presence of censoring is 
1 0 1 0 1 0 log ( ; ) log ( , ) (log( ) log( )) ( )nn n
i i i
i iif x f x d T       − = − − −  
, where d is the number of 
events.   The SPRT can be represented graphically when plotting the number of deaths (d) on the 
y axis against the total time on study 
n
iiT  on the x axis.  The continuation region in terms of d is 
bounded by two parallel lines given by  
1 0 1 0
1 0 1 0 1 0 1 0( ) ( ) log( ) log( )
(log log ) (log log ) (log log ) (log log )nn
ii
iiBAT d T   
               −−+   +        − − − −        
 
with common slope 
1 0 1 0 ( ) / (log log )   −− , and intercepts 
10 log / (ln ln )A −  and 
10 log / (ln ln )B −
, for the upper and lower bounds, respectively.  For monitoring purposes, at an 
interim analysis calendar time point s, sup pose that d(s) events have occurred and that the total 
time on study is 
()n
i
iTs .The cumulati ve number of events d(s) is plotted on the y axis against 
the total time on study,
()n
i
iTs .  When this graph crosses the upper boundary, the null 
hypothesis is rejected. In practice, monitoring will be scheduled monthly after the start of  
enrollment to the study.   
 
A truncated version of the SPRT can be obtained by specifying a maximum sample size.  We 
truncate the SPRT by declaring that if the test has failed to terminate after the maximum sample 
size, that the null hypothesis will be ac cepted.  Since the probability that the untruncated SPRT 
would reject the null at the maximum sample size is negligible, it makes little difference how the 
final boundary value is selected, and this rule is chosen for simplicity.  The operating 
characteris tics of this proposed truncated SPRT for censored exponential data can be estimated 
by simulation.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
G-1 APPENDIX G  
 
BLOOD PRESSURE LEVELS BY AGE AND HEIGHT  
PERCENTILE  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
G-2 APPENDIX G 
 
BLOOD PRESSURE LEVELS BY AGE AND HEIGHT PERCENTILE  
 
 
Blood Pressure Levels for Boys by Age and Height Percentile  
 
  
BP   Systolic BP (mmHg)       Diastolic BP (mmHg)    
 
                  
    Percentile of Height       Percentile of Height    
 Age Percentile       
 
                 
 (Year)   5th 10th 25th 50th 75th 90th 95th  5th 10th 25th 50th 75th 90th 95th 
 
 1 50th 80 81 83 85 87 88 89 34 35 36 37 38 39 39 
 
  90th 94 95 97 99 100 102 103 49 50 51 52 53 53 54 
 
  95th 98 99 101 103 104 106 106 54 54 55 56 57 58 58 
 
  99th 105 106 108 110 112 113 114 61 62 63 64 65 66 66 
 
                  
 2 50th 84 85 87 88 90 92 92 39 40 41 42 43 44 44 
 
  90th 97 99 100 102 104 105 106 54 55 56 57 58 58 59 
 
  95th 101 102 104 106 108 109 110 59 59 60 61 62 63 63 
 
  99th 109 110 111 113 115 117 117 66 67 68 69 70 71 71 
 
                  
 3 50th 86 87 89 91 93 94 95 44 44 45 46 47 48 48 
 
  90th 100 101 103 105 107 108 109 59 59 60 61 62 63 63 
 
  95th 104 105 107 109 110 112 113 63 63 64 65 66 67 67 
 
  99th 111 112 114 116 118 119 120 71 71 72 73 74 75 75 
 
                  
 4 50th 88 89 91 93 95 96 97 47 48 49 50 51 51 52 
 
  90th 102 103 105 107 109 110 111 62 63 64 65 66 66 67 
 
  95th 106 107 109 111 112 114 115 66 67 68 69 70 71 71 
 
  99th 113 114 116 118 120 121 122 74 75 76 77 78 78 79 
 
                  
 5 50th 90 91 93 95 96 98 98 50 51 52 53 54 55 55 
 
  90th 104 105 106 108 110 111 112 65 66 67 68 69 69 70 
 
  95th 108 109 110 112 114 115 116 69 70 71 72 73 74 74 
 
  99th 115 116 118 120 121 123 123 77 78 79 80 81 81 82 
 
                  
 6 50th 91 92 94 96 98 99 100 53 53 54 55 56 57 57 
 
  90th 105 106 108 110 111 113 113 68 68 69 70 71 72 72 
 
  95th 109 110 112 114 115 117 117 72 72 73 74 75 76 76 
 
  99th 116 117 119 121 123 124 125 80 80 81 82 83 84 84 
 
                  
 7 50th 92 94 95 97 99 100 101 55 55 56 57 58 59 59 
 
  90th 106 107 109 111 113 114 115 70 70 71 72 73 74 74 
 
  95th 110 111 113 115 117 118 119 74 74 75 76 77 78 78 
 
  99th 117 118 120 122 124 125 126 82 82 83 84 85 86 86 
 
                  
 8 50th 94 95 97 99 100 102 102 56 57 58 59 60 60 61 
 
  90th 107 109 110 112 114 115 116 71 72 72 73 74 75 76 
 
  95th 111 112 114 116 118 119 120 75 76 77 78 79 79 80 
 
  99th 119 120 122 123 125 127 127 83 84 85 86 87 87 88 
 
                  
 9 50th 95 96 98 100 102 103 104 57 58 59 60 61 61 62 
 
  90th 109 110 112 114 115 117 118 72 73 74 75 76 76 77 
 
  95th 113 114 116 118 119 121 121 76 77 78 79 80 81 81 
 
  99th 120 121 123 125 127 128 129 84 85 86 87 88 88 89 
 
                  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
G-3 Blood Pressure Levels for Boys by Age and Height Percentile (Continued)  
 
 
BP   Systolic BP (mmHg)       Diastolic BP (mmHg)    
 
                 
   Percentile of Height       Percentile of Height    
Age Percentile       
 
                
(Year)   5th 10th 25th 50th 75th 90th 95th  5th 10th 25th 50th 75th 90th 95th 
 
 10 50th 97 98 100 102 103 105 106 58 59 60 61 61 62 63 
 
  90th 111 112 114 115 117 119 119 73 73 74 75 76 77 78 
 
  95th 115 116 117 119 121 122 123 77 78 79 80 81 81 82 
 
  99th 122 123 125 127 128 130 130 85 86 86 88 88 89 90 
 
                   
11 50th 99 100 102 104 105 107 107 59 59 60 61 62 63 63 
 
 90th 113 114 115 117 119 120 121 74 74 75 76 77 78 78 
 
 95th 117 118 119 121 123 124 125 78 78 79 80 81 82 82 
 
 99th 124 125 127 129 130 132 132 86 86 87 88 89 90 90 
 
                 
12 50th 101 102 104 106 108 109 110 59 60 61 62 63 63 64 
 
 90th 115 116 118 120 121 123 123 74 75 75 76 77 78 79 
 
 95th 119 120 122 123 125 127 127 78 79 80 81 82 82 83 
 
 99th 126 127 129 131 133 134 135 86 87 88 89 90 90 91 
 
                 
13 50th 104 105 106 108 110 111 112 60 60 61 62 63 64 64 
 
 90th 117 118 120 122 124 125 126 75 75 76 77 78 79 79 
 
 95th 121 122 124 126 128 129 130 79 79 80 81 82 83 83 
 
 99th 128 130 131 133 135 136 137 87 87 88 89 90 91 91 
 
                 
14 50th 106 107 109 111 113 114 115 60 61 62 63 64 65 65 
 
 90th 120 121 123 125 126 128 128 75 76 77 78 79 79 80 
 
 95th 124 125 127 128 130 132 132 80 80 81 82 83 84 84 
 
 99th 131 132 134 136 138 139 140 87 88 89 90 91 92 92 
 
                 
15 50th 109 110 112 113 115 117 117 61 62 63 64 65 66 66 
 
 90th 122 124 125 127 129 130 131 76 77 78 79 80 80 81 
 
 95th 126 127 129 131 133 134 135 81 81 82 83 84 85 85 
 
 99th 134 135 136 138 140 142 142 88 89 90 91 92 93 93 
 
                 
16 50th 111 112 114 116 118 119 120 63 63 64 65 66 67 67 
 
 90th 125 126 128 130 131 133 134 78 78 79 80 81 82 82 
 
 95th 129 130 132 134 135 137 137 82 83 83 84 85 86 87 
 
 99th 136 137 139 141 143 144 145 90 90 91 92 93 94 94 
 
                 
17 50th 114 115 116 118 120 121 122 65 66 66 67 68 69 70 
 
 90th 127 128 130 132 134 135 136 80 80 81 82 83 84 84 
 
 95th 131 132 134 136 138 139 140 84 85 86 87 87 88 89 
 
 99th 139 140 141 143 145 146 147 92 93 93 94 95 96 97 
 
                   
BP, blood pressure   
* The 90th percentile is 1.28 SD, 95th percentile is 1.645 SD, and the 99th percentile is 2.326 SD over the mean.   
For research purposes, the standard deviations in Appendix Table B –1 allow one to compute BP Z -scores and percentiles for 
boys with height percentiles given in Table 3 (i.e., the 5th,10th, 25th, 50th, 75th, 90th, and 95th percentiles). These heigh t 
percentiles must be converted to h eight Z -scores given by (5% = -1.645; 10% = -1.28; 25% = -0.68; 50% = 0; 75% = 0.68; 90% = 
1.28%; 95% = 1.645) and then computed according to the methodology in steps 2 –4 described in Appendix B. For children with 
height percentiles other than these, follo w steps 1 –4 as described in Appendix B.  
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
G-4 Blood Pressure Levels for Girls by Age and Height Percentile  
 
  
BP   Systolic BP (mmHg)       Diastolic BP (mmHg)     
 
                   
    Percentile of Height       Percentile of Height     
 Age Percentile        
 
                  
 (Year)   5th 10th 25th 50th 75th 90th 95th  5th 10th 25th 50th 75th 90th 95th  
 
 l 50th 83 84 85 86 88 89 90 38 39 39 40 41 41 42  
 
  90th 97 97 98 100 101 102 103 52 53 53 54 55 55 56  
 
  95th 100 101 102 104 105 106 107 56 57 57 58 59 59 60  
 
  99th 108 108 109 111 112 113 114 64 64 65 65 66 67 67  
 
                   
 2 50th 85 85 87 88 89 91 91 43 44 44 45 46 46 47  
 
  90th 98 99 100 101 103 104 105 57 58 58 59 60 61 61  
 
  95th 102 103 104 105 107 108 109 61 62 62 63 64 65 65  
 
  99th 109 110 111 112 114 115 116 69 69 70 70 71 72 72  
 
                   
 3 50th 86 87 88 89 91 92 93 47 48 48 49 50 50 51  
 
  90th 100 100 102 103 104 106 106 61 62 62 63 64 64 65  
 
  95th 104 104 105 107 108 109 110 65 66 66 67 68 68 69  
 
  99th 111 111 113 114 115 116 117 73 73 74 74 75 76 76  
 
                   
 4 50th 88 88 90 91 92 94 94 50 50 51 52 52 53 54  
 
  90th 101 102 103 104 106 107 108 64 64 65 66 67 67 68  
 
  95th 105 106 107 108 110 111 112 68 68 69 70 71 71 72  
 
  99th 112 113 114 115 117 118 119 76 76 76 77 78 79 79  
 
                   
 5 50th 89 90 91 93 94 95 96 52 53 53 54 55 55 56  
 
  90th 103 103 105 106 107 109 109 66 67 67 68 69 69 70  
 
  95th 107 107 108 110 111 112 113 70 71 71 72 73 73 74  
 
  99th 114 114 116 117 118 120 120 78 78 79 79 80 81 81  
 
                   
 6 50th 91 92 93 94 96 97 98 54 54 55 56 56 57 58  
 
  90th 104 105 106 108 109 110 111 68 68 69 70 70 71 72  
 
  95th 108 109 110 111 113 114 115 72 72 73 74 74 75 76  
 
  99th 115 116 117 119 120 121 122 80 80 80 81 82 83 83  
 
                   
 7 50th 93 93 95 96 97 99 99 55 56 56 57 58 58 59  
 
  90th 106 107 108 109 111 112 113 69 70 70 71 72 72 73  
 
  95th 110 111 112 113 115 116 116 73 74 74 75 76 76 77  
 
  99th 117 118 119 120 122 123 124 81 81 82 82 83 84 84  
 
                   
 8 50th 95 95 96 98 99 100 101 57 57 57 58 59 60 60  
 
  90th 108 109 110 111 113 114 114 71 71 71 72 73 74 74  
 
  95th 112 112 114 115 116 118 118 75 75 75 76 77 78 78  
 
  99th 119 120 121 122 123 125 125 82 82 83 83 84 85 86  
 
                   
 9 50th 96 97 98 100 101 102 103 58 58 58 59 60 61 61  
 
  90th 110 110 112 113 114 116 116 72 72 72 73 74 75 75  
 
  95th 114 114 115 117 118 119 120 76 76 76 77 78 79 79  
 
  99th 121 121 123 124 125 127 127 83 83 84 84 85 86 87  
 
                   
 10 50th 98 99 100 102 103 104 105 59 59 59 60 61 62 62  
 
  90th 112 112 114 115 116 118 118 73 73 73 74 75 76 76  
 
  95th 116 116 117 119 120 121 122 77 77 77 78 79 80 80  
 
  99th 123 123 125 126 127 129 129 84 84 85 86 86 87 88  
 
                    
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
G-5 Blood Pressure Levels for Girls by Age and Height Percentile (Continued)  
 
 
BP   Systolic BP (mmHg)       Diastolic BP (mmHg)    
 
                 
   Percentile of Height       Percentile of Height    
Age Percentile       
 
                
(Year)   5th 10th 25th 50th 75th 90th 95th  5th 10th 25th 50th 75th 90th 95th 
 
11 50th 100 101 102 103 105 106 107 60 60 60 61 62 63 63 
 
 90th 114 114 116 117 118 119 120 74 74 74 75 76 77 77 
 
 95th 118 118 119 121 122 123 124 78 78 78 79 80 81 81 
 
 99th 125 125 126 128 129 130 131 85 85 86 87 87 88 89 
 
                 
12 50th 102 103 104 105 107 108 109 61 61 61 62 63 64 64 
 
 90th 116 116 117 119 120 121 122 75 75 75 76 77 78 78 
 
 95th 119 120 121 123 124 125 126 79 79 79 80 81 82 82 
 
 99th 127 127 128 130 131 132 133 86 86 87 88 88 89 90 
 
                 
13 50th 104 105 106 107 109 110 110 62 62 62 63 64 65 65 
 
 90th 117 118 119 121 122 123 124 76 76 76 77 78 79 79 
 
 95th 121 122 123 124 126 127 128 80 80 80 81 82 83 83 
 
 99th 128 129 130 132 133 134 135 87 87 88 89 89 90 91 
 
                 
14 50th 106 106 107 109 110 111 112 63 63 63 64 65 66 66 
 
 90th 119 120 121 122 124 125 125 77 77 77 78 79 80 80 
 
 95th 123 123 125 126 127 129 129 81 81 81 82 83 84 84 
 
 99th 130 131 132 133 135 136 136 88 88 89 90 90 91 92 
 
                 
15 50th 107 108 109 110 111 113 113 64 64 64 65 66 67 67 
 
 90th 120 121 122 123 125 126 127 78 78 78 79 80 81 81 
 
 95th 124 125 126 127 129 130 131 82 82 82 83 84 85 85 
 
 99th 131 132 133 134 136 137 138 89 89 90 91 91 92 93 
 
                 
16 50th 108 108 110 111 112 114 114 64 64 65 66 66 67 68 
 
 90th 121 122 123 124 126 127 128 78 78 79 80 81 81 82 
 
 95th 125 126 127 128 130 131 132 82 82 83 84 85 85 86 
 
 99th 132 133 134 135 137 138 139 90 90 90 91 92 93 93 
 
                 
17 50th 108 109 110 111 113 114 115 64 65 65 66 67 67 68 
 
 90th 122 122 123 125 126 127 128 78 79 79 80 81 81 82 
 
 95th 125 126 127 129 130 131 132 82 83 83 84 85 85 86 
 
 99th 133 133 134 136 137 138 139 90 90 91 91 92 93 93 
 
                   
BP, blood pressure   
* The 90th percentile is 1.28 SD, 95th percentile is 1.645 SD, and the 99th percentile is 2.326 SD over the mean.   
For research purposes, the standard deviations in Appendix Table B –1 allow one to compute BP Z -scores and percentiles for 
girls with height percentiles given in Table 4 (i.e., the 5th,10th, 25th, 50th, 75th, 90th, and 95th percentiles). These height 
percentiles must be converted to height Z -scores given by (5% = -1.645; 10% = -1.28; 25% = -0.68; 50% = 0; 75% = 0.68; 90% 
= 1.28%; 95% = 1.645) and then computed according to the methodology in steps 2 –4 described  in Appendix B. For children 
with height percentiles other than these, follow steps 1 –4 as described in Appendix B.  
 
REFERENCE: http://www.nhlbi.nih.gov/files/docs/guidelines/chil d_tbl.pdf   
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-1 APPENDIX H 
 
REFERENCES  
 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-2 APPENDIX H 
 
REFERENCE LIST  
 
Baker,K.S., Filipovich,A.H., Gross,T.G., Grossman,W.J., Hale,G.A., Hayashi,R.J., Kamani,N.R., 
Kurian,S., Kapoor,N., Ringden,O., and Eapen,M. (2008). Unrelated donor hematopoietic cell 
transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Tran splant. 42, 175 -180. 
Bruck,N., Suttorp,M., Kabus,M., Heubner,G., Gahr,M., and Pessler,F. (2011). Rapid and 
sustained remission of systemic juvenile idiopathic arthritis -associated macrophage activation 
syndrome through treatment with anakinra and corticosteroids. J. Clin. Rheu matol. 17, 23-27. 
Burroughs,L.M., Torgerson,T.R., Storb,R., Carpenter,P.A., Rawlings,D.J., Sanders,J., 
Scharenberg,A.M., Skoda -Smith,S., Englund,J., Ochs,H.D., and Woolfrey,A.E. (2010). Stable 
hematopoietic cell engraftment after low -intensity nonmyeloabla tive conditioning in patients 
with immune dysregulation, polyendocrinopathy, enteropathy, X -linked syndrome. J. Allergy 
Clin. Immunol. 126, 1000 -1005.  
Campbell,D.J. and Ziegler,S.F. (2007). FOXP3 modifies the phenotypic and functional 
properties of regulat ory T cells. Nat. Rev. Immunol. 7, 305 -310. 
Chatila,T.A., Blaeser,F., Ho,N., Lederman,H.M., Voulgaropoulos,C., Helms,C., and 
Bowcock,A.M. (2000). JM2, encoding a fork head -related protein, is mutated in X -linked 
autoimmunity -allergic disregulation syndrome . J. Clin. Invest 106, R75 -R81.  
Cohen,J.I., Jaffe,E.S., Dale,J.K., Pittaluga,S., Heslop,H.E., Rooney,C.M., Gottschalk,S., 
Bollard,C.M., Rao,V.K., Marques,A., Burbelo,P.D., Turk,S.P., Fulton,R., Wayne,A.S., 
Little,R.F., Cairo,M.S., El -Mallawany,N.K., Fowler ,D., Sportes,C., Bishop,M.R., Wilson,W., 
and Straus,S.E. (2011). Characterization and treatment of chronic active Epstein -Barr virus 
disease: a 28 -year experience in the United States. Blood 117, 5835 -5849.  
Conley,M.E., Notarangelo,L.D., and Etzioni,A. (19 99). Diagnostic criteria for primary 
immunodeficiencies. Representing PAGID (Pan -American Group for Immunodeficiency) and 
ESID (European Society for Immunodeficiencies). Clin. Immunol. 93, 190 -197. 
Cooper,N., Rao,K., Gilmour,K., Hadad,L., Adams,S., Cale,C. , Davies,G., Webb,D., Veys,P., and 
Amrolia,P. (2006). Stem cell transplantation with reduced -intensity conditioning for 
hemophagocytic lymphohistiocytosis. Blood 107, 1233 -1236.  
Cooper,N., Rao,K., Goulden,N., Webb,D., Amrolia,P., and Veys,P. (2008). The us e of reduced -
intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell 
histiocytosis. Bone Marrow Transplant. 42 Suppl 2 , S47 -S50. 
Davies,E.G. and Thrasher,A.J. (2010). Update on the hyper immunoglobulin M syndromes. Br . 
J. Haematol. 149, 167 -180. 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-3 Dorsey,M.J., Petrovic,A., Morrow,M.R., Dishaw,L.J., and Sleasman,J.W. (2009). FOXP3 
expression following bone marrow transplantation for IPEX syndrome after reduced -intensity 
conditioning. Immunol. Res. 44, 179 -184. 
Etzioni,A. (2010). Defects in the leukocyte adhesion cascade. Clin. Rev. Allergy Immunol. 38, 
54-60. 
Filipovich,A. (2008). Hematopoietic cell transplantation for correction of primary 
immunodeficiencies. Bone Marrow Transplant. 42 Suppl 1 , S49 -S52. 
Fischer,A., Lisows ka-Grospierre,B., Anderson,D.C., and Springer,T.A. (1988). Leukocyte 
adhesion deficiency: molecular basis and functional consequences. Immunodefic. Rev. 1, 39-54. 
Gennery,A.R., Khawaja,K., Veys,P., Bredius,R.G., Notarangelo,L.D., Mazzolari,E., Fischer,A., 
Landais,P., Cavazzana -Calvo,M., Friedrich,W., Fasth,A., Wulffraat,N.M., Matthes -Martin,S., 
Bensoussan,D., Bordigoni,P., Lange,A., Pagliuca,A., Andolina,M., Cant,A.J., and Davies,E.G. 
(2004). Treatment of CD40 ligand deficiency by hematopoietic stem cell tr ansplantation: a 
survey of the European experience, 1993 -2002. Blood 103, 1152 -1157.  
Gungor,T., Halter,J., Klink,A., Junge,S., Stumpe,K.D., Seger,R., and Schanz,U. (2005). 
Successful low toxicity hematopoietic stem cell transplantation for high -risk adult chronic 
granulomatous disease patients. Transplantation 79, 1596 -1606.  
Hannibal,M.C. and Torgerson,T. (1993). IPEX Syndrome.  
Henter,J.I., Elinder,G., Soder,O., and Ost,A. (1991). Incidence in Sweden and clinical features of 
familial hemophagocytic lymphohi stiocytosis. Acta Paediatr. Scand. 80, 428 -435. 
Henter,J.I., Horne,A., Arico,M., Egeler,R.M., Filipovich,A.H., Imashuku,S., Ladisch,S., 
McClain,K., Webb,D., Winiarski,J., and Janka,G. (2007). HLH -2004: Diagnostic and therapeutic 
guidelines for hemophagocyt ic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124 -131. 
Henter,J.I., Samuelsson -Horne,A., Arico,M., Egeler,R.M., Elinder,G., Filipovich,A.H., 
Gadner,H., Imashuku,S., Komp,D., Ladisch,S., Webb,D., and Janka,G. (2002). Treatment of 
hemophagocytic lymphohi stiocytosis with HLH -94 immunochemotherapy and bone marrow 
transplantation. Blood 100, 2367 -2373.  
Henzan,T., Nagafuji,K., Tsukamoto,H., Miyamoto,T., Gondo,H., Imashuku,S., and Harada,M. 
(2006). Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am. 
J. Hematol. 81, 59-61. 
Horne,A., Janka,G., Maarten,E.R., Gadner,H., Imashuku,S., Ladisch,S., Locatelli,F., 
Montgomery,S.M., Webb,D., Winiarski,J., Filipovich,A.H., and Henter,J.I. (2005). 
Haematopoietic stem cell transplantation in  haemophagocytic lymphohistiocytosis. Br. J. 
Haematol. 129, 622 -630. 
Horwitz,M.E., Barrett,A.J., Brown,M.R., Carter,C.S., Childs,R., Gallin,J.I., Holland,S.M., 
Linton,G.F., Miller,J.A., Leitman,S.F., Read,E.J., and Malech,H.L. (2001). Treatment of chronic 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-4 granulomatous disease with nonmyeloablative conditioning and a T -cell-depleted hematopoietic 
allograft. N. Engl. J. Med. 344, 881 -888. 
Imashuku,S., Hibi,S., Ohara,T., Iwai,A., Sako,M., Kato,M., Arakawa,H., Sotomatsu,M., 
Kataoka,S., Asami,K., Hasegawa,D., Kosaka,Y., Sano,K., Igarashi,N., Maruhashi,K., Ichimi,R., 
Kawasaki,H., Maeda,N., Tanizawa,A., Arai,K., Abe,T., Hisakawa,H., Miyashita,H. , and 
Henter,J.I. (1999). Effective control of Epstein -Barr virus -related hemophagocytic 
lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood 93, 1869 -1874.  
Janka,G.E. (1983). Familial hemophagocytic lymphohistiocytosis. Eur. J. Pediatr. 140, 221 -230. 
Jasinska,A., Kalwak,K., Trelinska,J., Borowiec,M., Piatosa,B., Zeman,K., and Mlynarski,W. 
(2013). Successful haploidentical PBSCT with subsequent T -cell addbacks  in a boy with 
HyperIgM syndrome presenting as severe congenital neutropenia. Pediatr. Transplant. 17, E37 -
E40. 
Jordan,M.B., Allen,C.E., Weitzman,S., Filipovich,A.H., and McClain,K.L. (2011). How I treat 
hemophagocytic lymphohistiocytosis. Blood 118, 4041 -4052.  
Kang,E.M., Marciano,B.E., DeRavin,S., Zarember,K.A., Holland,S.M., and Malech,H.L. (2011). 
Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J. Allergy 
Clin. Immunol. 127, 1319 -1326.  
Kikuta,A., Ito,M., Mochizuki,K.,  Akaihata,M., Nemoto,K., Sano,H., and Ohto,H. (2006). 
Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe 
organ dysfunction. Bone Marrow Transplant. 38, 665 -669. 
Kobayashi,Y., Salih,H.M., Kajiume,T., Nakamura,K., Mi yagawa,S., Sato,T., Nishimura,S., and 
Kobayashi,M. (2007). Successful treatment with liposteroid followed by reduced intensity stem 
cell transplantation in an infant with perforin deficiency presenting with hemophagocytic 
lymphohistiocytosis. J. Pediatr. H ematol. Oncol. 29, 178 -182. 
Kuhns,D.B., Alvord,W.G., Heller,T., Feld,J.J., Pike,K.M., Marciano,B.E., Uzel,G., 
DeRavin,S.S., Priel,D.A., Soule,B.P., Zarember,K.A., Malech,H.L., Holland,S.M., and Gallin,J.I. 
(2010). Residual NADPH oxidase and survival in chr onic granulomatous disease. N. Engl. J. 
Med. 363, 2600 -2610.  
Lee,W.I., Torgerson,T.R., Schumacher,M.J., Yel,L., Zhu,Q., and Ochs,H.D. (2005). Molecular 
analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood 
105, 1881 -1890. 
Levy,J., Espanol -Boren,T., Thomas,C., Fischer,A., Tovo,P., Bordigoni,P., Resnick,I., Fasth,A., 
Baer,M., Gomez,L., Sanders,E.A., Tabone,M.D., Plantaz,D., Etzioni,A., Monafo,V., Abinun,M., 
Hammarstrom,L., Abrahamsen,T., Jones,A., Finn,A., Klemola,T., De Vries,E., Sanal,O., 
Peitsch,M.C., and Notarangelo,L.D. (1997). Clinical spectrum of X -linked hyper -IgM syndrome. 
J. Pediatr. 131, 47-54. 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-5 Marsh,R.A., Allen,C.E., McClain,K.L., Weinstein,J.L., Kanter,J., Skiles,J., Lee,N.D., Khan,S.P., 
Lawrence,J., Mo,J.Q., Bleesing,J.J., Filipovich,A.H., and Jordan,M.B. (2013a). Salvage therapy 
of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr. Blood Cancer 60, 
101-109. 
Marsh,R.A., Jordan,M.B., and Filipovich,A.H. (2011). Reduced -intensity conditioni ng 
haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step 
forward. Br. J. Haematol. 154, 556 -563. 
Marsh, R. A., Kim, M. O., Liu, C., Bellman, D., Hart, L., Grimley, M., Kumar, A., Jodele, S., 
Myers, K. C., Chandra, S ., Leemhuis, T., Mehta, P., Bleesing, J. J., Davies, S. M., Jordan, M. B., 
and Filipovich, A. An intermediate alemtuzumab schedule reduces the incidence of mixed 
chimerism following reduced intensity conditioning hematopoietic cell transplantation for 
hemo phagocytic lymphohistiocytosis.  2013b.  
Ref Type: Unpublished Work  
Marsh,R.A., Vaughn,G., Kim,M.O., Li,D., Jodele,S., Joshi,S., Mehta,P.A., Davies,S.M., 
Jordan,M.B., Bleesing,J.J., and Filipovich,A.H. (2010). Reduced -intensity conditioning 
significantly i mproves survival of patients with hemophagocytic lymphohistiocytosis undergoing 
allogeneic hematopoietic cell transplantation. Blood 116, 5824 -5831.  
Martinez,C.A., Shah,S., Shearer,W.T., Rosenblatt,H.M., Paul,M.E., Chinen,J., Leung,K.S., 
Kennedy -Nasser,A.,  Brenner,M.K., Heslop,H.E., Liu,H., Wu,M.F., Hanson,I.C., and 
Krance,R.A. (2012). Excellent survival after sibling or unrelated donor stem cell transplantation 
for chronic granulomatous disease. J. Allergy Clin. Immunol. 129, 176 -183. 
McDonald,G.B., Hinds, M.S., Fisher,L.D., Schoch,H.G., Wolford,J.L., Banaji,M., Hardin,B.J., 
Shulman,H.M., and Clift,R.A. (1993). Veno -occlusive disease of the liver and multiorgan failure 
after bone marrow transplantation: a cohort study of 355 patients. Ann. Intern. Med. 118, 255-
267. 
Morris,E.C., Rebello,P., Thomson,K.J., Peggs,K.S., Kyriakou,C., Goldstone,A.H., 
Mackinnon,S., and Hale,G. (2003). Pharmacokinetics of alemtuzumab used for in vivo and in 
vitro T -cell depletion in allogeneic transplantations: relevance for early ad optive immunotherapy 
and infectious complications. Blood 102, 404 -406. 
Olin,R.L., Nichols,K.E., Naghashpour,M., Wasik,M., Shelly,B., Stadtmauer,E.A., and Vogl,D.T. 
(2008). Successful use of the anti -CD25 antibody daclizumab in an adult patient with 
hemopha gocytic lymphohistiocytosis. Am. J. Hematol. 83, 747 -749. 
Ouachee -Chardin,M., Elie,C., de Saint,B.G., Le,D.F., Mahlaoui,N., Picard,C., Neven,B., 
Casanova,J.L., Tardieu,M., Cavazzana -Calvo,M., Blanche,S., and Fischer,A. (2006). 
Hematopoietic stem cell trans plantation in hemophagocytic lymphohistiocytosis: a single -center 
report of 48 patients. Pediatrics 117, e743 -e750.  
Powell,B.R., Buist,N.R., and Stenzel,P. (1982). An X -linked syndrome of diarrhea, 
polyendocrinopathy, and fatal infection in infancy. J. Ped iatr. 100, 731 -737. 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-6 Qasim,W., Cavazzana -Calvo,M., Davies,E.G., Davis,J., Duval,M., Eames,G., Farinha,N., 
Filopovich,A., Fischer,A., Friedrich,W., Gennery,A., Heilmann,C., Landais,P., Horwitz,M., 
Porta,F., Sedlacek,P., Seger,R., Slatter,M., Teague,L., Eapen ,M., and Veys,P. (2009). Allogeneic 
hematopoietic stem -cell transplantation for leukocyte adhesion deficiency. Pediatrics 123, 836 -
840. 
Rada,B. and Leto,T.L. (2008). Oxidative innate immune defenses by Nox/Duox family NADPH 
oxidases. Contrib. Microbiol. 15, 164 -187. 
Rao,A., Kamani,N., Filipovich,A., Lee,S.M., Davies,S.M., Dalal,J., and Shenoy,S. (2007). 
Successful bone marrow transplantation for IPEX syndrome after reduced -intensity conditioning. 
Blood 109, 383 -385. 
Rebello,P., Cwynarski,K., Varughese,M., Eades,A., Apperley,J.F., and Hale,G. (2001). 
Pharmacokinetics of CAMPATH -1H in BMT patients. Cytotherapy. 3, 261 -267. 
Schuetz,C., Hoenig,M., Gatz,S., Speth,F., Benninghoff,U., Schulz,A., Debatin,K.M., and 
Friedrich,W . (2009). Hematopoietic stem cell transplantation from matched unrelated donors in 
chronic granulomatous disease. Immunol. Res. 44, 35-41. 
Seger,R.A. (2010a). Advances in the diagnosis and treatment of chronic granulomatous disease. 
Curr. Opin. Hematol.  
Seger,R.A. (2010b). Hematopoietic stem cell transplantation for chronic granulomatous disease. 
Immunol. Allergy Clin. North Am. 30, 195 -208. 
Seger,R.A., Gungor,T., Belohradsky,B.H., Blanche,S., Bordigoni,P., Di,B.P., Flood,T., 
Landais,P., Muller,S ., Ozsahin,H., Passwell,J.H., Porta,F., Slavin,S., Wulffraat,N., Zintl,F., 
Nagler,A., Cant,A., and Fischer,A. (2002). Treatment of chronic granulomatous disease with 
myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the Europe an 
experience, 1985 -2000. Blood 100, 4344 -4350.  
Seidel,M.G., Fritsch,G., Lion,T., Jurgens,B., Heitger,A., Bacchetta,R., Lawitschka,A., Peters,C., 
Gadner,H., and Matthes -Martin,S. (2009). Selective engraftment of donor CD4+25high FOXP3 -
positive T cells in I PEX syndrome after nonmyeloablative hematopoietic stem cell 
transplantation. Blood 113, 5689 -5691.  
Soncini,E., Slatter,M.A., Jones,L.B., Hughes,S., Hodges,S., Flood,T.J., Barge,D., Spickett,G.P., 
Jackson,G.H., Collin,M.P., Abinun,M., Cant,A.J., and Gennery ,A.R. (2009). Unrelated donor 
and HLA -identical sibling haematopoietic stem cell transplantation cure chronic granulomatous 
disease with good long -term outcome and growth. Br. J. Haematol. 145, 73-83. 
Strout,M.P., Seropian,S., and Berliner,N. (2010). Alemt uzumab as a bridge to allogeneic SCT in 
atypical hemophagocytic lymphohistiocytosis. Nat. Rev. Clin. Oncol. 7, 415 -420. 
Thompson,P.A., Allen,C.E., Horton,T., Jones,J.Y., Vinks,A.A., and McClain,K.L. (2009). 
Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. 
Pediatr. Blood Cancer 52, 621 -625. 
BMT CLINICAL TRIALS NETWORK  RICHI – Protocol 1204  
  Version 4.0 dated June 16, 2015  
H-7 Tomaske,M., Amon,O., Bosk,A., Handgretinger,R., Schneider,E.M., and Niethammer,D. (2002). 
Alpha -CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. M ed. 
Pediatr. Oncol. 38, 141 -142. 
Vowells,S.J., Sekhsaria,S., Malech,H.L., Shalit,M., and Fleisher,T.A. (1995). Flow cytometric 
analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J. 
Immunol. Methods 178, 89-97. 
Wildin,R .S., Ramsdell,F., Peake,J., Faravelli,F., Casanova,J.L., Buist,N., Levy -Lahad,E., 
Mazzella,M., Goulet,O., Perroni,L., Bricarelli,F.D., Byrne,G., McEuen,M., Proll,S., Appleby,M., 
and Brunkow,M.E. (2001). X -linked neonatal diabetes mellitus, enteropathy and endocrinopathy 
syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18-20. 
Winkelstein,J.A., Marino,M.C., Ochs,H., Fuleihan,R., Scholl,P.R., Geha,R., Stiehm,E.R., and 
Conley,M.E. (2003). The X -linked hyper -IgM syndrome: clinical and immunologi c features of 
79 patients. Medicine (Baltimore) 82, 373 -384. 
Zhan,H., Sinclair,J., Adams,S., Cale,C.M., Murch,S., Perroni,L., Davies,G., Amrolia,P., and 
Qasim,W. (2008). Immune reconstitution and recovery of FOXP3 (forkhead box P3) -expressing 
T cells after  transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked) syndrome. Pediatrics 121, e998 -1002.  
 
 
 
 